An investigation into the role of Rab-Coupling Protein and EphA2 during cancer cell migration by Gundry, Christine
 
 
 
 
 
 
 
 
 
Gundry, Christine (2015) An investigation into the role of Rab-Coupling 
Protein and EphA2 during cancer cell migration. PhD thesis. 
 
 
https://theses.gla.ac.uk/6217/  
 
 
 
Copyright and moral rights for this work are retained by the author  
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge  
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author  
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author  
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses  
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
 
 
 
 
 
 
An investigation into the role of Rab-
Coupling Protein and EphA2 during cancer 
cell migration 
 
 
 
 
 
Christine Gundry 
MBiochem 
 
 
 
 
 
Submitted in fulfilment of the requirements for the Degree 
of Doctor of Philosophy 
 
 
 
 
Beaston Insitute for Cancer Research 
College of Medical, Veterinary and Life Sciences 
University of Glasgow 
 
 
 
 
 
March 2015 
 
 
 
  
2 
 
Abstract 
The gene encoding Rab-Coupling Protein (RCP), a Rab11 GTPase effector, is 
found on a chromosomal locus that is frequently amplified in cancer. We have 
previously shown that RCP drives α5β1-integrin and EGFR recycling to the plasma 
membrane, thus contributing to the invasive migration of tumour cells. Using 
MALDI-TOF mass spectrometry, I have identified EphA2 and two Rab GTPases, 
Rab6 and Rab14, as novel RCP-associated proteins. Immunoprecipitation-based 
studies confirm these associations using several different cancer cell lines.  
EphA2 is a receptor tyrosine kinase (RTK) that is required for contact inhibition 
of locomotion (CIL), and this process is thought to contribute to cancer cell 
invasion. To determine whether the EphA2-RCP association has functional 
significance, I tested whether RCP, Rab GTPases and other Rab11 effector 
proteins are required for CIL. siRNA knockdown of either RCP or Rab14 
prevented efficient CIL, but depletion of Rab11 or Fip2 expression was 
ineffective in this regard. Likewise, HGF-induced scattering of cell colonies was 
opposed by suppression of EphA2, RCP or Rab14 expression. Since RCP and Rab14 
are involved in RTK trafficking, EphA2 internalisation kinetics were investigated. 
HGF increased EphA2 trafficking in an RCP- and Rab14-dependent fashion. Live 
cell imaging demonstrated that EphA2 is delivered to an RCP and Rab14 positive 
compartment upon HGF treatment. Furthermore, HGF drove phosphorylation of 
RCP on Serine435, which enhanced the association between EphA2, RCP and 
Rab14. Indeed, mutating the phosphor-acceptor site on RCP (RCPS435A) reduced 
its association with EphA2 and Rab14, and blocked HGF-driven cell scattering. 
EphA2 is frequently overexpressed in human pancreatic cancer and this is 
associated with poor patient prognosis. The role of EphA2 and RCP in metastasis 
was investigated in an autochthonous model of pancreatic ductal 
adenocarcinoma (PDAC) by crossing EphA2-/- and RCPfl/fl mice into the KPC (Pdx1-
Cre, KrasG12D/+, p53R172H/+) PDAC model. Indeed, ablation of EphA2 or RCP 
expression in the mouse pancreas reduced the formation of liver metastases. 
Furthermore, PDAC lines from KPC EphA2-/- and KPC RCPfl/fl mice had a less 
scattered phenotype and were less invasive in vitro thus corroborating the 
observations indicating that EphA2 and RCP have an important role in cell-cell 
repulsion. 
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1 Introduction 
1.1 Cancer metastasis 
1.1.1.1 The hallmarks of cancer 
Cancer is an ancient disease dating back to the dinosaur era (Rothschild et al., 
2003) and which now occurs in the majority of multicellular organisms. 
Carcinomas are the most common form of human cancer. They arise from 
epithelial cells and account for 80% of cancer deaths (Weinberg, 2007). Other 
types of tumour include sarcomas, which arise from mesenchymal cells; 
haemopoietic cancers, which arise from immune cells; and neuroectodermal 
tumours, which arise from the nervous system and melanomas (Weinberg, 2007). 
Cancer can be compared to a complex organ, since it is comprised of many 
different cells co-operating together. Each tumour has its own array of 
developing genetic mutations and epigenetic changes, and adapts to its 
surroundings in a similar fashion to Darwinian evolution but at a much more 
rapid pace. In 2000, Hanahan and Weinberg categorised 6 key features that 
tumour cells must acquire to render them malignant, termed the hallmarks of 
cancer (Hanahan and Weinberg, 2000). New studies have revealed other 
characteristics that tumour cells require for malignancy, which has increased the 
number of hallmarks of cancer to 10 (Hanahan and Weinberg, 2011). These 
hallmarks are: genome instability and mutation, sustaining proliferative signals, 
evading growth suppressors, enabling replicative immortality, avoiding immune 
destruction, tumour promoting inflammation, inducing angiogenesis, 
deregulating cellular energetics, resisting cell death and activating invasion and 
metastasis (Hanahan and Weinberg, 2011). As 90% of cancer deaths are caused 
by secondary tumours, which have arisen from primary tumours (Leber and 
Efferth, 2009), it is apparent that metastasis is important to investigate. 
1.1.1.2 Metastasis in human cancer 
Metastasis is a complex process, which has been described as a cascade divided 
into five key steps (Figure 1.1) (Leber and Efferth, 2009). First, cancer cells 
detach from the primary tumour, secrete proteases to degrade the extracellular 
matrix and activate cell migration. Second, intravasation occurs in which cancer 
cells migrate into the lumen of a blood or lymphatic vessel. Third, the tumour 
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cell travels through the circulation system to a distant site. For a cancer cell to 
survive in the circulation it must overcome anoikis (anchorage-dependent cell 
death) and survive high shear forces. Fourth, extravasation occurs in which the 
cancer cell leaves the blood vessel. This can occur by two mechanisms; either 
the cell proliferates in the vessel until the vessel wall is destroyed, or the cell 
degrades the endothelium and basement membrane in a similar fashion to 
intravasation (Leber and Efferth, 2009). The final step is colonisation of the new 
site, which requires cell proliferation, angiogenesis and survival in the new 
environment. There is clear evidence that tumours metastasise to particular 
sites, for example pancreatic cancer tends to metastasise to the liver, lung and 
peritoneum. Metastasis via blood or lymphatic vessels is complex and the cancer 
cells have to adapt to several environmental changes and unfavourable 
conditions to survive. There is increasing evidence that some types of cancer, 
such as leukemias and ENT tumours, metastasise via perineural invasion of 
nerves (Liebig et al., 2009), and more work is required to understand this route 
of metastasis.  
 
Figure 1-1 Cancer metastasis cascade 
Cancer metastasis is a multi-step process: tumour cells invade neighbouring tissue, intravasate 
into blood vessels, are transported in the blood, extravasate out of the vessel and colonise another 
tissue. 
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1.1.1.3 Complexity of cell migration in metastasis 
Successful metastasis requires cancer cells to migrate in different environments, 
therefore, they must adapt to their surroundings. Cancer cell migration in vivo is 
complex and controlled by many mechanisms. Despite this, many findings in cell 
migration in vitro are also apparent in vivo. Cancer cell migration may be 
determined by a number of factors. First, the complement of misregulated and 
mutated genes will define how a cancer cell migrates and responds to different 
environmental cues. The tumour microenvironment encompasses both the 
extracellular matrix (ECM) and other cells. The ECM is composed of a complex 
mix of proteins, such as fibronectin and collagen. Its components and stiffness 
can affect cell migration (Levental et al., 2009). Cells neighbouring cancer cells 
(such as stromal cells) can promote cancer cell invasion, for example, cancer 
associated fibroblasts (Kalluri and Zeisberg, 2006). These cells and the cancer 
cells themselves can secrete soluble factors, such as growth factors, that can 
stimulate the cancer cells to migrate. Also, cancer cell migration will depend on 
whether contact with other cancer cells or stromal cells promotes cell-cell 
adhesion or repulsion (Section 1.1.3). All these factors will determine whether a 
cancer cell invades and which mechanism it will adopt.  
1.1.2 Cell migration 
Cell migration is essential for normal physiological processes such as embryonic 
development, wound healing and immune response as well as during cancer cell 
metastasis. Cell migration is dependent on molecular parameters, physical 
forces and the microenvironment and can be divided into two broad categories: 
collective cell migration and single cell migration. 
1.1.2.1 Collective cell migration 
Cells migrate collectively in several physiological processes, such as mammary 
gland branch morphogenesis, wound healing, vascular sprouting and neural crest 
migration (Carmona-Fontaine et al., 2008; Ewald et al., 2008). While these 
processes are fairly well understood in vitro, the mechanisms and kinetics of 
collective migration in vivo are less well understood. Collective invasion of this 
type is observed by histology in many tumour types, such as breast, prostate and 
pancreatic cancer (Christiansen and Rajasekaran, 2006). During collective cell 
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migration, some carcinoma cells can continue to assume a more epithelial-type 
morphology (Christiansen and Rajasekaran, 2006), whilst maintaining functional 
cell-cell contacts, such as tight and adherence junctions (Theveneau and Mayor, 
2012). In contrast, some cancers including melanoma and breast cancer contain 
small strands of migrating cells with the cytoskeleton of each cell acting 
independently (Hegerfeldt et al., 2002; Roussos et al., 2011). The organisation 
of collective cell migration is maintained by cell adhesion to the ECM, guided by 
growth factors and proteolysis (Friedl et al., 2012). There is evidence that during 
this migration there are leading cells that degrade the ECM and following cells 
that increase the diameter of the gap in the ECM allowing more cells to follow 
(Wolf et al., 2007). Indeed, cancer-associated fibroblasts can lead the invasive 
process of cancers that retain epithelial traits (Ewald et al., 2008).  
1.1.2.2 Single cell migration 
Once separated from their neighbours, cancer cells can migrate individually via 
several different mechanisms. The strategy of single cell migration depends on 
the strength of cell adhesion with the ECM, cytoskeleton contractibility, and the 
capability of remodelling and clearing a path in the ECM (Ridley et al., 2003). 
Two main types of single cell migration have been identified, mesenchymal and 
amoeboid, however, this is probably an over-simplification. Mesenchymal 
migration is characterised by cell elongation and requires extracellular 
proteolysis, while in amoeboid migration the cell is rounded, less dependent on 
proteolysis but has an elevated contractility of the actin cytoskeleton (Sanz-
Moreno and Marshall, 2010). Cancer cells originating from different tissues often 
employ different modes of migration, for example, sarcomas and carcinomas 
normally migrate mesenchymally (Davies et al., 2005b), while, haematopoietic 
cancer cells adopt amoeboid migration (Friedl et al., 2001). Cancer cells can 
switch between different types of single cell migration, depending on the 
relative activities of Rho GTPase sub-families, which enables cancer cells to 
adapt and migrate in the appropriate way for their environment (Sanz-Moreno et 
al., 2008).  
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1.1.3 Contact inhibition of locomotion (CIL) 
1.1.3.1 Historical perspective 
Contact inhibition of locomotion (CIL) was defined by Michael Abercrombie in 
1979 as: ‘the stopping of the continued locomotion of a cell in the direction 
which has produced a collision with another cell’ (Abercrombie, 1979). His 
studies on the social behaviour of cells were performed by placing two explants 
of chicken embryonic cells close together and observing fibroblast migration 
when they collide with each other (Abercrombie and Heaysman, 1954). CIL can 
occur between the same cell type (homotypic) or between different cell types 
(heterotypic) (Abercrombie, 1970). More recently a typical sequence of events 
has been used to define reciprocal CIL: two migrating cells collide into each 
other, protrusions at the site of contact are inhibited, new protrusions form at a 
new site away from the collision point and the cells migrate in the direction that 
the new protrusions have formed (Figure 1.2A) (Carmona-Fontaine et al., 2008). 
This description includes not just contact inhibition, but also includes 
subsequent cell-cell repulsion. However, some cells respond differently, and fail 
to form a new protusion and migrate after collisions. 
Since Abercrombie’s initial explant experiments, several different techniques 
have been developed to analyse CIL. CIL can be measured between two single 
cells in culture. Simple methods to quantify CIL on 2D surfaces include 
measuring the time cells remain in contact during collisions (Stramer et al., 
2010), comparing the position of cells before and after a collision (Matthews et 
al., 2008) or illustrating the positions of de novo versus existing protrusions after 
CIL (Kadir et al., 2011). More recently, several studies have used the contact 
acceleration index (Cx) to quantify CIL (Astin et al., 2010; Sugiyama et al., 
2013), by tracking each cell’s migratory path before and after the collision. This 
index represents the difference between where the cell would have progressed 
if there had been no collision and where the cell has actually migrated. To 
determine how collisions have altered the cell’s path, Cx is compared between 
colliding and free-moving cells. There are several limitations to using Cx, 
including the fact that the cells stay in contact for different periods of time and 
often rotate whilst in contact, thus altering the direction of subsequent cell 
migration. Also, cells have a stronger repulsive response in head-on collisions 
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(leading edge to leading edge) compared to side-on collisions (leading edge to 
cell body) (Abercrombie and Dunn, 1975), so it is essential to carefully compare 
like-for-like collisions when analysing this data. It is best to use a combination of 
methods to analyse CIL, as all of them have different drawbacks. 
1.1.3.2 The functions of contact inhibition of locomotion 
To date a variety of proteins have been shown to be required for CIL (Table 
1.1), however further work is required to achieve a better mechanistic 
understanding of CIL. CIL is thought to contribute to several processes, such as 
development, axon guidance and angiogenesis, and I have summarised these in 
the following sections.  
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Figure 1-2 Contact inhibition of locomotion in vitro and in vivo 
A. In vitro contact inhibition of locomotion occurs when two migrating cells collide. Their 
lamellipodia collapse upon contact and then the cells form new lamellipodia away from the site of 
collision. The cells migrate away from each other. B. Neural crest cell migration is regulated by 
contact inhibition of locomotion and chemotactic signals (represented with + and -). Cells 
surrounded by others, undergo CIL preventing the formation of lamellipodia (red inhibition signs), 
however, cells at the front form lamellipodia and can migrate away (blue arrows). C. During axon 
guidance the growth cone extends and comes into contact with other cells. If it is an unfavourable 
cell, upon contact, the growth cone collapses and moves away from the cell. 
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Protein Role in contact inhibition of locomotion (CIL) 
Cadherins Downregulation of E-cadherin reduces CIL in epithelial cells (Bracke 
et al., 1997), while in myoblasts overexpressing N-cadherin prevents 
repulsion after a cell-cell collision (Huttenlocher et al., 1998). 
Cdc42 Cdc42 is activated by EphB3/B4 in heterotypic collisions between 
fibroblasts and PC3 cells resulting in defective CIL (Astin et al., 2010). 
Ephs and 
Ephrins 
EphA4/B1 and EphrinB1 are expressed in distinct cell populations in 
embryonic development. Disrupting this expression results in failure of 
CIL and cells migrate into different territories (Smith et al., 1997). 
Several different Ephs and Ephrins are expressed in prostate cancer 
cells in which they have a role in CIL, influencing invasion and 
metastasis (Astin et al., 2010).  
Integrin Ectopically expressing α5-integrin in myoblasts inhibits migration upon 
cell-cell contact, resulting in aggregates of cells. Without cell-cell 
contact these cells migrate normally (Huttenlocher et al., 1998). 
Microtubules Microtubules de-stabilise at the cell-cell contact site and stabilise in 
the new lamellipodia in macrophages colliding in vitro (Kadir et al., 
2011). Disruption of microtubules in haemocytes prevent CIL in vivo 
during embryogenesis (Stramer et al., 2010). 
Nectins Necl-5 is localised in the lamellipodia of fibroblasts. Upon collision it 
associates with Nectin-3, resulting in Necl-5 downregulation and 
reducing cell movement (Fujito et al., 2005; Takai et al., 2008). 
Notch Notch is found on growth cones while its ligand Delta is expressed on 
neighbouring cells. This guides the growth cone to repel or adhere its 
neighbouring cells (Crowner et al., 2003; Šestan et al., 1999). 
Par3 Par3 is essential for CIL in neural crest migration. It reduces 
microtubule catastrophe at the contact site (Moore et al., 2013). 
Rac1 Dominant negative Rac1 expression results in defective heterotypic 
CIL in fibroblast explant experiments by altering RhoA activation 
(Anear and Parish, 2012). 
RhoA RhoA is required for efficient CIL in neural crest cells (Carmona-
Fontaine et al., 2008) and in fibroblasts (Kadir et al., 2011).  
ROCK Inhibition of ROCK in fibroblasts prevents CIL and cell-cell repulsion 
by mediating the microtubule cytoskeleton (Kadir et al., 2011). In PC3 
cell retraction, EphAs signal to ROCK, which regulates actomyosin 
contractibility (Astin et al., 2010). 
Semaphorins Semaphorins and their receptors, neuropilins and plexins, have a role 
in growth cone guidance (Koropouli and Kolodkin, 2014) and 
development. Sema3F and Npn2 are expressed in distinct cell 
populations, which is required for cranial neural crest development 
(Gammill et al., 2007). 
Wnt Inhibition of the non-canonical Wnt and PCP pathway prevents 
efficient CIL and directionality of neural crest cell migration in vivo. 
Wnt is found at the cell-cell contact site, which activates RhoA 
(Carmona-Fontaine et al., 2008; Matthews et al., 2008). 
Table 1-1 Role of proteins in contact inhibition of locomotion  
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Development                 
CIL has a role in development and has been most studied in neural crest cell 
(NCC) migration in Xenopus, Zebrafish, Chick and Drosophila embryogenesis 
(Davis et al., 2012; Kulesa and Fraser, 2000; Teddy and Kulesa, 2004). NCCs are 
highly migratory and are capable of differentiating into many different cell 
types, including neurons, Schwann cells, melanocytes and odontoblasts. In vitro 
studies have shown that NCCs undergo homotypic CIL, but not heterotypic CIL 
with mesodermal cells (Carmona-Fontaine et al., 2008). In vivo, CIL and 
chemotaxis work together so that NCCs migrate in a coordinated fashion through 
the embryo (Figure 1.2B). CIL inhibits trailing cells from forming protrusions and 
migrating away from the pack, while inhibitory signals prevent cell dispersal into 
the surrounding area. In contrast, CIL promotes the formation of protrusions and 
migration of the leading cells away from each other (Carmona-Fontaine et al., 
2008). External signals promote migration of the leader cells in one particular 
direction, thus it is through a combination of chemotaxis and CIL that NCCs 
migrate in such a coordinated fashion. Furthermore, in vivo studies in Drosophila 
embryos, in which haemocytes are fluorescently labelled and tracked in real 
time, demonstrate that CIL is required to form the distinct pattern of haemocyte 
dispersal during embryogenesis (Davis et al., 2012; Stramer et al., 2010).  
Axon guidance           
Growth cones at the tips of axons travel long distances to find the correct target 
cell to form a synapse (Figure 1.2C). This is highly regulated and is thought to 
be controlled by a number of mechanisms, including chemo-attraction, chemo-
repulsion, contact-mediated attraction or contact-mediated repulsion with other 
cells or the ECM (Mueller et al., 2006). The latter mechanism is reminiscent of 
CIL. A study was performed in vitro with embryonic chick retinal and 
sympathetic neurons (Kapfhammer and Raper, 1987). When these neurons are 
grown separately, their growth cones locate other neurons and form 
connections. However, when these neurons are co-cultured and a retinal growth 
cone contacts a sympathetic neuron, the growth cone collapses, extends in a 
different direction, and no connections are formed (Kapfhammer and Raper, 
1987). Furthermore, a similar phenomenon has been observed in motor neurons 
from chick embryos, which form contacts with the anterior sclerotome, but 
avoid the posterior sclerotome (Oakley and Tosney, 1993). Interestingly, many of 
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the proteins required for axon guidance are also thought to have a role in CIL in 
cancer cells. 
Angiogenesis                
New blood vessels are formed by angiogenic sprouting. The basement membrane 
is degraded by proteases secreted by endothelial cells and these cells migrate 
into the connective tissue, proliferate and tubulate to form a new vessel with a 
lumen (Ribatti and Crivellato, 2012). In a newly formed vessel, it is thought that 
there are two types of cells: ‘tips’ that migrate into new regions and ‘stalks’ 
that proliferate providing the cells for new vessels (Gerhardt et al., 2003). New 
sprouts form in response to mechanical or chemical stimulation, such as VEGF 
(Ribatti and Crivellato, 2012). During the migrating phase of angiogenesis, 
protrusions on stalk cells are inhibited whereas on tip cells they are promoted, 
in a process that is reminiscent of the type of CIL that occurs during neural crest 
migration. Indeed, VE-cadherin, a key component of endothelial cell-cell 
junctions, prevents stalk cell sprouting and Rac1 driven migration by inhibiting 
VEGFR signalling (Abraham et al., 2009). As tip cells express less VE-cadherin 
than stalk cells, VEGF is then able to drive migration via Rac1 activation. 
Fibroblasts have been shown to have a role in angiogenesis (Orimo et al., 2005). 
Co-cultures of endothelial cells and heart fibroblasts in fibrin gels demonstrate 
that when the density of fibroblasts is low the endothelial cells form sprouts and 
grow, while, in higher fibroblast densities sprout formation is inhibited leading 
to endothelial cell retraction (Nehls et al., 1998).  
1.1.3.3 CIL in cancer 
As far back as 1979 Michael Abercrombie postulated that CIL may be important 
in cancer cell invasion and metastasis. He cultured two non-cancerous explants 
side by side, and the cells segregated via heterotypic CIL. However, when one 
explant contained cancerous cells it invaded into the other explant in which the 
cells failed to undergo heterotypic CIL (Abercrombie, 1979). Accumulating 
observations indicated that genes involved in development, which are often 
required for CIL, are frequently misregulated in cancer (Hanahan and Weinberg, 
2011). Indeed, large scale genetic analysis of many human pancreatic ductal 
carcinomas (Biankin et al., 2012) and lung cancers (Nasarre et al., 2010) have 
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revealed that many genes involved in axon guidance were altered, many of 
which have a role in CIL. 
During cancer metastasis, cancer cells must become motile and invade into the 
surrounding tissue. Thus neighbouring cells must no longer prevent the invasion 
of the cancer cells into their territory. Therefore, it is likely that both 
homotypic and heterotypic collisions will be relevant here. Indeed a situation 
has been envisaged in which homotypic collisions occur (allowing cancer cells to 
break away from the primary tumour and disperse), while heterotypic collisions 
are prevented (allowing cancer cells to continue to migrate into the surrounding 
tissue)(Astin et al., 2010; Mayor and Carmona-Fontaine, 2010; Paddock and 
Dunn, 1986; Veselý and Weiss, 1973). Evidence supporting this has been 
observed in invasive prostate cancer cell lines (Astin et al., 2010). These studies 
demonstrate an important role of Ephs/Ephrins and Rho GTPases in CIL (Astin et 
al., 2010) (Section 4.1), but more work is required to uncover the mechanism of 
CIL in cancer and to determine whether the mechanisms that control CIL can 
influence metastasis in vivo. 
1.2 Ephs and Ephrins 
Ephrins are a family of membrane-anchored proteins that act as ligands for their 
cognate receptors the Ephs, which are a subfamily of receptor tyrosine kinases 
(RTKs). Ephs and Ephrins are involved in a plethora of functions, including axon 
guidance, development, angiogenesis, and organisation of the crypt-villus axis, 
and these are frequently misregulated in cancer. It is thought that Ephs and 
Ephrins contribute to processes by regulating whether cells adhere or repel each 
other. 
1.2.1 Historical perspective 
The Ephrin receptor, EphA1 was discovered in 1987 during a search for tyrosine 
kinases in EPH cells (Erythropoietin-Producing Hepatocellular carcinoma) (Hirai 
et al., 1987). Ephs are highly conserved in metazoans and the human genome 
contains 14 members of the Eph subfamily, making this the largest subfamily of 
RTKs (Drescher, 2002). The ligands for Ephs, the Ephrins, are normally tethered 
by GPI linkages to the plasma membrane of adjacent cells, although some 
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Ephrins may be cleaved and shed from the cell surface to act as soluble ligands 
(Wykosky et al., 2008). The Ephs are divided into two subclasses based on Ephrin 
binding: the 9 EphAs are receptors for 5 GPI membrane-anchored EphrinAs, and 
the 5 EphBs associate with 3 transmembrane-anchored EphrinBs. There is 
mounting evidence that some EphAs associate with EphrinBs and vice versa, and 
EphA4 is particularly promiscuous (Qin et al., 2010).  
1.2.2 Eph structure and clusters 
Eph structure is conserved, and all the family members possess multiple domains 
both sides of the plasma membrane, which are connected by a single spanning 
hydrophobic transmembrane helix (Figure 1.3). Eph ectodomains contain a 
ligand binding domain (LBD), a Cys rich region composed of a Sushi, EGF-like and 
two fibronectin type 3 domains. The intracellular portion contains a small 
juxtamembrane region, a tyrosine kinase domain, a sterile-α motif and often a 
Psd-95, Dlg and ZO1 (PDZ) domain binding motif (PBM). Although the whole 
molecule has not been crystallised, the structures of the ectodomain and SAM 
domain have been solved (Himanen et al., 1998; Himanen and Nikolov, 2002; 
Thanos et al., 1999). Indeed, several Eph ectodomains have been crystallised in 
association with Ephrins, revealing a heterotetrameric complex with two ligands 
and receptors. In the LBD a class-specific loop has been identified, which differs 
in EphAs and EphBs, perhaps allowing specificity of ligand binding (Himanen et 
al., 2001; Xu et al., 2013). 
One major factor determining whether Ephs will stimulate adhesion or repulsion 
is the degree of Eph/Ephrin clustering. Upon activation by engagement with 
Ephrins expressed on neighbouring cells, Eph/Ephrin tetramers recruit more 
Ephs, without further ligand association to form large clusters (Lane et al., 1998; 
Wimmer-Kleikamp et al., 2004). These clusters can contain multiple different 
Eph subtypes, which modulate downstream signalling (Jørgensen et al., 2009). 
Indeed, it has been shown that ectopic expression of soluble EphA7 associates 
with EphA2 and inhibits its signalling (Oricchio et al., 2011). Furthermore, most 
cells express both Ephs and Ephrins, which can also associate on the same 
membrane in ‘cis’ (Yin et al., 2004), to inhibit ‘trans’ activation of Ephs by 
Ephrins on neighbouring cells (Falivelli et al., 2013). In summary, association of 
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different Ephs and Ephrins in ‘cis’ or ‘trans’ can alter downstream signalling 
resulting in different cellular responses. 
 
 
Figure 1-3 Structure of Eph and Ephrin 
EphrinB is a transmembrane protein with a Receptor Binding Domain (RBD), Cytoplasmic Domain 
(CD) which contains phosphorylation sites and a PDZ binding motif (PMB). EphrinA is a GPI 
anchored protein with an extracellular RBD.  Ephs contain many domains: a Ligand Binding 
Domain (LBD), Sushi domain and EGF-like domain, two fibronectin type3 domains (FN), a single 
spanning transmembrane region, juxtamembrane region (JM), kinase domain (KD), sterile α-motif 
(SAM) and a PBM. The structure of EphA2 and EphrinA5 are shown with the domains coloured the 
same as the schematic representation. This has been adapted from Seiradake et al. (2010) 
 
1.2.3 Signalling 
RTKs follow a classical cascade of activation: the ligand binds the receptor, the 
receptor autophosphorylates, signalling proteins associate and are 
phosphorylated, these signalling proteins activate other proteins and the cell 
responds to the signal. Ephs follow this activation cascade. However, Ephrins can 
also activate signalling proteins in neighbouring cells, which is called reverse 
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signalling. Ephs can influence a large array of signalling proteins and these 
pathways vary depending on cell type and the complement of Ephs and Ephrins 
expressed in the cell. Different intracellular domains of Ephs can influence 
signalling output. For example, the juxtamembrane region activates Src 
(Jørgensen et al., 2009), the kinase domain associates with and activates a Rho 
GEF, ephexin (Shamah et al., 2001), and the PDZ-binding motif can associate 
with PDZ binding proteins (Torres et al., 1998) potentially activating them.  
1.2.3.1 Autophosphorylation 
Upon ligand activation Ephs form large clusters, bringing Ephs in close proximity, 
which promotes trans-phosphorylation of two highly conserved residues in the 
juxtamembrane region (Tyr588 and Tyr594 in EphA2). Phosphorylation of these 
residues relieves inhibitory interactions with the kinase domain leading to a 
structural rearrangement of this domain, resulting in activation of the kinase 
activity (Binns et al., 2000; Wybenga-Groot et al., 2001). Indeed, a study using 
FLIM-FRET between membrane-labelled RFP and GFP-EphA3 indicates that the 
kinase domain physically moves away from the juxtamembrane region upon 
activation (Janes et al., 2009). There is an activation loop in the Eph kinase 
domain that also has a phosphor-acceptor tyrosine. Phosphorylation of this 
residue activates the kinase as the loop no longer blocks the active site. 
Although mutating this tyrosine in EphA4 prevents activation (Binns et al., 2000), 
further work is required to determine whether this loop is required for activation 
of other Ephs. 
1.2.3.2 Forward signalling 
Ephs can activate a variety of downstream signalling pathways that are required 
for their functions (Figure 1.4). The major signalling pathways downstream of 
Eph activation will be outlined. It is worth noting that different studies often 
show conflicting results with regards to Eph signalling, perhaps owing to 
difference in cell type and the microenvironment. 
Chapter 1  30 
 
 
Figure 1-4 EphA and EphrinA Signalling 
EphAs and EphrinAs are activated upon binding, which activates many signalling pathways. 
EphrinA reverse-signals to the Src family of kinases. EphA can inhibit Abl and the Ras-MAPK 
pathway, whilst activating Src and several Rho-GEFs (Tiam1, Ephexin and Vav), which can 
promote cell migration via Rho GTPases. Akt phosphorylates unbound EphA, but upon ligand 
association Eph negatively regulates Akt. 
Rho GTPases                
Rho, Ras and Rab GTPases are found in both active GTP-bound and inactive GDP-
bound states, and this is controlled by GEFs (guanine nucleotide exchange 
factors) that exchange GDP with GTP, and GAPs (GTPase activating proteins) 
that promote hydrolysis of GTP to GDP. Prominent members of the Rho GTPases 
are: RhoA, which promotes contraction of the actin cytoskeleton and the 
formation of stress fibres; Rac1, which promotes formation of lamellipodia; and 
Cdc42, which promotes the formation of filopodia. Active Ephs have been shown 
to signal to Rho-GTPases during axon guidance and CIL (Figure 1.4) (Astin et al., 
2010; Wahl et al., 2000). The GEFs, Ephexin and two of the Vav family are 
required for Ephs to activate RhoA and Rac1 to initiate growth cone collapse 
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(Cowan et al., 2005; Shamah et al., 2001). Other GEFs, such as Kalirin, Tiam1 
and Intersectin are thought to have a role downstream of EphA2 in regulating 
dendritic spine morphogenesis (Irie and Yamaguchi, 2002; Penzes et al., 2003; 
Tolias et al., 2007). In prostate cancer cells, EphinA1 stimulation decreases cell 
adhesion via Rac1 inhibition and RhoA activation (Astin et al., 2010). 
Furthermore, Eph-Ephrin association activates LMW-PTP, which in turn 
dephosphorylates and inactivates its substrate p190RhoGAP, to drive RhoA 
activation leading to de-adhesion and promoting cell rounding (Buricchi et al., 
2007). It is likely that EphA function in cancer may be dependent on Rho 
GTPases. Further work is required to understand Eph signalling to these GTPases 
and the functional responses downstream of this.  
Ras-MAPK                 
Ras activates the MAP kinase pathway, which is important for transcriptional 
regulation, cell migration and axon guidance (Forcet et al., 2002). Indeed, 
EphA2 is a direct transcriptional target of this pathway (Macrae et al., 2005). 
Ephs can negatively regulate Ras in many cell lines, for example in epithelial, 
endothelial and tumour cells (Miao et al., 2001). It has been shown that 
p120RasGAP, which converts Ras into its inactive GDP-bound form, can mediate 
Eph’s inhibition of Ras (Elowe et al., 2001). Ephs can act as a tumour suppressors 
by suppressing Erk1/2 activation, which is stimulated by other RTKs (Macrae et 
al., 2005). Despite this, in some instances Ephs activate the MAPK pathway. For 
example, EphB2 has been shown to activate Erk, which promotes cell-cell 
repulsion (Poliakov et al., 2008), and EphB1 activates Ras via the adaptor, Grb2, 
which promotes cell migration (Vindis et al., 2003). In summary, Eph signalling 
to the MAPK pathway is complex and may differ in different cell types. 
Akt                   
Akt is a serine/tyrosine kinase that is typically activated by PI3Kinase and signals 
to downstream proteins such as mTOR. Eph signalling can both activate and 
deactivate Akt and this depends on the cell type. In some studies, Eph activation 
was found to indirectly de-phosphorylate and suppress Akt (Menges and 
McCance, 2008; Miao et al., 2009). Indeed, active EphB3 inhibits Akt activity in 
non-small-cell lung carcinoma cells. Nevertheless, Eph has also been shown to 
activate Akt in T-lymphocytes and pancreatic cancer cells (Chang et al., 2008; 
Maddigan et al., 2011). Interestingly, a recent report demonstrates crosstalk 
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between Akt and Eph signalling. Upon serum stimulation, Akt phosphorylates 
EphA2 at Serine-897 promoting cell migration (Miao et al., 2009). However, upon 
EphrinA1 stimulation EphA2 is dephosphorylated at this site, which 
dephosphorylates Akt, thus inactivating it and inhibiting cell migration (Miao et 
al., 2009). 
Src and Abl                
Ephs can signal to other downstream tyrosine kinases, such as Src and Abl, which 
regulates the actin cytoskeleton and cell migration (Kalo and Pasquale, 1999). 
Indeed, Fyn, a member of the Src family of kinases, is activated downstream of 
EphA8 (Choi and Park, 1999). In contrast, EphrinB1 stimulation of EphB2 
decreases Abl activity (Yu et al., 2001).  
1.2.3.3 Reverse signalling 
Upon Eph association, Ephrins are activated and can influence signalling 
pathways in the cells in which they are expressed. This is defined as reverse 
signalling. Studies reveal that EphrinA can reverse-signal via association with 
other RTKs, for example, Ret (Bonanomi et al., 2012). It has been shown that 
upon Eph binding, EphrinAs are found in microdomains, which increases cell 
adhesion (Davy et al., 1999; Davy and Robbins, 2000). Several studies have 
shown that EphrinAs signal to Src kinases in these microdomains (Figure 1.4), for 
example, EphrinA5 activates Fyn (Davy et al., 1999). Indeed, over-expression of 
EphrinA5 increases cell invasiveness, which is blocked by the Src kinase inhibitor, 
PP2 (Campbell et al., 2006). EphrinBs can also reverse-signal via their 
cytoplasmic domain and C-terminal PDZ binding motif (PBM). Upon Eph binding, 
EphrinBs are phosphorylated by Src kinases, which enables them to activate 
signalling output (Cowan and Henkemeyer, 2001).  
1.2.3.4 Modulation of Eph signalling 
Eph signalling may be modulated by several different mechanisms, including: 
internalisation (examined in Section 1.3.5), cis-association with Ephrins and 
dephosphorylation by many different phosphatases. Indeed, it has been shown 
that EphA2 is dephosphorylated by LMW-PTP (Kikawa et al., 2002) and EphA3 is 
dephosphorylated by PTB1B. Both phosphatases attenuate Eph forward 
signalling. Furthermore, conserved phosphorylation sites in the juxtamembrane 
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domain of Eph can be de-phosphorylated by tyrosine phosphatase receptor type 
O (Shintani et al., 2006). Cis association between Eph and Ephrins can attenuate 
Eph forward signalling. Indeed, EphrinA5 can associate with the second FN type 3 
domain of EphA3 in cis, which blocks the trans-association between EphA3 and 
EphrinAs (Carvalho et al., 2006).  
Ephs are activated by ligand binding at the plasma membrane, where they are 
thought to activate downstream signalling pathways. Interestingly, a recent 
study showed that EphA2 remains phosphorylated once it is internalised into 
vesicles, suggesting that EphA2 could actively signal from an internal 
compartment. Boissier et al. (2013) demonstrated that phospho-Y594-EphA2 is 
located in EEA1-positive early endosomes after soluble EphrinA1 addition. To 
determine whether internalisation of Eph is required for its downstream 
signalling, further experiments should be conducted. For example, endocytosis 
inhibitors such as Dynasore could be used to determine whether endocytosis of 
Eph is required for Ephrin-induced cell rounding. 
1.2.4 Ephs crosstalk with other membrane proteins 
1.2.4.1 Ephs crosstalk with integrins 
Integrins are cell-surface receptors that contain two subunits (α and β), which 
associate with ECM proteins to mediate cell-matrix adhesion and to induce 
signalling to produce a variety of cellular responses. Numerous studies have 
shown that there is crosstalk between the Eph/Ephrin and integrin signalling 
pathways, and their interaction is proposed to contribute to the coordination of 
cell migration. Two studies have demonstrated a physical association between 
Ephs and integrins: EphA4 with β3-integrin in platelets (Prévost et al., 2005) and 
EphrinAs/EphA2 with α3-integrin in a glioblastoma cell line (Makarov et al., 
2013). Interestingly, internalised α3-integrin co-localises in vesicles with EphA2 
(Makarov et al., 2013). The interaction of these pathways has been shown to 
have an important role in various cellular functions, including platelet activation 
(Prévost et al., 2005), structural organisation of dendritic spines in excitatory 
synapses  (Bourgin et al., 2007), production of ECM (Jülich et al., 2009), and 
angiogenesis (Huynh-Do et al., 2002).  
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Ephs can promote integrin activation and signalling resulting in cell adhesion to 
the ECM. Eph/Ephrin signalling initiates integrin clustering during zebrafish 
somite morphogenesis (Jülich et al., 2009), while in vitro Ephs have been found 
to activate β1-integrin signalling to increase cell adhesion to laminin (Huai and 
Drescher, 2001) and fibronectin (Davy and Robbins, 2000). Many signalling 
proteins activated by Eph have a role in activating integrins including: Src (Davy 
and Robbins, 2000), Paxillin (Vindis et al., 2004), the PI3K subunit—p110γ (Gu 
and Park, 2001), FAK (Carter et al., 2002; Parri et al., 2007), p130Cas (Carter et 
al., 2002) and p120 (Huai and Drescher, 2001). Nevertheless, numerous studies 
have shown that Eph can also inhibit integrin signalling resulting in a less 
adherent phenotype. Overexpression of EphB4 decreases adhesion independently 
of the ligand EphrinB2 (Noren et al., 2009), whilst ligand activated EphB2 
triggers the phosphorylation of R-Ras, which attenuates integrin-mediated 
adhesion (Zou et al., 1999). Moreover, ligand-activated EphA2 may promote the 
inactive conformation of integrins to inhibit cell spreading (Miao et al., 2000). 
Focal adhesion kinase (FAK) associates with both integrins and EphA2. Upon 
Ephrin-A1 stimulation, SHP2 (a tyrosine phosphatase), is recruited to EphA2 and 
de-phosphorylates FAK, thereby inhibiting FAK kinase activity and suppressing 
integrin activity (Miao et al., 2000). Thus Ephs/Ephrins have been shown to both 
activate and deactivate integrins in different studies, perhaps due to differences 
in cell lines and the microenvironment (Section 1.2.7).   
1.2.4.2 Ephs crosstalk with other receptor tyrosine kinases 
RTKs are activated by external growth factors, which stimulate receptor 
dimerization, activation and autophosphorylation, resulting in a variety of 
cellular responses. Crosstalk between Ephs and several RTKs has been identified. 
In glioma cells an association between FGFR1 and EphA4 promotes FGFR1 
signalling, thus increasing cell proliferation and migration (Fukai et al., 2008). 
EGFR and EphA2 can be co-immunoprecipitated and these co-localise in the 
plasma membrane. Indeed, suppression of EphA2 expression inhibits EGFR based 
motility (Larsen et al., 2007; Larsen et al., 2010). EphA2 depletion impairs 
breast cancer initiation and metastasis in models driven by overexpression of 
ErbB2, but not in those driven by polyomavirus middle T-antigen. Furthermore, 
in breast cancer cells ErbB2 was found associated with EphA2 and this enhanced 
RhoA and Ras-MAPK signalling (Brantley-Sieders et al., 2008). RTKs can also 
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crosstalk with Ephrins. Indeed, active FGFR phosphorylates EphrinB1 preventing 
it from signalling during Xenopus development (Lee et al., 2009). Interestingly, 
EphrinB2 promotes VEGFR2/3 internalisation and signalling during angiogenesis 
(Sawamiphak et al., 2010; Wang et al., 2010).  
1.2.4.3 Ephs crosstalk with cadherins 
Many studies demonstrate crosstalk between Ephs and cadherins. Indeed, E-
cadherin increases EphA2 expression, surface localisation and EphrinA1-activated 
signalling (Orsulic and Kemler, 2000; Zantek et al., 1999). Moreover, EphA2 
signalling increases E-cadherin dependent cell adhesion, indicating that the 
crosstalk between these two receptors can be bidirectional (Miura et al., 2009). 
In HT-29 colon cancer cells, EphB2 signalling increases E-cadherin membrane 
localisation and cell-cell adherence. However, if EphB2 is depleted in these 
cells, EphrinB1 induces cell separation and migration; suggesting EphB2 
activation is required for E-cadherin dependent cell-cell adherence (Cortina et 
al., 2007). On the other hand, E-cadherin has an important role in Eph/Ephrin-
driven cell segregation. Upon EphB activation by EphrinB, E-cadherin is cleaved 
by ADAM10, thus adherens junctions do not form between EphB and EphrinB-
expressing MDCK cells (Solanas et al., 2011).  Further work shows that Ephs and 
N-cadherins crosstalk. EphA4 is essential for N-cadherin driven EMT in developing 
zebrafish somites (Barrios et al., 2003) and EphA2 mutations in human cells or 
loss of EphA2 in mice disrupts N-cadherin junctions (Jun et al., 2009). Taken 
together, these studies demonstrate that bidirectional crosstalk between 
cadherins and Ephs may determine whether cells repel or adhere.  
1.2.5 Eph and Ephrin functions 
1.2.5.1 The role of Eph/Ephrin in neuronal patterning 
In neuronal development Ephs and Ephrins are required for correct neuronal 
patterning. They are involved in growth cone guidance, axon branching, and 
dendritic branching. To study axon guidance, in vitro striping assays are used in 
which neural explants are grown next to strips of different substrates. If the 
molecules on the strips are attractive the axons move down the strips, however 
if they are repulsive the axons are repelled from the strips (Yates et al., 2001). 
Using this assay it has been shown that EphrinA5 acts as a growth cone repellent, 
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and EphA signalling in the growth cone is required for this repulsion (Drescher et 
al., 1995) Furthermore, EphA2-rich growth cones are repelled by EphrinA2 
regions (Figure 1.5A) (Hansen et al., 2004). Striping assays are also used to 
monitor axon branching. Axons move into regions of high EphrinA concentration 
but axon branching is inhibited. At lower EphrinA concentration, axon branching 
is promoted (Yates et al., 2001). This demonstrates the importance of 
Ephs/Ephrins in axon branching and guidance. Knockout and knockin mice of 
various Ephs and Ephrins have been used to study topological defects in vivo. 
Indeed, EphA3 was ectopically expressed in a subset of retinal ganglion cells, 
which enhances a repulsive response to Ephrin, causing incorrect positioning of 
axons (Brown et al., 2000). Also, EphrinA2 and EphrinA5 knockout mice contain 
incorrectly targeted axons (Feldheim et al., 2000).  
As well as axon guidance and branching, EphB signalling is involved in 
morphogenesis of dendritic spines (Ethell et al., 2001; Penzes et al., 2003). Upon 
EphrinB activation, EphB signalling recruits proteins required in the dendrites, 
allowing the formation of a synapse (Dalva et al., 2000). Interestingly, EphrinAs 
are expressed on glial cells that surround the synapse. They regulate dendritic 
spine density, which is required for learning (Murai et al., 2003).  
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Figure 1-5 Eph and Ephrin functions 
A. During axon guidance, the growth cone enriched with EphA extends and contacts an EphrinA 
positive cell. Upon Eph and Ephrin engagement, Eph is activated and signals to Src, Rho GTPases 
and β1-integrin, which stimulates rapid growth cone retraction. B. During somatogenesis, cells 
expressing EphA4 are found on the anterior half, whilst cells expressing EphrinB2 are found on the 
posterior half of the embryo. EphA4 and EphrinB2 interactions stimulate epithelisation forming the 
intersomatic furrow. C. Ephs and Ephrins are required for the organisation of the intestinal crypt. 
Paneth cells are found at the base of the crypt and have high EphB3 expression. EphB2 
expression decreases up the crypt, whilst, EphrinB1/2 expression increases. 
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1.2.5.2 The role of Eph/Ephrin in development 
Ephs/Ephrins have an important role in multiple stages of development. EphA1 
and EphrinA1/A3 are expressed during the very early stages of embryogenesis, in 
somatogenesis (Duffy et al., 2006). Indeed, EphA4 is found expressed in the 
anterior region, while EphrinB2-positive cells reside on the posterior half of the 
embryo (Durbin et al., 1998). At the boundary, between EphA4 and EphrinA1/B2 
positive cells, the ligand and receptor interact causing EphA4 and EphrinA1/B2 
positive cells to detach from each other and undergo epithelisation to form the 
intersomatic furrow (Figure 1.5B) (Barrios et al., 2003). However, EphA4 
knockout mice have no defects in somatic segmentation indicating a possible 
redundancy with other Ephs.  
Neural crest cells (NCCs) migrate from the dorsal region of the neural tube to 
populate the embryo and in doing so can differentiate into many cell types. Ephs 
and Ephrins spatially restrict the migration of these cells. EphrinBs are expressed 
in the posterior region of the somite, and this acts as a repulsive cue for the 
EphB expressing neural crest cells (Krull et al., 1997; Wang and Anderson, 1997). 
Neural crest cells that are specified as neurons and glia migrate ventrally, while 
those specified as melanoblasts migrate in the dorsolateral pathway. EphrinBs 
are expressed in the dorsolateral pathway and if this expression is disrupted 
neural crest cells migrate incorrectly along the dorsolateral pathway (Santiago 
and Erickson, 2002). In vitro migration assays demonstrate that melanoblasts 
migrate towards EphrinB1 and express EphBs (Santiago and Erickson, 2002). 
Therefore, EphrinB is acting as an inhibitory migration signal to neuron-specified 
neural crest cells, while promoting the migration of melanoblasts. 
1.2.5.3 The role of Eph/Ephrin in epithelial cell segregation and migration 
As well as a role in developmental cell segregation, Ephs and Ephrins are thought 
to have a role in epithelial cell segregation. C.elegans only express one Eph and 
one Ephrin, and disrupting either of these causes defects in the ventral closure 
of the epidermis (George et al., 1998). In adult tissue, epithelial cell segregation 
is best studied in the context of mammary gland branching-morphogenesis and in 
the generation of the crypt-villus axis. In the mammary gland, EphB4 is 
expressed in myoepithelial cells, while EphrinB2 is expressed in luminal 
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epithelial cells. This expression pattern is regulated by the oestrous cycle 
(Munarini et al., 2002) and its disruption results in carcinogenesis (Nikolova et 
al., 1998). Also, Ephs/Ephrins prevent intermingling of distinct cell populations 
in the intestinal crypt. Paneth cells are found at the base of the crypt and have 
high EphB3 expression. As proliferative cells migrate up the crypt they commit 
to different lineages, such as absorptive and goblet cells (Figure 1.5C). In these 
cells, EphB2 expression decreases with progress up the crypt, while, 
EphrinB1/B2 levels increase. This expression pattern is under the control of Wnt 
(van de Wetering et al., 2002). Disrupting EPHB2 or EPHB3 genes in mice results 
in loss of organisation in the crypt and intermingling of different cell populations 
(Batlle et al., 2002), thus suggesting that Ephs and Ephrins have an important 
role for the cellular organisation of intestinal crypts. 
1.2.5.4 The role of Eph/Ephrin in vasculogenesis  
Ephs and Ephrins have an important role in the development and maintenance of 
blood vessels. In mouse embryos EphB4 is expressed on primordial veins (Gerety 
et al., 1999), while EphrinB2 is expressed on primordial arteries. (Wang et al., 
1998) Indeed, null mutations in either EphB4 or EphrinB2 cause embryonic 
lethality. Other Ephs and Ephrins are co-expressed on arteries and veins leading 
to complex patterning. Ephs and Ephrins are also involved in angiogenesis, which 
is best studied during tumourigenesis (Section 1.2.6.3). 
1.2.6 The role of Ephs and Ephrins in cancer  
1.2.6.1 Misregulation of Eph and Ephrin expression 
Eph and Ephrin expression are frequently misregulated in cancer for a number of 
different reasons, including chromosomal addition or loss, epigenetics, 
alterations in mRNA stability and transcriptional changes (Arvanitis and Davy, 
2012). Some Ephs are upregulated, while others are downregulated. For 
example, EphA2 is frequently upregulated and linked to poor prognosis in breast 
cancer (Wykosky et al., 2008), while EphA1 is downregulated in skin and 
colorectal cancers (Hafner et al., 2006; Herath et al., 2009). Indeed, in some 
cancers, inverse expression is seen for Ephs and Ephrins, for example in breast 
cancer cell lines EphA2 is often upregulated, while EphrinA1 is downregulated 
(Macrae et al., 2005). Most interestingly, in colorectal cancer, some EphBs are 
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initially overexpressed in tumourigenesis, but later repressed by 
hypermethylation (Herath and Boyd, 2010). It is rare that more than one Eph is 
significantly overexpressed in a tumour, suggesting altered expression of one Eph 
is sufficient for tumour cell evolution. Interestingly, the expression of Ephs and 
Ephrins on neighbouring cells may influence tumourigenesis. Indeed, EphrinA1 
expression is upregulated in endothelial cells by VEGF, TNF or HIF2a that is 
secreted by cancer cells, thereby regulating tumour neovascularisation (Pandey 
et al., 1995; Yamashita et al., 2008). 
1.2.6.2 Eph mutations 
There is emerging evidence that Ephs are frequently mutated in cancer. EPHB2 
mutations have been identified in prostate, melanoma and colorectal cancer, 
(Alazzouzi et al., 2005; Pia et al., 2004; Prickett et al., 2009), while EPHA3 and 
EPHA5 are mutated in lung cancer (Davies et al., 2005a; Ding et al., 2008). 
These mutations are found throughout the protein and the effects of these 
mutations are largely unknown. EphA3 mutations are the best studied and many 
lead to loss of function (Lisabeth et al., 2012; Zhuang et al., 2012). EphA2 is less 
frequently mutated. Nevertheless, a mutation is found in its FN type 3 repeat in 
lung cancer that promotes cell invasiveness (Faoro et al., 2010). Interestingly, in 
human tumour samples multiple Ephs are mutated at once (Lisabeth et al., 
2012). It would be interesting to thoroughly study these mutations and the 
consequences they have in tumourigenesis and metastasis. 
1.2.6.3 The role of Ephs in tumourigenesis and metastasis 
The role of Ephs and Ephrins in cancer is clearly not straightforward. They can 
act as both oncogenes and tumour suppressors, and are likely to have multiple 
functions in tumourigenesis and metastasis. In this section I will focus of EphA2 
to outline the main functions of Ephs in cancer. 
Stem cells                 
Cancer stem cells are self-renewing and thought to drive tumourigenesis, 
although the existence of such cells remains controversial. EphA2 is found 
overexpressed in glioblastoma stem cells and its expression correlates with 
tumour initiating properties (Binda et al., 2012). Indeed, suppressing EphA2 
expression prevents stem cell renewal (Binda et al., 2012). Furthermore, in lung 
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cancer EphA2 expression correlates with the expression of stem cell markers 
such as ALDH (Song et al., 2014). Indeed, suppressing EphA2 expression in these 
cells inhibits the formation of spheroids in vitro (Song et al., 2014). EphA3 is also 
expressed in undifferentiated cancer cells (Day et al., 2013). The role of Ephs in 
cancer stem cells requires more thorough investigation. 
Tumour angiogenesis          
Tumours contain many blood vessels, which are required for supplying the 
cancer cells with nutrition and providing a route for metastasis. The involvement 
of Ephs and Ephrins in angiogenic sprouting is well studied. EphA2 is expressed in 
angiogenic sprouting cells, but is not detected in embryonic or adult endothelial 
cells. Nevertheless, EphA2 deficient mice have vessels with defective pericyte 
coverage (Okazaki et al., 2009). Ephrins expressed on cells adjacent to 
endothelial cells can promote repulsive signals that stimulate migration of the 
endothelial cells, which form sprouts. Indeed, EphrinA1-expressing tumour cells 
contain EphA2-expressing endothelial cells. Disruption of EphA2 prevents 
endothelial cells from assembling into vascular structures in response to pro-
angiogenic EphrinA1 (Brantley-Sieders et al., 2004). Interestingly, when cancer 
cells were implanted subcutaneously into EphA2-deficient mice, angiogenesis 
was inhibited, thus suggesting that EphA2 expression in the endothelial cells, 
and not the cancer cells, is important for tumour angiogenesis (Brantley-Sieders 
et al., 2005). Furthermore, Ephs and Ephrins are required for maximal VEGF 
functions. VEGF increases EphrinA1 expression, which interacts with EphA2 and 
is required for endothelial cell migration and sprouting. Treatment with soluble 
EphA2 decreases neovascularisation by preventing endothelial cell migration 
(Cheng et al., 2002). EphBs/EphrinBs are also important for tumour 
angiogenesis. EphrinB2 is highly expressed on angiogenic vessels (Adams et al., 
2001) and its reverse-signalling to Src is required for angiogenesis (Palmer et al., 
2002). Indeed, in tumour angiogenesis EphrinB2 promotes sprouting in response 
to VEGF by inducing VEGFR internalisation and signalling (Sawamiphak et al., 
2010; Wang et al., 2010).   
Epithelial-mesenchymal transition         
During carcinoma tumourigenesis, the cancer cells often change from an 
epithelial-type to a mesenchymal-type phenotype in a process that is termed 
epithelial-mesenchymal transition (EMT). During this process, cancer cells lose 
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epithelial polarity and E-cadherin junctions, and become more migratory. In 
gastric cancer, overexpression of EphA2 correlates with a more mesenchymal-
type phenotype (Hou et al., 2012). Indeed, EphA2 can activate EMT signal 
transduction pathways (Hou et al., 2012). Furthermore, overexpression of EphA2 
upregulates mesenchymal markers, such as N-cadherin and Snail, and 
downregulates epithelial markers, such as E-cadherin (Huang et al., 2014). Other 
Ephs have been linked to EMT, for example, EphB2 expression in cervical cancer 
cells promotes EMT (Gao et al., 2014). EMT and a migratory and invasive 
phenotype are closely linked; the latter will be examined next. 
Cancer cell invasion and metastasis            
Ephs have a conflicting role in invasion and metastasis, and opposing results are 
often reported. Normally, EphA2 overexpression correlates with increased 
metastasis, for example, in oesophageal squamous cell carcinoma high EphA2 
expression correlates with lymph node metastasis (Miyazaki et al., 2003). 
Furthermore, in vitro work demonstrates that EphA2 overexpression increases 
cell invasion into Matrigel (Chen et al., 2014). Perhaps EphA2 is best studied in 
breast cancer, in which it is highly overexpressed and its levels correlate with 
poor prognosis (Brantley-Sieders et al., 2008). EphA2 drives metastasis via its 
association with ErbB2 and by forward signalling to Akt, Src and Rho GTPases. 
Indeed, in breast cancer EphA2 clusters with ErbB2, which enhances Ras and Rho 
signalling and drives cell migration (Brantley-Sieders et al., 2008).  
In colorectal cancer EphA2 is overexpressed in the early stages of tumourigenesis 
but is lost as the tumour metastasises (Kataoka et al., 2004). Conversely, in 
melanoma distant metastases express much higher levels of EphA2 than the 
primary tumour (Easty et al., 1995). Interestingly, EphA2 is overexpressed in 
pancreatic cancer and expressed in lymph node, but not liver, metastases 
(Mudali et al., 2006). Together this suggests that EphA2 expression may vary 
during tumourigenesis and may be involved in targeting cancer cells to particular 
sites for metastases. Interestingly, it is not only tumour cells that have a role in 
metastasis but also the cells that the tumour cells come into contact with, such 
as stromal and endothelial cells. There is emerging evidence that tumour cells 
interact with stromal cells via Ephs and Ephrins (Astin et al., 2010). These 
interactions may determine whether cancer cells invade into their local 
environment via contact inhibition of locomotion (Section 4.1.1). Interestingly, 
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immunohistochemistry of human prostate cancer demonstrates that EphB4 is 
highly expressed in prostate cancer cells, while EphrinB2 is highly expressed in 
endothelial and smooth muscle cells (Astin et al., 2010). Further work is 
required to mechanistically understand the role of Ephs and Ephrins in 
metastasis. 
1.3 Receptor trafficking in cancer  
The endocytic trafficking pathway is composed of several distinct intracellular 
membrane compartments. Transmembrane proteins are internalised into vesicles 
via different mechanisms, including micropinocytosis, clathrin-mediated 
endocytosis or calveolar-mediated endocytosis. These proteins are transported 
to early endosomes and then sorted into recycling or degradation pathways 
(Figure 1.6). Recycled proteins can either be returned directly from early 
endosomes to the plasma membrane or indirectly via the peri-nuclear recycling 
compartment.  Proteins targeted for degradation are transported through late 
endosomes into lysosomes, which are enriched with lysosomal hydrolases. 
Althernatively, proteins are delivered to multivesicular bodies that contain small 
vesicles in their lumen, enriched with ubiquitylated transmembrane proteins, 
which are either degraded (by fusion with lysosomes) or secreted in small 
vesicles called exosomes. Many proteins have been found to localise in distinct 
compartments along the endocytic pathway. Most interestingly, each 
compartment contains different members of the family of Rab-GTPases (Figure 
1.6) (Zerial and McBride, 2001). Indeed, different Rab-GTPases can occupy 
different regions of the same compartment, for example, Rab4, Rab11 and Rab5 
are found at distinct locations on the same early endosome (Sonnichsen et al., 
2000), whilst Rab7 and Rab9 occupy distinct microdomains on late endosomes 
(Barbero et al., 2002). Perhaps, the pressence of multlpe Rabs on the same 
compartment may allow differential sorting of proteins internalised into the 
same compartment. 
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Figure 1-6 Intracellular localisation of RabGTPases 
Membrane-bound proteins are synthesised in the ER (endoplasmic reticulum), trafficked through 
the Golgi apparatus and transported to the appropriate subcellular compartment. Internalised 
proteins are transported to the EE (early endosomes) where they are sorted for direct recycling, 
indirect recycling through the PNRC (peri-nuclear recycling compartment), or targeted for 
degradation via LE (late endosomes), the MVB (multi-vesicular body) and lysosomes. The 
localisation of key Rab-GTPases is indicated.  
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1.3.1 Rab GTPases 
The human Rab GTPase family of proteins has over 60 members (Zerial and 
McBride, 2001). The best characterised role of Rab GTPases is in vesicular 
trafficking, including endocytosis and exocytosis, which requires the dynamic 
coupling of Rab proteins with vesicles to accurately deliver vesicular cargo to 
their appropriate destination (Figure 1.6). These monomeric GTPases act as 
molecular switches, which cycle between an active GTP-bound and inactive 
GDP-bound state (Figure 1.7). Key proteins involved in regulating this cycle 
include: guanine nucleotide exchange factors (GEF) which trigger GTP binding 
and GTP activating proteins (GAP) which increase hydrolysis of bound GTP. 
Disruption of this cycle often alters the subcellular localisation of the Rab-
GTPases and the morphology of the compartment, for example mutant GTP-
locked Rab5 enlarges early endosomes, whilst the GDP-locked mutant has the 
opposite effect (Stenmark et al., 1994). More recently, Rab-GEFs have been 
shown to have a role in targeting Rab-GTPases to their appropriate membrane 
(Blumer et al., 2013; Gerondopoulos et al., 2012). Rab-GDP dissociation 
inhibitors (GDI) can also relocate Rab-GTPases to different compartments, by 
associating with GDP-bound Rab proteins, and are capable of retrieving the Rab 
from intracellar membranes (Ullrich et al., 1993). 
Rab effectors bind specifically to GTP-bound Rabs and have diverse roles in 
membrane trafficking (Grosshans et al., 2006). Some Rab effectors interact with 
components of the actin or microtubule cytoskeleton, such as Rabkinesin 6, a 
Rab6 effector, which acts as a microtubule motor aiding vesicular mobility 
during cytokinesis (Echard et al., 1998). Other effectors have been implicated in 
the tethering of vesicles and in membrane fusion such as the Rab5 effector, 
EEA1 (Christoforidis et al., 1999). The Rab GTPase cycle allows temporal and 
spatial association with various effectors, which regulate membrane trafficking 
by controlling vesicle budding, tethering, motility or fusion (Pfeffer and 
Aivazian, 2004). Several Rab-GTPases are investigated in this thesis, including 
Rab14 (Section 3.2.2.1), Rab6 (Section 3.2.3.1) and Rab11 (Section 1.32). 
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Figure 1-7 Rab-GTPase switch 
Rab GEFs (guanine nucleotide exchange factors) trigger GTP binding to the Rab, which activates it 
and allows it to associate with effector proteins. Rab GAPs (GTPase activating proteins) hydrolyse 
the GTP into GDP, which dissociates the Rab effectors from the Rab. GDIs (GDP dissociation 
inhibitors) are found in the cytoplasm and can associate with GDP-bound Rabs. 
 
1.3.2 The Rab11 family of GTPases 
Rab11 has three isoforms, Rab11A, Rab11B and Rab11C/Rab25, which have a role 
in various trafficking pathways, including the secretory pathway (Golgi to plasma 
membrane) (Jung et al., 2012), receptor recycling via the peri-nuclear recycling 
compartment (Caswell et al., 2008) and transcytosis in epithelial cells (Casanova 
et al., 1999). These Rab11 pathways are important for cell migration, 
cytokinesis, cilogenesis, oogenesis and neuritegenesis (Welz et al., 2014). Rab11 
is of particular interest as it has been reported to act as both an oncogene and a 
tumour suppressor protein (Section 1.3.6), and has been shown to regulate the 
trafficking of integrins and RTKs during cancer cell migration (Caswell et al., 
2008; Caswell et al., 2007).  
Several Rab11 GAPs have been identified, including TBC1D11, TBC1D14 and Evi5. 
Indeed, GTP-bound Rab11 recruits Evi5 to the recycling endosome and Evi5 
knockdown blocks receptor recycling and cell migration (Laflamme et al., 2012). 
In contrast to the GAPs, few Rab11 GEF has been identified including Crag1, 
which has an important role in regulating rhodopsin recycling in Drosophila 
(Xiong et al., 2012). Rab11 has been shown to associate with several motor 
proteins, such as Myosin Vb, allowing the transportation of Rab11-positive 
vesicles along the cytoskeleton (Lapierre et al., 2001).  
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1.3.3 Rab11-Fips 
A number of Rab11 effectors have been identified, including Rabphilin-11 
(Mammoto et al., 1999) and the Rab11-Fips (Rab11-family of interacting 
proteins) (Hales et al., 2001). Rab11-Fips have a conserved Rab binding domain 
(RBD) at their C-terminus, which contains a YID (tyrosine-isoleucine-aspartic 
acid) motif. Mutating these residues significantly reduces the ability of Rab11-
Fips to interact with Rab11a (Lindsay and McCaffrey, 2004). Interestingly, the 
structure of the RBD from Fip2 bound to Rab11-GTP has been solved, and found 
to form a heterotetramer with a central dimer of Fip2-RBD forming an 
amphipathic alpha helix embedded between two Rab11 molecules (Jagoe et al., 
2006).  
The Rab11-Fip family contains five members, which can be divided into two sub-
classes, class I and class II (Figure 1.8). Class I Rab11-Fips include Rab Coupling 
Protein (RCP/Fip1), Fip2 and Rip11/Fip5, which have a conserved C2 domain at 
the N-terminus that interacts with phospholipids (Lindsay and McCaffrey, 2004). 
All three Class I Rab11-Fips localise to the perinuclear recycling compartment 
(PNRC), although a recent paper demonstrates that they localise in distinct 
regions within this compartment (Baetz and Goldenring, 2013). Class I Rab11-
Fips regulate receptor recycling, for example, Rab11-Fip2 is involved in 
returning internalised transferrin receptor to the plasma membrane (Fan et al., 
2004). Furthermore, Fip2 has been shown to associate with EHD proteins, which 
control the exit of internalised proteins (Naslavsky et al., 2006) and with 
Myosin5b, which regulates the movement of vesicles (Schafer et al., 2014).  
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Figure 1-8 Schematic representation of the Rab11-Fips 
Rab11-Fips are split into 2 classes: class I Rab11-Fips contain a C2 domain and include RCP, Fip2 
and Rip11, and class II Rab11-Fip2 contain an EF hand and include Fip3 and Fip4. (RBD: Rab 
binding domain, C-C: coiled-coiled domains, EF: EF hand, PRR: proline rich region) 
 
 
There are two members of the class II Rab11-Fips, Fip3 and Fip4, which contain 
a proline-rich region and an ERM (erzin/radixin/moesin) domain. Some members 
of this family have been shown to interact with the Arf (ADP ribosylation factor) 
subfamily of GTPases as well as Rab11, for example Fip3 associates with both 
Rab11 and Arf6 (Shiba et al., 2006). Both Fip3 and Fip4 are thought to have a 
role in delivering membrane from recycling endosomes to the cleavage furrow, 
and are required for cytokinesis (Fielding et al., 2005). Interestingly, more 
recently Fip3 has been reported to have a role in the development of dendritic 
spines in neurons (Yazaki et al., 2014) and is required for breast cancer cell 
(MDA-MB231) motility in the control of Rac1 activity (Jing et al., 2009). 
1.3.3.1 RCP 
RCP was named as it was initially thought to interact with both Rab4 and Rab11 
and thus potentially couple the two GTPases (Lindsay et al., 2002). However, a 
subsequent study only detected a weak interaction between RCP and Rab4 in 
vitro and no interaction in vivo, indicating that RCP does not act as a Rab4 
effector, at least in this cell type (Peden et al., 2004). The gene that encodes 
for RCP is alternatively spliced producing eight different gene transcripts that 
are differentially expressed in various cell types (Jin and Goldenring, 2006). 
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Indeed, some variants lack the RBD so may not be involved in Rab11 functions 
(Jin and Goldenring, 2006). The exact role of these transcripts remains elusive. 
At least one of the RCP gene transcript products is involved in trafficking from 
the PNRC to the plasma membrane, Rab11-Fip1c, which is the most abundant. 
This isoform is the one commonly referred to as RCP and has been shown to 
regulate transferrin trafficking (Peden et al., 2004) and in macrophages is 
thought to regulate recycling from phagosomes (Damiani et al., 2004). More 
recent work demonstrates the involvement of RCP in EGFR and α5β1-integrin 
trafficking, which has an important role in cancer cell migration (Caswell et al., 
2008).  
1.3.4 Integrin trafficking 
Integrin trafficking is complex and has been well studied. Integrin heterodimers 
are internalised via various pathways, including: clathrin-dependent, clathrin-
independent and caveolar mechanisms (Caswell and Norman, 2006). Rab21 is 
known to contribute to the internalisation of the heterodimers and it associates 
with the cytoplasmic tail of integrin α-subunits in early endosomes (Pellinen et 
al., 2006). Once they have reached the early endosomes, internalised integrins 
can be sorted three ways: into vesicles to the plasma membrane, recycling 
endosomes or late endosomes (Figure 1.9). αvβ3-integrin is trafficked directly 
from the early endosomes back to the plasma membrane in the rapid route 
under control of Rab4 (Parker et al., 2004). αvβ3-integrin recycling via this 
pathway is promoted by growth factor induced autophosphorylation of PKD1, 
which enables the recruitment of this kinase to the β3 cytoplasmic tail (Roberts 
et al., 2004). Indeed, mutating the Serine916 autophosphorylation site on PKD1 
inhibits recycling of αvβ3-integrin (White et al., 2007).  
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Figure 1-9 Rab GTPase control of integrin trafficking 
Integrins are internalised into early endosomes (EE) via several mechanisms, which can be 
regulated by Rab21. In early endosomes, integrins can be recycled straight back to the plasma 
membrane in Rab4 positive vesicles or via the perinuclear recycling compartment (PNRC) in 
RCP/Rab11 positive vesicles. Alternatively, integrin can be trafficking to the late endosome (LE) in 
which they are either: recycled back the plasma membrane in a Rab25 dependent fashion, are 
secreted in exosomes via the multivesicular body (MVB) or are ubiquitylated and targeted for 
lysosomal degradation. 
 
In contrast, many different integrin heterodimers are sorted from early 
endosomes into recycling endosomes before returning to the plasma membrane 
via the Rab11-dependent route (Figure 1.9). For example, α5β1 (Roberts et al., 
2001), αvβ3  (Roberts et al., 2001), αLβ2, α6β1 (Strachan and Condic, 2004) and 
α6β4 (Yoon et al., 2005) are recycled this way. Numerous pro-migratory kinases 
are thought to have a regulatory role in this recycling pathway; 
PKCε phosphorylates vimentin (Ivaska et al., 2005) to release β1 integrin vesicles 
from the PNRC, and PKB/Akt phosphorylates GSK-3 (Roberts et al., 2004) and 
ACAP1 (Li et al., 2007) to stimulate β1 delivery from the PNRC to the plasma 
membrane. Furthermore, RCP regulates α5β1-integrin and EGFR delivery to the 
plasma membrane. Upon mutant-p53 overexpression or inhibition of αvβ3-
integrin, RCP’s association with α5β1-integrin and EGFR is enhanced and drives 
recycling of α5β1 to the plasma membrane, which drives cancer cell invasion 
(Section 3.1) (Caswell et al., 2008).  
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Lastly, integrins can be transported from early endosomes into late endosomes 
(Figure 1.9). Indeed, immunogold staining demonstrates that α5β1-integrin 
localises to late endosomes (Lobert et al., 2010). Furthermore, in ovarian cancer 
cells α5β1-integrin has to be bound to its ligand, fibronectin, for it to reach the 
Rab25-positive late endosomes (Dozynkiewicz et al., 2012). Ubiquitylation sites 
have been identified on both integrin subunits, which can target α5β1-integrin 
for lysosomal degradation (Böttcher et al., 2012; Lobert et al., 2010). 
Alternatively, α5β1-integrin can be recycled back to the plasma membrane from 
late endosomes in a Rab25 and CLIC3 dependent fashion (Demory Beckler et al., 
2013; Dozynkiewicz et al., 2012). Lastly, late endosomes can mature into multi-
vesicular bodies (MVB) with integrins localised in the intraluminal vesicles, which 
can be secreted from the cell as exosomes (Vesiclepedia - 
http://microvesicles.org).  
1.3.5 Trafficking of Receptor Tyrosine Kinases  
The traditional view of RTK trafficking is that the ligand binds the receptor, the 
receptor auto-phosphorylates and activates downstream signalling pathways, 
meanwhile the receptor is ubiquitylated, internalised and degraded. However, 
recent reports suggest this situation is more complex and that RTKs can be 
recycled. For example, EGFR is internalised and recycled with α5β1-integrin via 
the RCP/Rab11 compartment and this is enhanced in cells expressing mutant-p53 
(p53175H or p53273H) (Caswell et al., 2008). Furthermore, it has been shown that 
EGFR internalises via clathrin-independent routes resulting in its degradation, 
and via clathrin-dependent routes resulting in its recycling and prolonged 
signalling (Sigismund et al., 2008). 
cMet is the receptor for HGF and diverges structurally from most RTKs as it is a 
heterodimer linked by a disulphide bond with an extracellular α-subunit and a 
transmembrane β-subunit, which contains an intracellular tyrosine kinase 
domain (Giordano et al., 1989). Upon HGF stimulation, cMet undergoes rapid 
internalisation (Figure 1.10). The E3 ubiquitin ligase, Cbl, can ubiquitylate 
cMet, which internalises and targets the receptor for lysosomal degradation 
(Petrelli et al., 2002). Nevertheless, it has been shown that internalisation and 
sorting into signalling endosomes is important for cMet signalling. Indeed, this is 
essential for downstream Erk1/2 signalling, which is dependent on microtubules 
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and PKCα (Kermorgant et al., 2004). There is emerging evidence that cMet is 
also recycled (Figure 1.10). Indeed, it has been shown that cMet is recycled 
through a Rab4 endosome, which is regulated by Arf6, and is required for Erk1/2 
signalling (Parachoniak et al., 2011). In cancer cells, mutations have been found 
in cMet that promote recycling and downstream signalling to Rac1 and increase 
tumourigenesis and metastasis in vivo (Joffre et al., 2011). Furthermore, tumour 
cells that express mutant-p53 have increased c-Met recycling, which is required 
for mutant-p53 driven cell scatter and invasion (Muller et al., 2013). These 
studies demonstrate that perturbed RTK trafficking can influence tumourigenesis 
and metastasis. 
 
 
 
Figure 1-10 cMet trafficking 
cMet is rapidly internalised upon ligand activation into EE (early endosomes), which can activate 
Erk signalling. cMet can be recycled back to the plasma membrane via Rab4 vesicles, while in 
cancer cells mutant-p53 can promote RCP dependent recycling of cMet. Alternatively, Cbl can 
ubiquitylate cMet targeting it for lysosomal degradation. 
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1.3.6 Eph Trafficking 
1.3.6.1 Eph and Ephrin detachment 
As Eph is normally associated with its cognate ligand on a neighbouring cell, it 
can only be internalised once the ligand is cleaved by proteolysis or the Ephrin 
can be internalised with the receptor via trans-endocytosis. Ephs and Ephrins 
can be proteolytically cleaved by ADAM metalloproteases, γ-secretase proteases 
and MT1-MMP. ADAM10 is a membrane protein that acts as a sheddase and can 
cleave many membrane proteins. The ADAM10 cleavage site sequence is 
conserved in all vertebrate Ephrins. ADAM10 is found loosely associated to EphA3 
(Janes et al., 2005). EphrinA2 binding stimulates autophosphorylation of the 
juxtamembrane region of EphA3 causing a structural rearrangement (Janes et 
al., 2009), which positions the proteinase domain of ADAM10 onto EphrinA2, 
stimulating its cleavage (Figure 1.11A). Two other members of the ADAM 
protease family are thought to cleave Ephrins: Kuzbanian cleaves EphrinA2, 
which is required for axon withdrawal (Hattori et al., 2000), and ADAM12 cleaves 
EphrinA1 (Ieguchi et al., 2014). EphrinAs are GPI-anchored proteins so cleavage 
generates an extracellular protein, which can be internalised with the Eph on a 
neighbouring cell or that can be released to act in a paracrine fashion. Indeed, 
GFP-EphrinA2 has been shown to be locally dispersed from cells after 
detachment from their neighbours (Hattori et al., 2000). Secreted EphrinA1 has 
been shown to disrupt EphA1/EphrinA1 associations on neighbouring cells, 
causing lung hyperpermeability and promoting the spread of cancer cells 
(Ieguchi et al., 2014). In contrast, EphrinBs are transmembrane proteins that are 
cleaved in the extracellular domain leaving a truncated form of activated 
EphrinB in the plasma membrane. It has been shown that γ-secretase cleaves 
EphrinBs a second time, after the cleavage by a metalloprotease, and the 
remaining truncated protein activates Src reverse-signalling (Georgakopoulos et 
al., 2006; Tomita et al., 2006).  
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Figure 1-11 Eph and Ephrin detachment 
A. ADAM proteases can associate with EphA/EphrinA complexes and cleave Ephrin. The Eph can 
then internalise and the Ephrin is released, stimulating cell-cell repulsion. B. MT1-MMP proteases 
can associate with EphA/EphrinA complexes and cleave EphA in its FN type 3 repeat. The 
transmembrane EphA product is internalised and activates Src kinases and Rho GTPases, which 
promote cell-cell repulsion. C. EphB/EphrinB can internalise, while associated, by transendocytosis 
forming a double membrane vesicular structure, which stimulates cell-cell repulsion. 
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There is some evidence that Ephs can be cleaved in a similar fashion to Ephrins. 
EphA4 is cleaved by γ-secretase (Inoue et al., 2009) and EphA2 is cleaved in its 
fibronectin type 3 repeats by MT1-MMP (Sugiyama et al., 2013). MT1-MMP 
cleavage of EphA2 triggers internalisation of the membrane bound cleaved 
product, which activates Src and RhoA in a vesicular compartment (Figure 
1.11B) (Sugiyama et al., 2013). These studies demonstrate that proteolytic 
cleavage of Ephs/Ephrins may be an important step in cell-cell repulsion. 
Ephs and Ephrins are internalised together into one of the cells in a double-
membrane vesicle. This poorly understood mechanism is termed trans-
endocytosis and has only been reported to occur with the B subgroup of Ephs and 
Ephrins (Figure 1.11C). Marston et al. showed in both fibroblasts and primary 
endothelial cells that EphrinB4 associates with EphB2 and they internalise 
together into EphB2-positive cells. The double-membrane vesicles contains 
phosphorylated EphB2 that remains bound to EphrinB4 and is therefore capable 
of signalling (Marston et al., 2003). In primary neurons EphB2 and EphrinB1 were 
found to trans-endocytose into either cell; this was required for efficient growth 
cone retraction (Zimmer et al., 2003). Furthermore, double membrane vesicles 
were observed by electron microscopy in vivo in the rat hippocampus (Spacek 
and Harris, 2004). 
1.3.6.2 Eph internalisation 
Ephs are endocytosed via clathrin-dependent and independent mechanisms. 
Purified clathrin-positive vesicles are enriched in EphA4 (Bouvier et al., 2010) 
and EphA8 co-localises with clathrin heavy chain in HEK293 cells (Yoo et al., 
2010). EphA2 and EphB1 colocalise with caveolin1 and, upon ligand stimulation, 
these Ephs physically associate with caveolin1 (Vihanto et al., 2006). Several 
studies have demonstrated that internalised Ephs co-localise with early 
endosome antigen (EEA1) (Figure 1.12) (Parker et al., 2004; Yoo et al., 2010). 
EphrinBs internalise via Clathrin dependent mechanisms (Parker et al., 2004) and 
in raft microdomains (Brückner et al., 1999).  
Several proteins have been identified as positive or negative regulators of Eph 
endocytosis. Two proteins have been found that promote Eph endocytosis: Rin1 
and Vav2. Rin1 is a Rab5-GEF that promotes EphA4 endocytosis into Rab5-
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positive vesicles in postnatal amygdala neurons, which is thought to have an 
important role in synaptic plasticity (Deininger et al., 2008). Vav2 is a Rho-GEF 
that is transiently activated upon EphinA1 stimulation. Vav2 depletion inhibits 
EphA4 internalisation resulting in defects in growth cone repulsion (Cowan et 
al., 2005). Also, two proteins have been found that negatively regulate Eph 
internalisation: Tiam1 and SHIP2 (Src homology 2 domain-containing 
phosphoinositide 5-phosphatase 2). SHIP2 is recruited to the SAM domain of 
EphA2 upon ligand stimulation, and this is thought to attenuate EphA2 receptor 
endocytosis (Zhuang et al., 2007). Tiam1 is a Rac-GEF that associates with the 
juxtamembrane region of EphA8. Suppression of Tiam1 expression inhibits the 
internalisation of EphA8 (Yoo et al., 2010). More work is required to determine 
whether these proteins have a role of regulating Eph endocytosis in cancer cells. 
1.3.6.3 Eph degradation 
Ligand activated Ephs are ubiquitylated and targeted for lysosomal degradation 
(Figure 1.12). Cbl is an E3 ubiquitin ligase, which associates and ubiquitylates 
both EphA2 and EphB1 (Fasen et al., 2008; Wang et al., 2002). Blocking 
lysosomal degradation with lysosomotropic agents such as bafilomycin, inhibits 
EphB1 degradation upon stimulation with EphrinB1 (Fasen et al., 2008). Eph 
degradation is thought to be a control mechanism to terminate Eph signalling. 
For example, an Ank family protein, Odin, is found associated with the SAM 
domain of EphA2 and EphA8, which protects these proteins from being 
ubiquitylated (Kim et al., 2010). In contrast to Ephs, EphrinBs have been shown 
to be ubiquitylated by Smurf E3 ligases, which regulates EphrinB degradation 
(Hwang et al., 2013). 
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Figure 1-12 Eph trafficking 
Upon Ephrin binding, Ephs are internalised into a Rab5 and EEA1 positive early endosome (EE). In 
early endosomes Ephs can activate Tiam1, which activates cell-cell repulsion. Ephs colocalises 
with Rab4 and Rab11 in vesicles and are recycled back to the plasma membrane. Ephs can be 
ubiquitylated by Cbl at the plasma membrane, which targets them for lysosomal degradation. 
 
1.3.6.4 Eph recycling 
Only one study has been published on Eph recycling. Upon EphrinA2 stimulation 
40% of EphA2 is internalised and 30% of this internalised protein is recycled back 
to the plasma membrane (Boissier et al., 2013). At early time points after 
EphrinA1 stimulation, EphA2 co-localises with Rab4 and at later times with 
Rab11 (Figure 1.12). EphA2 remains ligand-associated and phosphorylated in 
vesicles where it associates with Tiam1 (a cytosolic Rho-GEF), while EphA2 
remaining at the cell surface did not associate with Tiam1 (Boissier et al., 2013). 
Suppression of Tiam1 expression with siRNA inhibited EphA2 internalisation and 
EphrinA1-induced Rac1 activation, which triggered cell-cell repulsion. This 
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demonstrates the potential impact of EphA2 trafficking on its downstream 
signalling (Boissier et al., 2013).  
1.3.6.5 Ephs and Ephrins regulate the trafficking of other growth factor 
receptors  
Ephs/Ephrins have an important role in regulating the internalisation and 
signalling of other growth factor receptors and vice versa. This has been shown 
in several biological settings, for example EphB2 activation stimulates 
phosphorylation of synaptojanin-1, a phosphatase, which is important for 
clathrin-mediated endocytosis. Thus, upon EphrinB2 stimulation EphB2 activation 
promotes internalisation of TfnR in HEK 293 cells and AMPA in hippocampal 
neurons (Irie et al., 2005). In vascular smooth muscle cells depletion of Ephrin-
B2 redistributes PDGFRβ from caveolin to clathrin associated membrane 
fractions, which enhances PDGFRβ internalisation and activates MAPK and JNK 
signalling, while impairing TIAM1-Rac1 signalling (Irie et al., 2005). EphrinB2 also 
regulates endothelial sprouting by controlling VEGRF2 or VEGFR3 internalisation, 
which regulates downstream signalling to Rac1, Akt and Src (Sawamiphak et al., 
2010; Wang et al., 2010). Indeed, suppressing EphrinB2 expression impairs 
tumour vascularisation and growth (Sawamiphak et al., 2010). In glioma cell 
lines EphrinA5 enhances Cbl binding to EGFR and promotes its internalisation and 
degradation (Li et al., 2009).   
1.3.7 Receptor trafficking in cancer 
Receptor trafficking is often perturbed in cancer, which often increases RTK 
signalling and promotes tumourigenesis and metastasis. For example, mutations 
in cMet promote recycling and prolonged signalling, while inhibiting degradation, 
which increases tumourigenesis and metastasis in vivo (Joffre et al., 2011). 
Altered expression of several Rab GTPases, such as Rab5, Rab20, Rab23, Rab25 
and Rab34, has been identified in tumours (Chia and Tang, 2009). Rab25 is the 
most studied Rab in cancer and has an interesting and complex role. Its mRNA 
levels are significantly increased in 89% of ovarian cancers (Schaner et al., 2003) 
and in 67% of breast cancers (Sorlie et al., 2003) and patients with high Rab25 
expression have a poor rate of survival (Cheng et al., 2005). Overexpression and 
siRNA studies demonstrate that Rab25 accelerates the growth and aggressiveness 
of breast and ovarian tumours via a mechanism that is likely to involve the 
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activation of PKB/Akt signalling (Cheng et al., 2005; Wei et al., 2001). Rab25 
directly associates with the cytoplasmic tail of β1-integrin. Overexpression of 
Rab25 increases α5β1-integrin recycling from late endosomes, which increases 
cell invasion into fibronectin-rich 3D matrices (Caswell et al., 2007; 
Dozynkiewicz et al., 2012). Conversely, Rab25 also has tumour suppressor 
functions. In some breast cancer cells, Rab25 expression is lost (Cheng et al., 
2006) and re-expressing Rab25 reduces tumour growth and invasion in vivo 
(Cheng et al., 2010). Furthermore, Rab25 expression is lost in colonic neoplasms 
and colonic adenocarcinomas, which is associated with poor survival (Goldenring 
and Nam, 2011). More work is required to determine how other Rab GTPases 
contribute to carcinogenesis.   
Not many studies have investigated the role of Rab effectors in tumourigenesis. 
However, it has been reported that the RCP gene is amplified breast tumour 
cases (Garcia et al., 2005), small lung carcinomas (Balsara et al., 1997), 
colorectal cancers (Nakao et al., 2004) and urinary bladder tumours (Simon et 
al., 2001). As RCP expression is frequently misregulated in cancer (Section 
3.1.1), it is an interesting and relevant protein to study to gain a better 
molecular understanding of its role in cancer. 
1.4 Aims and preamble to results 
RCP clearly contributes to cancer cell invasion by controlling the trafficking of 
adhesion receptors, such as α5β1-integrin, and RTKs, such as EGFR and cMet. 
However, it is likely that these receptors are not the only cargoes of RCP-
mediated transport that have relevance to cancer cell migration and invasion. In 
this study I set out to use an unbiased proteomic approach to characterise RCP’s 
interactome and in this way identify potential new cargo for RCP-regulated 
recycling pathways. Using this approach I have identified EphA2 as an RTK whose 
trafficking and function is controlled by RCP. I then proceeded to study the role 
played by RCP in influencing EphA2’s ability to mediate contact inhibition of 
locomotion and cell-cell repulsion. In particular I have focused on how 
phosphorylation of RCP at a potential residue enables it to mediate EphA2-
dependent cell-cell repulsion, thus describing a new pathway through which a 
Rab11 effector may contribute to the dissemination and metastasis of cancer. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Reagents 
Reagent Supplier 
1kB ladder Thermo Scientific 
2% gelatin (in PBS) Sigma 
AEBSF Melford 
Agarose (high gel strength) Melford Laboratories 
ALLN  Calbiochem 
Ampicillin Sigma 
Aprotinin Sigma 
Ascorbic Acid Sigma 
Bacto-trypton Melford 
BamH1 New England Biolabs 
Benzamidine Sigma 
BL21(DE3)pLysS Promega 
Bradford (Coomassie plus) reagent Thermo scientific 
Bromo-phenol Blue Sigma 
BSA First link 
Calcein-AM Life Technologies 
Cilengitide Bachem 
Cirtrate retrieval buffer Thermo scientific 
Citric acid Sigma 
Collagen 1 (rat tail high concentration) BD bioscience 
Coomassie Life Technologies 
cRAD Bachem 
cRGD Bachem 
DH5α cells Life Technologies 
Dialysis cassettes Pierce 
DNAse1 Roche 
dNTP (100mM) Life Technologies 
DTT Melford 
Dulbecco’s Modified Eagle Medium (DMEM) Gibco 
Dynabeads anti-mouse Life Technologies 
Dynabeads anti-rabbit Life Technologies 
ECL Western blotting substrate Pierce 
EcoR1 New England Biolabs 
EDTA Sigma 
EGF Peprotech 
EGTA Sigma 
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EphrinA1-Fc R & D systems 
Ethidium Bromide Sigma 
Falcon tissue culture dishes (10 & 15cm2) BD Biosciences 
Fc Millipore 
Fibronectin (1mg/ml soluble) Sigma 
Foetal Calf Serum Autogen Bioclear 
Fungizone Sigma 
Geltrex Life Technologies 
Glass bottom 3 cm2 and 6 well plates Maktek 
Glutathione Sigma 
Glutathione (4% agarose beads) GE Healthcare 
Glycerol Fisher Scientific 
H2PO4 Sigma 
HCL Sigma 
HGF Sigma 
Hybond-P PVDF membrane GE Healthcare 
Hydrogen peroxide Fisher Scientific 
Igepal CA-630 Fluka 
IgG Jackson immunoResearch 
IHC Dako envision rabbit secondary Dako 
Iodoacetamide (IAA) Sigma 
IPTG Melford 
Kanamycin Sigma 
KCl Fisher Scientific 
Leupeptin Melford 
L-Glutamine (200mM) Life Technologies 
Lysozyme Sigma 
MatrigelTM Basement membrane mix Becton Dickson 
Maxisorp 96 well plates Life Technologies 
MesNa Fluka 
Milk powder Marvel 
Na2CO3 Fisher Scientific 
Na2HPO4 Fisher Scientific 
Na3V04 Fisher Scientific 
NaCl Fisher Scientific 
NaF Sigma 
NAHCO3 Fisher Scientific 
NaOH Fisher Scientific 
Nunc tissue culture plates TCS biologicals 
NuPAGE MES SDS running buffer Life Technologies 
NuPAGE MOPS SDS running buffer Life Technologies 
NuPAGE pre-cast gels (4-12%, 10, 12, 14 wells) Life Technologies 
NuPAGE sample buffer Life Technologies 
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NuPAGE transfer buffer Life Technologies 
Osteopontin Sigma 
Parafilm wrap Fisher Scientific 
Paraformaldehyde Electron microscopy sciences 
PBS containing calcium and magnesium Sigma 
PD150606 Calbiochem 
Penicillin/Streptomycin Life Technologies 
PLATINUM Taq DNA polymerase high fidelity Life Technologies 
Precision plus protein all blue standard Biorad 
Primaquine Sigma 
Propan-2-ol Fisher 
Protease inhibitor cocktail Roche 
Pst1 New England Biolabs 
Rapid ligation buffer Promega 
RMPI-1640 medium Gibco 
Sal1 New England Biolabs 
SDS Fisher Scientific 
siRNA Dharmacon 
SOC media Life Technologies 
Sulfo-NHS-SS-Biotin 
 
Pierce 
Super RX medical x-ray film Fuji 
T4 DNA ligase Promega 
TOP10 OneShot cells Life Technologiesa 
Transwell Permeable Support (8µm pore size) Fisher Scientific 
Tris HCl Melford 
Triton-X100 Sigma 
Tween-20 Sigma 
Vectashield mounting media (+/- DAPI) Vector laboratories 
Xho1 New England Biolabs 
Yeast extract Fisher Scientific 
β-mercaptoethanol Sigma 
Table 2-1 Reagents and suppliers 
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2.1.2 Solutions 
Solution Recipe 
Eluate buffer 50mM Tris-HCl (pH6.8), 92 mg/ml DTT, 10% SDS (w/v), 15% glycerol (w/v), 1% bromo-phenol blue (v/v) 
 
Biotin reduction buffer 50mM Tris HCl (pH7.5), 10mM NaCl, add 10N HCl until buffer reaches pH8.6 (~1.4ml) at 4ºC 
ELISA coating buffer 0.05M Na2CO3, pH9.6 at 4ºC 
ELISA developing reagent 
0.56 mg/ml ortho-phenylenediamine , 25.4mM Na2HPO4, 
12.3mM citric acid, pH5.4 with 0.003% H2O2 
4 
LB agar 
85mM NaCl, 1% bacto-trypton (w/v), 0.5% yeast extract 
(w/v), 1.5% agarose (w/v), +/- 100µg/ml ampicillin or 
50µg/ml kanamycin 
LB broth 85mM NaCl, 1% bacto-trypton (w/v), 0.5% yeast extract (w/v), +/- 100µg/ml Ampicillin or 50µg/ml Kanamycin 
No detergent NDLB 
50mM Tris HCl (pH7.0), 150mM NaCl, 10mM NaF, 1mM 
Na3V04, 5mM EDTA, 5mM EGTA 
 
 
PBS 
 
170mM NaCl, 3.3mM KCl, 1.8mM Na2HPO4, 10.6mM H2PO4 
PBS-T PBS, 0.1% Tween-20 (v/v) 
 TBS 10mM Tris-HCl (pH7.4), 150mM NaCl 
TBS-T TBS, 0.1% Tween-20 (v/v) 
Triton NDLB No detergent NDLB lysis buffer, 1.5% Triton-X100 (v/v), 0.75% Igepal CA-630 (v/v) 
Tween NDLB No detergent NDLB lysis buffer, 0.15% Tween-20 (v/v) 
Table 2-2 Recipes of solutions 
 
2.1.3 Kits 
Kits Supplier 
F-410 DyNAmo SYBR Green qPCR kit Thermo Scientific 
ImProm-IITM reverse transcription system Promega 
Nucleofector Kit T Amaxa 
Nucleofector Kit V Amaxa 
Pierce BCA protein assay kit Thermo Scientific 
Platinum PCR SuperMix High Fidelity Life technologies 
QIAGEN Plasmid maxi kit Qiagen 
QIAprep Spin miniprep kit Qiagen 
QIAquick gel extraction kit Qiagen 
QIAquick PCR purification kit Qiagen 
Quick ligation kit NEB 
RNeasy mini kit Qiagen 
Western Blotting equipment and solutions Life Technologies 
Table 2-3 Kits and suppliers 
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2.1.4 DNA Plasmids 
Plasmid Supplier/ Cloned by 
pEGFP-C1-3 Clonetech 
pEGFP-C2-Rab6A Mary McCaffrey 
pEGFP-C2-Rab6B Christine Gundry 
pEGFP-C3-Fip2 Mary McCaffrey 
pEGFP-C3-Fip3 Mary McCaffrey 
pEGFP-C3-Fip4 Mary McCaffrey 
pEGFP-C3-Rab14 Mary McCaffrey 
pEGFP-C3-RCP Mary McCaffrey 
pEGFP-C3-RCP199-649 Mary McCaffrey 
pEGFP-C3-RCP2-199 Mary McCaffrey 
pEGFP-C3-RCP379-639 Mary McCaffrey 
pEGFP-C3-RCPI621E Mary McCaffrey 
pEGFP-C3-RCPS435A Patrick Caswell 
pEGFP-C3-Rip11 Mary McCaffrey 
pEGFP-farnesylated Juliana Schwarz 
p-EGFP-N1 Clonetech 
pEGFP-N1-EphA2 Christine Gundry 
pGEX-4T1 Pharmacia Biotech 
pGEX-4T1- Rab6B Christine Gundry 
pmCherry Roger Tsien 
pmCherry-Rab14 Mary McCaffrey 
pmCherry-RCP Mary McCaffrey 
pTRCHisA Life technologies 
pTRCHisA-RCP Mary McCaffrey 
Table 2-4 DNA plasmids and suppliers 
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2.1.5 Primers 
Primer Use Sequence/ Company 
Actin F & R RT-PCR/PCR Quantitect 
EphA2 middle 1 Sequencing ACTGTGCAGTGGATGGCG AGT 
EphA2 middle 2 Sequencing GAGTGTGGAAGTACGAGGTCAC 
GAPDH F & R RT-PCR Quantitect 
Fip2 F &R RT-PCR Quantitect 
pEGFP-C2-Rab6B F Cloning AAAGAATTCATGTCCGCAGGGGGAGATTTTG 
pEGFP-C2-Rab6B R Cloning TTTGTCGACGCTGGCCGGGGCTCCTGGGGT 
pEGFP-N1-EphA2 F Cloning CCCGAATTCACATGGAGCTCCAGGCAGCCCGCGCCT 
pEGFP-N1-EphA2 R Cloning GGGGTCGACAGGATGGGGATCCCCACAGTGTTCACC 
Rab6A/Aʹ F PCR ATGTCCACGGGCGGA 
Rab6A/Aʹ R PCR CTGAAGAAGGTTGAAGATG 
Rab6B F PCR TCGACAACACATACCAGGCA 
Rab6B R PCR TGCTTCACGTTGTAGCCAGT 
Table 2-5 Primer uses and sequences  
(F: forward, R: reverse) 
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2.1.6 Antibodies 
Andibody Species Technique (dilution) Supplier 
Alexa-fluor 488 
α-mouse Goat IF (1/300) Life Technologies 
Alexa-fluor 568 
α-chicken Goat IF (1/300) Life Technologies 
Alexa-fluor 568 
α-rabbit Donkey IF (1/300) Life Technologies 
cMet Goat ELISA (5µg/ml) R & D Systems 
EGFR Mouse IB (1/1K), ELISA (5µg/ml) BD Pharmingen 
EphA2 Mouse IB (1/1K), IP (1.5µg/ml), IF (1/200), ELISA (5µg/ml) Millipore 
Fip2 Rabbit IB (1/500) Proteintech 
Fip3 Rabbit IB (1/500) Mary McCaffrey 
GFP Mouse IB (1/2K) Abcam 
GFP Rabbit IP (1.5µg/ml) Abcam 
HRP α-mouse Goat IB (1/3K) Sigma 
HRP α-rabbit Goat IB (1/3K) Sigma 
Phospho-RCP Rabbit IB (1/500) Eurogentech 
Rab11A Rabbit IB (1/1K), IF (1/100) Zymed 
Rab14 Rabbit IB (1/500) Abnova 
Rab14 Rabbit IB (1/500) Abcam 
Rab4 Rabbit IB (1/1K) Transduction labs 
Rab5 Mouse IB (1/1K) Transduction labs 
Rab6A Rabbit IB (1/1K) Proteintech 
RCP (human) 
 
Chicken IB (1/7K), IF (1/300) Genway 
RCP (human) Rabbit IB (1/1K), IF (1/300) Eurogentech 
RCP(mouse) Rabbit IB (1/1K), IHC (1/1.5K) Eurogentech 
RG-16 Rabbit IP (1.5µg/ml) Sigma 
Tnf Receptor Mouse ELISA (5µg/ml) BD Pharmingen 
α5 integrin Mouse IB (1/1K) BD Transduction 
α5 integrin Mouse ELISA (5µg/ml) BD Phamingen 
β-tubulin Mouse IB (1/10K) Sigma 
Table 2-6 Antibodies  
(IB: immunoblotting, IP: immunoprecipitation, IHC: immunohistochemistry, IF: 
immunofluorescence) 
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2.2 Methods 
2.2.1 Cell culture 
2.2.1.1 Cell lines 
A2780-DNA3 and A2780-Rab25 cell lines were generated and donated by 
Professor Gordon Mills (Cheng et al., 2005). As I wanted to use the PC3 cell in 
which the Ephs and Ephrins have been characterised (Astin et al., 2010), 
Professor Kate Nobes kindly gave us their PC3 cells. Several cell lines were 
obtained from others at the Beatson Institute, including the H1299 cells (Patricia 
Muller) and the pancreatic ductal adenocarcinoma (PDAC) mouse lines (Bryan 
Miller/Jen Morton). 
2.2.1.2 Cell cultivation 
The cell lines were grown at 37ºC and 10% CO2 in a humidified incubator. A2780 
and PC3 cells were cultured in RMPI-1640 media, whilst H1299 cells and the 
PDACs were cultured in DMEM media. All media was supplemented with 10% 
foetal calf serum, 2mM L-glutamine, 100IU/ml penicillin, 100µg/ml streptomycin 
and 250µg/ml fungizone. Cells were split once they reached 80-90% confluence 
(H1299 cells at 65-75%). Briefly, the cells were washed twice in PBS, 1ml 10% 
Trypsin/PE solution was added and left until the cells had detached. Media was 
added and the appropriate number of cells seeded in fresh culture dishes.  
2.2.1.3 Nucleotransfection 
Amaxa nucleotranfection kits were used according to the manufacturer’s 
instructions. A2780 cells were transfected using kit T, whilst H1299 and PC3 cells 
were transfected using kit V. An 80% confluent 15cm2 plate of cells was required 
per transfection. The cells were washed twice with PBS, detached with 1ml 10% 
Trypsin/PE solution, resuspended in 10ml media and centrifuged at 1,000rpm for 
5 minutes. The media was removed and the cells were washed in 10ml PBS and 
centrifuged at 1,000rpm for 5 minutes. The cells were resuspended and 
thoroughly mixed in 100µl solution T/V with added supplements and the 
appropriate DNA (3µg) or siRNA (5µl of 20mM stock). The suspension was 
transferred into a cuvette and electroporated on the appropriate setting (A2780: 
A-023, H1299: X-001, PC3: T-020). 500µl media was quickly added and the cells 
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were removed gently with a pipette onto the appropriate tissue culture dishes. 
The cells were left to recover for 24 hours before any experiments were 
performed. 
2.2.1.4 Cell proliferation 
To measure cell proliferation, 5,000 cells were seeded into each well of a 12-
well plate and counted 24, 48, 72 and 96 hours later. To detach the cells, they 
were washed twice in PBS and 200µl 10% trypsin/PE solution was added for 
precisely 5 minutes. To inhibit the trypsin, 200µl media was added. 200µl of cell 
suspension was added to 19.8ml PBS and the cell number was measured using a 
Casy cell counter. Each condition was measured in triplicate and the experiment 
was performed twice. 
2.2.1.5 Cell Lysis 
After cells had reached 70-90% confluency, the cell culture media was aspirated 
off and the cells were washed twice on ice with cold PBS. Triton NDLB was 
supplemented with protease inhibitors (50µgml leupeptin, 50µg/ml aprotinin and 
1mM AEBSF) and calpain inhibitors (20µM ALLN and 100µM PD150606). For cell 
lysis, 300µl was added to each 10cm2 plate (Tween NDLB was used for 
immunoprecipitations) and the cells were scraped off the base of the plate. The 
cell suspension was passed through a 25G needle four times and clarified by 
centrifugation at 14,000rpm for 10 minutes at 4ºC. The supernatant was 
carefully removed and either used immediately or stored at -20ºC.  
2.2.2 DNA 
2.2.2.1 PCR (polymerase chain reaction) 
PCR was set up using Platinum PCR SuperMix High fidelity, following 
manufacturers’ instructions. For each reaction, 10ng/µl template plasmid and 
5µM of each primer were used (Table 2.5). PCR was carried out in a DNA engine 
Thermal Cycler (Biorad). First, the DNA strands were denatured at 95ºC for 2 
minutes. Then the DNA was amplified in 30 cycles of: 95ºC for 45 seconds to 
denature the DNA, 60ºC for 45 seconds to anneal the primers, and 72ºC for 60 
seconds to extend the strand. To ensure all DNA was fully extended, it was 
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incubated for a final 8 minutes at 72ºC. The DNA product was analysed by 
agarose gel electrophoresis. 
2.2.2.2 Agarose gel electrophoresis and purification 
The sizes of amplified or digested DNA products were analysed by gel 
electrophoresis. First, a 1% (w/v) agarose gel was produced by heating agarose 
in TAE buffer, supplementing it with 0.2µg/ml ethidium bromide and leaving it 
to solidify. DNA was mixed with DNA loading dye and loaded into the wells. 1kB 
ladder was run in adjacent lanes to estimate the size of DNA bands. 
Electrophoresis was run in a gel container filled with TAE and run at 100V for 1 
hour. DNA was visualised using UV translumination. DNA products were cut out of 
the gel and purified using the QIAquick gel extraction kit following the 
manufacturer’s protocol.  
2.2.2.3 Restriction Digestion  
DNA digestion with restriction enzymes was carried out according to 
manufacturer’s instructions using the buffers provided with the enzymes. 
Briefly, 1µg of DNA was digested with two restriction enzymes (1Unit per 
enzyme) in 20µl at 37ºC for 2 hours. To determine whether the reaction was 
successful, the DNA products were separated by gel electrophoresis. 
2.2.2.4 DNA Ligation 
To ligate two DNA fragments together the Quick Ligation Kit was used according 
to manufacturer’s instructions. Briefly, 50ng of vector was mixed with 150ng 
insert, water, the provided buffer and T4 DNA ligase, and incubated at room 
temperature for 30 minutes.  
2.2.2.5 Transformation of E.coli 
DH5α or TOP10 competent cells were used for cloning, and BL21(DE3)pLysS cells 
were used for protein production. The appropriate cells were thawed and mixed 
with 2µl of the ligation mix or 5ng of DNA on ice. The cells were heat-shocked at 
42ºC for 45 seconds and then immediately returned to ice for 2 minutes. The 
cells were recovered by adding 450µl SOC media and shaking them at 37ºC for 
one hour. Half the cells were plated onto LB agar containing the appropriate 
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antibiotic (ampicillin or kanamycin) at 37ºC overnight. To store DNA plasmids, 
500µl glycerol was mixed with 500µl transformed bacteria and kept at -80ºC.  
2.2.2.6 Plasmid preparation and sequencing 
To determine whether any E.coli colonies contained the correctly ligated 
plasmid, the DNA was prepared and purified for sequencing. The colonies were 
picked and grown in 5ml LB media supplemented with the appropriate antibiotic 
at 37ºC overnight. The cells were pelleted by centrifugation at 3000rpm for 10 
minutes in a Beckman Coulter centrifuge. DNA was prepared using the QIAprep 
Spin Miniprep kit according to manufacturer’s instructions. DNA sequencing was 
performed on an Applied Biosystems 3130x1 sequencer by the Beatson Molecular 
Technology services using specifically designed primers (Table 2.5). Four 
primers were required to sequence the full length of EphA2.  
For large quantities of DNA, the Beatson Institute central services performed 
Maxipreps using the QIAprep Spin Maxiprep kit, according to manufacturer’s 
instructions. Before the DNA was used, its concentration was measured using a 
NanoDrop spectrophotometer.  
2.2.3 RNA 
2.2.3.1 Extraction of mRNA 
RNA was isolated from cells at 70% confluency. The cells were washed twice with 
cold PBS and drained to remove any residual PBS. Cell lysis was performed by 
scraping the cells off the plate in RLT buffer mixed with β-mercaptoethanol, 
provided by the RNeasy kit. This kit was used according to manufacturer’s 
instructions, including the extra steps to further homogenise lysates using 
QIAshredder columns and to digest any DNA using the oncolumn DNAse1 
digestion. RNA was eluted in sterile water and either used immediately or snap 
frozen on dry ice. 
2.2.3.2 Synthesis of cDNA 
cDNA was synthesised from RNA using a DNA engine Thermal Cycler (Biorad) and 
the ImProm-IITM reverse transcription system kit, according to manufacturer’s 
instructions. Briefly, 1µg RNA was mixed with 0.5µg/ml oligo(dT)s and water,  
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heated to 70ºC for 5 minutes and then immediately chilled. ImProm-II reverse 
transcriptase, reaction buffer, 24mM MgCl2, 10mM dNTPs and 40U/µl RNasin was 
added. To allow annealing the mix was kept at 25ºC and then the cDNA was 
extended at 42ºC for 1 hour. Once the stands had been synthesised the reaction 
was heat inactivated at 70ºC for 5 minutes. 
2.2.3.3 RT-PCR 
Quantitative PCR was performed using the QuantiTect SYBR green PCR kit and a 
BioRAD DNA engine thermal cycler with a chromo4 engine and Opticon Monitor3 
software. Briefly, 10µl SYBR Green mix was mixed with 1µl cDNA (synthesised 
from 1µg RNA) and 2µl of Quantitect primers (Table 2.5). Each condition was 
performed in triplicate and pipetted into a 96 well plate. The DNA was 
denatured at 95ºC for 15 minutes. Next, the DNA was amplified in 40 cycles of: 
95ºC for 30 seconds to denature the DNA, 60ºC for 30 seconds to anneal the 
primers and 72ºC for 30 seconds to extend the strand. To ensure all the DNA was 
fully extended, it was incubated for 5 minutes at 72ºC. A dissociation curve was 
produced by increasing the temperature from 70ºC to 90ºC in 0.3ºC steps. 
Opticon Monitor 3 software was used to calculate the changes in gene 
expression, which was normalised to GAPDH. Each experiment was performed in 
triplicate. 
2.2.4 Protein 
2.2.4.1 Protein production and purification 
His-RCP and GST-Rab6B were expressed and purified in E.coli for use in in vitro 
binding assays. GST-Rab6B was transformed into BL21(DE3)pLysS cells as 
previously described (Section 2.2.1.4). A colony was picked and cultivated in 
10ml LB media supplemented with 100µg/µl Ampicillin at 37ºC overnight. This 
culture was added to 1L LB media supplemented with 100µg/µl Ampicillin. Once 
the culture reached an optical density of 0.6-0.8 (at 600nm), 0.25mM IPTG was 
added to induce GST-Rab6B expression. The cells were grown for a further 2 
hours. The cells were then centrifuged at 4,000rpm for 30min at 4ºC. The pellet 
was re-suspended in 20ml PBS pH7.4/0.1% Triton X-100 supplemented with the 
protease inhibitor cocktail and 1mg/ml lyzosyme. The cells were lysed by 
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sonication on ice in 8 second cycles until the suspension turned to liquid. Cell 
debris was removed by centrifugation at 11,000rpm for 30 minutes at 4ºC.  
The fusion protein was purified by adding 0.5ml of pre-swollen 50% glutathione 
(4%) agarose beads to the supernatant and gently mixed for 2 hours at 4ºC. The 
beads were gently collected by centrifugation at 1,000rpm for 5 minutes at 4ºC 
and the supernatant was discarded. The beads were resuspended in 20ml PBS 
0.1% Triton X-100 and centrifuged at 1,000pm at 4ºC for 5 minutes. This wash 
step was repeated a further 4 times and then twice with PBS alone. 250µl 
elution buffer (5mg/ml Glutathione in 50mM Tris, 100mM NaCl, pH8.0) was 
added and mixed by gently inverting the tube. The slurry was centrifuged at 
6,000rpm for 3mins at 4ºC. This elution step was repeated a further two times. 
The proteins were dialysed in Pierce Dialysis cassettes (10kDA molecular weight 
cut off) in 5L PBS overnight at 4ºC. To assess the protein concentration Bradford 
assays were performed (Section 2.2.4.3). A similar method was used to 
generate and purify His-RCP. The proteins were stored at -80ºC. 
2.2.4.2 In vitro binding assays 
First, GST-tagged protein was coupled to agarose beads. Agarose glutathione 
bead slurry was washed 3 times in PBS (100µl/condition), using centrifugation at 
1,000rpm for 3 minutes. They were re-suspended in 1ml PBS 0.15% Tween-20 
supplemented with protease (50µgml leupeptin, 50µg/ml aprotinin and 1mM 
AEBSF) and calpain inhibitors (20µM ALLN and 100µM PD150606) and split into 
two tubes. 50µg of GST or GST-Rab6B were added to the beads and rotated for 1 
hour at 4ºC. To remove excess protein, the beads were washed twice with PBS 
0.15% Tween-20 supplemented with protease and calpain inhibitors. The pellets 
were re-suspended in 0.5ml 37µg His-RCP 0.15% Tween-20 supplemented with 
protease and calpain inhibitors and rotated for 2 hours at 4ºC. To remove 
unbound proteins, the suspension was washed four times. All the remaining 
liquid was removed from the beads. 100µl reducing sample buffer was added and 
boiled at 100ºC for 5 minutes. The samples (20µl) were immediately analysed by 
SDS-PAGE or stored at -20ºC. Each in vitro binding assay was repeated three 
times. 
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2.2.4.3 Bradford assays 
Protein concentration was determined using Bradford reagent. Protein standards 
were used (0.1, 0.2, 0.4, 0.6, 0.8 and 1mg/ml of BSA) to generate a standard 
curve. Protein samples, standards and the appropriate blank were pipetted in 
triplicate into a 96 well plate. Bradford reagent was used according to 
manufacturer’s instructions: 200µl was added to each well and incubated at 
room temperature for 10 minutes. The absorbance was read at 595nm on a 
Dynatech MR7000 plate reader and protein concentration was determined from 
the standard curve. 
2.2.4.4 SDS-PAGE 
To resolve protein samples SDS-PAGE (sodium dodecyl sulphate-polyacrylamide) 
gels were used. Approximately 30µg protein was reduced in reducing sample 
buffer at 100ºC for 5 minutes. Molecular weight markers were run in adjacent 
lanes to the samples. The proteins were resolved on 4-12% denaturing pre-cast 
gels in MES or MOPs running buffer (depending on protein size) at 120V for 2 
hours. These gels were then analysed by Coomassie staining or Western blotting. 
2.2.4.5 Coomassie staining 
Prior to Coomassie staining, proteins were resolved by SDS-PAGE. The gels were 
washed three times with distilled water for 5 minutes and then incubated in 
SimplyBlue SafeStain Coomassie for 30 minutes, rocking at room temperature. 
To remove background staining, the gel was washed in distilled water until the 
bands were distinct for analysis. 
2.2.4.6 Western blotting 
Prior to Western blotting, proteins were resolved by SDS-PAGE. The proteins 
were transferred from the gel onto PVDF membrane by wet transfer in NuPage 
blotting buffer at 30V for 90 minutes. The membrane was blocked in 5% milk in 
TBS-T (or 5% BSA for phospho-antibodies) rocking for 30 minutes at room 
temperature. Membranes were then incubated in the appropriate antibody in 1% 
milk in TBS-T (or BSA) (Table 2.6) overnight at 4ºC. To remove excess antibody, 
the membranes were washed in TBS-T three times for 10 minutes. The 
membranes were incubated in the appropriate HRP-conjugated secondary 
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antibody for 1 hour at room temperature. To remove excess antibody, the 
membranes were washed in TBS-T three times for 10 minutes. The membranes 
were incubated in ECL Western blotting solution for 3 minutes and placed in 
cassettes. Protein bands were visualised by autoradiography using Fuji Super 
medical x-ray films in a Kodak X-Omat 488 x-ray processor. 
2.2.4.7 Immunoprecipitation 
First, the antibody of interest was coupled to magnetic Dynabeads. 30µl 
Dynabead slurry (per lysate from a 15cm2 plate) was washed twice in 2 volumes 
0.1% BSA in PBS, using a magnetic rack to separate the beads and solution. The 
beads were resuspended in 2 volumes of 0.1% BSA in PBS with 1.5µg appropriate 
antibody (per lysate) and rotated at 4ºC for 1 hour. The bead slurry was washed 
a further two times. Cell lysates were prepared in NDLB-Tween-20 (Section 
2.2.1.5) and 70µl was kept for analysis. The remaining lysates were added to 
the beads and rotated for 2 hours at 4ºC. To remove any unbound protein, the 
bead slurry was washed in 1ml NDLB-Tween-20 four times. All buffer was 
removed, 100µl 1x reducing sample buffer was added and boiled at 100ºC for 5 
minutes to detach and denature the proteins. The proteins were resolved by 
SDS-PAGE and subjected to Western blotting. Each immunoprecipitation 
experiment was repeated three times. 
2.2.4.8 Proteomic screen 
For mass spectrometry analysis high protein concentration is required so five 
15cm2 plates were used per condition. A2780 cells transfected with GFP or GFP-
RCP were treated with 1µM Cilengitide or vehicle control for 30 minutes prior to 
immunoprecipitation (as in Section 2.2.4.7). Immunoprecipitated protein was 
eluted off the beads in 100µl 1%SDS Tris pH6.8 at room temperature for 5 
minutes. The eluate was immediately removed and added to 50µl eluate buffer 
(Table 2.1.2). Proteins were resolved on 10% pre-cast polyacrylamide gels and 
Coomassie stained. The gel was given to the Beatson Institute proteomic facility 
(David Sumpton and Willie Bienvenut) where the proteins were extracted and 
analysed by MALDI-TOF mass spectroscopy. The peptides were analysed using 
Scaffold viewer. This screen was performed with Jim Norman. 
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2.2.5 Trafficking assays 
2.2.5.1 Capture- ELISA 
Maxisorp 96 well microtiter plates were incubated with 50µl ELISA coating buffer 
(Table 2.1.2) and the appropriate antibody per well at 4ºC, rocking overnight. 
Approximately one hour prior to use, the plate was blocked in 5% BSA in PBS-T at 
4ºC. The plate was washed with PBS-T twice and any residual liquid was drained 
off. Cell lysates were added to the plate, which was then incubated at 4ºC 
rocking overnight. To remove unbound protein, the plate was extensively 
washed four times with PBS-T. Streptavidin-conjugated HRP was added to 1% BSA 
in PSB-T (1:1000), 50µl was added to each well and the plate was incubated for 
1 hour gently rocking at 4ºC. The plate was extensively washed four times with 
PBS-T, once with PBS and then drained. 50µl ELISA developing reagent (Table 
2.1.2) was added to each well and the plate was incubated at room temperature 
for ~10 minutes. The absorbance of each well was read at 490nm on a plate 
reader.  
2.2.5.2 Internalisation assays 
If appropriate, cells were transfected 48 hours prior to this assay so that they 
were ~70% confluent for the assay. Cell culture media was aspirated off the cells 
and they were washed twice in cold PBS on ice. The proteins on the cell 
membrane were labelled with membrane impermeable 5ml 0.13mg/ml sulfo-
NHS-SS-Biotin in PBS for 30 minutes at 4ºC. Surplus label was washed from the 
cells twice in cold PBS on ice. Plates of cells used to measure total protein were 
kept on ice until cell lysis, whilst the plates used for the blank were kept on ice 
until MesNa treatment. To allow internalisation, the remaining plates were 
incubated in DMEM media at 37ºC for the appropriate times. For some 
experiments, the media was supplemented with 10ng/ml HGF or 0.6mM 
primaquine. The cells were washed with 5ml PBS and with 5ml biotin reduction 
buffer on ice (Table 2.1.2). To remove the biotin from the membrane proteins, 
20mM MesNa in biotin reduction buffer was incubated on the cells for 30 minutes 
at 4ºC. This reaction was quenched by adding 20mM IAA for a further 10 minutes 
at 4ºC. The plates were washed and lysed in 100µl 1.5% Triton NDLB as described 
earlier (Section 2.4.4.5). The levels of biotinylated-EphA2, α5-integrin, cMet, 
EGFR and TfnR were determined by capture-ELISA (Section 2.2.5.1).  
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2.2.6 Protein localisation studies 
2.2.6.1 Immunofluorescence 
H1299 cells were seeded onto glass coverslips in 6 well plates and left to adhere 
and grow for 48 hours. The cells were fixed with 4% paraformaldehyde for 15 
minutes and permeabilised in 0.2% Triton X-100 in PBS for 5 minutes. The 
coverslips were immediately washed twice in PBS and then blocked in 1% BSA in 
PBS for 30 minutes. Primary antibodies were incubated on the coverslips, at the 
appropriate concentration (Table 2.6) in block solution for 2 hours at room 
temperature. The coverslips were washed three times in PBS for 5 minutes and 
incubated in the appropriate secondary antibody in 1% BSA PBS for 1 hour at 
room temperature in the dark. Any remaining antibody was washed from the 
coverslips in four washes in PBS, each for 5 minutes. The coverslips were 
mounted onto slides using Vectashield mounting reagent. Cells were visualised 
by confocal microscopy using an Olympus FV-1000 microscope. Sequential 
scanning was used to prevent signal bleed through. Controls with no primary 
antibody were performed for each secondary antibody to ensure that there was 
no auto-fluorescence. 
2.2.6.2 Ephrin stimulation 
A2780 cells were transfected with pEGFP-f (farnesylated-GFP) or pEGFP-EphA2 
(Section 2.2.1.3) and seeded onto glass coverslips in 6 well plates for 24 hours. 
EphrinA1-Fc was pre-clustered at a ratio of 1µg/ml EphrinA1-Fc/Fc to 10µg/ml 
IgG in RMPI media at 37ºC for 30 minutes. The media was aspirated from the 
cells and 500µl clustered EphrinA1-Fc or Fc was added for 30 minutes. The cells 
were fixed with 4% paraformaldehyde for 15 minutes and mounted onto slides 
using Vectashield mounting reagent. Cells were visualised by confocal 
microscopy using an Olympus FV-1000 microscope. 
2.2.6.3 Live cell imaging 
A2780 or H1299 cells were transfected with 3µg of the appropriate plasmids and 
seeded onto glass-bottomed plates for live cell imaging. To maximise the signal, 
cells were visualised 24 hours after transfection on an Olympus FV-1000 
microscope. Images or 2 minute movies were taken and cells were treated with 
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10ng/ml HGF if appropriate. ImageJ software was used to generate images 
showing co-localised pixels, by first thresholding images using max-entropy and 
then using the co-localisation highlighter tool. To quantify co-localisation the 
number of co-localised pixels was measured and normalised to the number of 
pixels in the red and green channel. 
2.2.7 Migration assays 
2.2.7.1 Matrigel and Geltrex invasion assays 
The inverted invasion assay was first described by Hennigan et al. (1994) and has 
been adapted for this study (Hennigan et al., 1994). Matrigel was used for the 
experiments in chapter 3 and Geltrex for the experiments in chapter 4. Both are 
a gelatinous protein mix secreted from Engelbreth-Holm-Swarm mouse sarcoma 
cells, which contains many ECM components, including laminin, entactin and 
collagen. Geltrex/Matrigel was mixed 1:1 with cold PBS, supplemented with 
25µg/ml fibronectin and 100µl was put in each transwell. The transwells were 
incubated at 37ºC for 1 hour to allow the proteins to polymerise. Meanwhile, the 
appropriate cells were detached, counted and 5x105 cells were prepared in 1ml 
of media. Transfected cells were left to recover for 18 hours before setting up 
invasion assays. To adhere the cells to the transwell, 100µl cell suspension was 
incubated on the base of each transwell at 37ºC for 4 hours. The base of the 
transwell was washed by sequential dipping in 1ml serum free media and then 
placed in 1ml serum free media. Serum rich media was supplemented with 
either 25ng/ml EGF or 10ng/ml  HGF and 100µl was carefully placed inside the 
transwell, which created a chemotactic gradient promoting cell invasion into the 
plug. These plugs were incubated at 37ºC for 3 days to allow cell invasion. To 
visualise invasion, the transwells were placed in a fresh 24 well plate and 1ml 
4µM calcein-AM (acetomethyl ester) in serum free media was incubated on the 
transwells for 1 hour at 37ºC. Calcein-AM is a fluorescent dye that is transported 
into live cells, which was visualised on an Olympus-FV1000 microscope. Optical 
sections were taken every 10µm/15µm from the base of the transwell in three 
randomly selected areas of each plug. ImageJ’s area calculator plugin was used 
to quantify the calcein-AM signal from each image. Fold change in invasion was 
calculated by dividing the signal in images over 30µm or 45µm by the total signal 
in the strip and normalising it to the non-targeting control. Mean values were 
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generated from three independent experiments and within each experiment six 
optical sections were taken from two different transwells per condition.  
2.2.7.2 Contact inhibition of locomotion assays 
This assay was first described by Astin et al. (2010) and has been adapted for 
this study. First the plates were coated in 150µl Matrigel in 300µl 0.5% Serum 
RPMI-1640 by pipetting it onto glass-bottomed 6 well plates. To polymerise the 
Matrigel, the plate was sealed and incubated at room temperature for 1 hour. 
2,000 transfected PC3 cells (24 hours before this assay- Section 2.2.1.3) were 
seeded onto each well, and incubated at 37ºC for 24 hours. To starve the cells, 
they were washed three times with 0.5% Serum media and then incubated in this 
media for 24 hours. To stimulate migration, 10ng/ml HGF was added and 
incubated on the cells for a further 12 hours. Cell migration was visualised on a 
Nikon timelapse microscope. Images were taken every 5 minutes of 8 different 
regions in each well for 20 hours. Time of cell-cell contact during collision was 
counted for any collision in which only two cells were involved and both cells 
were migrating towards each other. The distance and direction each cell 
migrated 40 minutes before and after the collision was measured using ImageJ 
software. The average migratory speed and angle was measured for 50 cells 
from 3 separate experiments, whilst contact time during a collision was 
measured for every collision that occurred in these experiments. 
2.2.7.3 Scattering assays 
To analyse the timecourse of HGF induced scattering, 2,000 H1299 cells (Section 
2.2.1.3) were seeded onto each well in a 6 well plate. The cells formed small 
colonies containing 4-8 cells 43 hours after transfection. At this time, 5 pictures 
were taken on an Olympus CKX41 microscope and 10ng/ml HGF/mock was added 
to the appropriate wells. 3, 6, 9, 24 and 30 hours later, 5 pictures were taken 
from each condition. To analyse scattering, the cells in each picture were 
counted as either ‘scattered’, defined as cells attached to fewer than 2 other 
cells, or ‘unscattered’, defined as cells attached to 3 or more other cells. For 
each condition 20 pictures from 4 separate experiments were analysed. For later 
experiments the same protocol was used, however, pictures were only taken 6 
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hours after HGF stimulation as it was observed that this is when cells are the 
most scattered. 
2.2.7.4 Time-lapse scattering assays 
To analyse H1299 cell migration upon HGF stimulation, 2,000 transfected H1299 
cells (Section 2.2.1.3) were seeded onto each well in a 6 well plate. Within 43 
hours the cells formed small colonies containing 4-8 cells. Cell migration was 
visualised on a Nikon timelapse microscope. Images were taken every 5 minutes 
of 8 different regions in each well. After the first round of pictures was taken, 
10ng/ml HGF was added to appropriate wells. To track cell migration, ImageJ 
manual tracking and chemotaxis plugins were used. Every cell that was in a 
colony of 4-10 cells and did not divide was tracked for 6 hours. The HGF-induced 
cell speed and distance were calculated by subtracting the untreated value from 
the HGF treated value and normalising to the non-targeting siRNA control. 
Averages and SEM of migratory speed, distance, HGF-induced speed and distance 
were calculated from 3 independent experiments. 
2.2.8 Mouse work 
2.2.8.1 Genetically modified mice 
KPC (Pdx1-Cre, KrasG12D/+, p53R172H/+) mice have previously been described 
(Morton et al., 2010). EphA2-/- mice were obtained from the Jackson laboratory, 
and RCPfl/fl mice were generated by the Beatson transgenic production service. 
PCR was used to check the genotype of the mice (Transnetyx Inc). Mice were 
monitored daily and kept in conventional animal facilities. All experiments were 
performed in compliance with UK Home Office guidelines. Tumourigenesis was 
assessed by gross pathology and confirmed by histology. This work was carried 
out by Bryan Miller and Joan Grindlay and the Beatson Institute mouse house 
facilities. 
2.2.8.2 Immunohistochemistry 
Histological staining was performed by Joan Grindlay and Colin Nixon (Beatson 
Institute Histology services). Briefly, tissue sections that had been formalin fixed 
and embedded in paraffin, were deparaffinised, rehydrated in xylene and passed 
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through a graded ethanol series (twice 100%, once 70%). Endogenous peroxidase 
activity was prevented using 3% hydrogen peroxide/methanol for 5 minutes and 
antigens were retrieved in heated citrate buffer (pH6). The sections were 
washed in TBS-T and then blocked in 5% serum at room temperature for 1 hour. 
RCP was stained by incubation of the sections in an antibody that recognises 
mouse-RCP for 1 hour at room temperature. The sections were washed in TBS-T 
and incubated with Dako EnVision rabbit secondary for 45 minutes at room 
temperature. Tissue sections were washed in TBS-T, stained with DAB colour 
reagent for 1 minute at room temperatures and counterstained with Gills 
Haematoxylin. Immunohistochemical staining on sections of PDACs were 
visualised using a Zeiss Acioskop 50 microscope. 
2.2.8.3 Generating cell lines 
Primary mouse cell lines were derived from PDACs harvested from KPC (Pdx1-
Cre, KrasG12D/+, p53R172H/+) WT, KPC EphA2-/- and KPC RCPfl/fl mice. Tumour 
samples were chopped up into small pieces and incubated in DMEM media until 
cell lines were established. The cell lines were authenticated by morphology, 
Western blotting and growth curve analysis. 
2.2.9 Statistics 
Statistical analysis was performed on all relevant experiments. To compare two 
data sets, Student’s T-tests (if data were normally distributed) or Mann-Whitney 
tests (if data were not normally distributed) were used, whilst to compare 
multiple data sets, two-way ANOVA tests were used. p-values are indicated on 
graphs and the statistical test that was used is written in the figure legends. 
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3 The RCP interactome  
3.1 Introduction  
3.1.1 RCP is amplified in some cancers and has a role in metastasis  
RCP is overexpressed in some breast (Zhang et al., 2009), head and neck (Dai et 
al., 2012), colon and lung cancers (Mills et al., 2009). The gene for RCP is 
located on the 8p11-12 chromosomal locus, which has been found amplified in 
10-25% of breast cancers (Zhang et al., 2009) and in non-small cell lung 
carcinoma (NSCLC) (Balsara et al., 1997). Studies in human breast cancer and 
head and neck cancer demonstrate that RCP over-expression decreases survival 
and increases metastatic progression (Zhang et al., 2009). Indeed, it has been 
shown that implanting breast cancer cells (MDA-MB-231) expressing shRNAs to 
suppress RCP expression into mammary fat pads of NOD-SCID mice, reduces 
tumour growth and metastasis to the lungs. Furthermore, several cell culture 
based studies have shown that RCP is required for efficient invasion into 3D 
microenvironments (Caswell et al., 2008; Muller et al., 2009). Understanding the 
function of RCP may help us understand metastatic progression and determine 
whether it could be a potential drug target. 
3.1.2 RCP regulates integrin and growth factor receptor trafficking 
In a human ovarian carcinoma cell line (A2780) α5β1-integrin promotes tumour 
cell invasion while αvβ3-integrin restrains it (Caswell et al., 2008). Two 
compounds inhibit αvβ3-integrin: osteopontin, a secreted ligand for αvβ3-
integrin (Rangaswami et al., 2006), and Cilengitide, a cyclic RGD peptide 
(cRGDfV) that mimics the RGD receptor binding motif found in integrin ligands 
(Dechantsreiter et al., 1999). Inhibition of αvβ3-integrin promotes association of 
RCP with α5β1-integrin, and drives RCP-dependent recycling of α5β1-integrin to 
the plasma membrane (Caswell et al., 2008). This causes rapid and random cell 
migration in 2D and an increase in 3D cell invasion into a collagen rich 
microenvironment. Unexpectedly, α5β1-integrin recycling does not influence the 
strength of its interaction with its extracellular ligand fibronectin. Instead, RCP 
recruits α5β1-integrin and EGFR into a complex. This integrin associates with the 
C-terminus of RCP while EGFR associates with a region found in its N-terminus. 
The formation of this complex results in the two receptors returning to the 
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plasma membrane with similar kinetics and in an RCP-dependent fashion 
(Caswell et al., 2008). RCP is not required for transferrin receptor trafficking 
(Caswell et al., 2008), which suggests RCP is not involved in all recycling in the 
cell but only that of specific cargo. RCP contains a C2 domain that associates 
with phosphatidic acid, which is synthesised by diacylglycerol kinase (DGKα) 
(Rainero et al., 2012). This kinase is required for RCP-positive vesicles, 
containing α5β1-integrin and EGFR, to be tethered to the plasma membrane at 
the tip of invasive pseudopods, and for efficient cell invasion. Indeed, a 
constitutively active mutant of DGKα is sufficient to drive RCP-dependent 
invasion in the absence of αvβ3 inhibition (Rainero et al., 2012) (Figure 3.1).  
Further work has addressed the downstream mechanism through which RCP-
dependent recycling may increase pro-migratory signalling and the invasiveness 
of cancer cells. Morello et at. (2011) have shown that silencing β1-integrin 
expression in NSCLC A549 cells dampens EGFR activation, but increases the 
amount of EGFR at the plasma membrane. Overexpressing RCP in these β1-
integrin depleted cells recovers this reduction in EGFR signalling (Morello et al., 
2011), although the authors did not study the effect of overexpression of RCP on 
EGFR trafficking. These observations differ slightly from the study by Caswell et 
al. (2008) but this may be due to differences in the two cell lines. In breast 
cancer cells it has been shown that RCP overexpression increases H-Ras 
activation, which increases downstream MAPK signalling. Furthermore, RCP 
directly associates with this proto-oncogene (Zhang et al., 2009). Perhaps in 
cells expressing H-Ras this is another downstream mechanism by which RCP may 
increase cancer cell invasion.  
Recent work has identified a novel Akt substrate, RacGAP1, which acts 
downstream of RCP-driven α5β1/EGFR recycling (Jacquemet et al., 2013). 
Activated RacGAP1 associates with IQGAP1 in the tips of the invasive pseudopod 
where it locally inhibits Rac1 activity, preventing Rac1’s inhibition of RhoA 
(Figure 3.1). This results in an increase in RhoA activity at the front of the cell, 
which is required for RCP driven invasion into a 3D matrix (Jacquemet et al., 
2013), thus demonstrating that recycling can promote the activity of proteins 
involved in the dynamics of the actin cytoskeleton required for cell migration.   
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Figure 3-1 RCP-dependent integrin and RTK trafficking in the invasive pseudopod 
Inhibition of αvβ3-integrin or expression of the gain-of-function mutation of p53 (273H) promotes 
the association of RCP with α5β1-integrin/EGFR/cMet and increases the recycling of RCP-positive 
vesicles in the tip of the pseudopod. DGK phosphorylates DAG into PA that tethers RCP positive 
vesicles at the tip of the pseudopod and localises downstream signalling to Akt/Erk in the tip of the 
pseudopod. Akt phosphorylates RacGAP1, which is recruited to IQGAP1 into the pseudopod tip 
and leads to the inhibition of Rac1. Rac1’s inhibition on RhoA is damped, resulting in increased 
RhoA activity, which drives the extension of the pseudopod and cell invasion. Green arrows 
represent the activation of a pathway, red inhibitory arrows represent the inhibition of a pathway 
and a black arrow shows the route of trafficking. 
 
3.1.3 RCP is required for mutant-p53 driven cell invasion 
The tumour suppressor protein p53 acts as a transcription factor to slow cell 
growth or induce cell death in response to oncogenic stress. p53 is frequently 
mutated in human cancers (Vogelstein et al., 2000), often in the DNA binding 
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domain of the protein. Recent work has demonstrated that some of these 
mutations result in p53 gaining functions (Olive et al., 2004; Tepper et al., 
2005). In particular it has been shown in cell lines and mouse models that 
expression of two transcriptionally inactive mutants of p53 (p53175H or p53273H) 
drives cell migration, invasion and metastasis (Adorno et al., 2009; Morton et 
al., 2010; Muller et al., 2009). RCP has an important role in mutant-p53 driven 
invasion in 3D. Indeed, Muller et al. (2009) showed that in several cell lines, 
including H1299 cells (a NSCLC line), expression of p53175H or p53273H enhances 
RCP/α5β1-integrin/EGFR association and increases RCP-dependent α5β1-integrin 
and EGFR recycling, thus activating EGFR signalling. Mutant p53 also has a role in 
RCP-dependent trafficking of other RTKs. Indeed, RCP associates with the 
hepatocellular growth factor (HGF) receptor cMet (Muller et al., 2013). 
Expression of p53273H in H1299 cells enhances cMet signalling and recycling in an 
RCP dependent fashion. Mutant-p53 expression has been shown to increase RCP-
dependent invasion towards a gradient of EGFR or HGF but not PDGFβ or IGF1 
(Muller et al., 2013), demonstrating some specificity. 
In summary, RCP is required for the enhanced cMet, EGFR and α5β1-integrin 
recycling and signalling, which are responsible for mutant-p53 (p53175H or 
p53273H) driven invasion (Figure 3.1). Since p53 is frequently mutated in many 
human cancers (Vogelstein et al., 2000), a drug that inhibits the gain of function 
activities of mutant-p53 would be a good therapeutic target. More work is 
required to further understand the role of RCP in cancer in order to investigate 
its potential as a drug target. 
3.1.4 Aims 
In this chapter I aim to identify novel RCP-associated proteins by performing a 
non-biased proteomic screen. Any interesting hits will be confirmed using co-
immunoprecipitation approaches and the site of the association will be 
investigated. Imaging techniques, such as immunofluorescence and the use of 
fluorescently tagged proteins, will be used to determine whether the identified 
hits co-localise with RCP. Finally, the role of these proteins in cancer cell 
invasion will be investigated.   
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3.2 Results  
3.2.1 Identification of novel RCP associated proteins 
3.2.1.1 Development of the proteomic approach 
To further understand the role of RCP in cancer cell migration I sought to 
identify novel RCP-interacting proteins using a proteomic approach. To do this, 
RCP was immunoprecipitated from cancer cell lysates and mass spectrometry 
was used to identify any co-immunoprecipitated proteins. As most functional 
studies of RCP have been performed in ovarian carcinoma A2780 cells, these 
cells were chosen for this screen. I was unable to find an antibody capable of 
efficiently immunoprecipitating endogenous RCP, so I choose to use an 
overexpression plasmid in which RCP was N-terminally tagged to GFP (Figure 
3.2A), as this can be efficiently immunoprecipitated with an anti-GFP antibody. 
A2780 cells were transfected with GFP-RCP and visualised by live cell 
microscopy. GFP-RCP was localised in a peri-nuclear compartment and small 
vesicles in the cytoplasm (Figure 3.2B). This localisation concurs with that of 
previous studies using an anti-RCP antibody, which showed that endogenous RCP 
co-localises with Rab11 in the PNRC (Peden et al., 2004). 
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Figure 3-2 Schematic representation and cellular localisation of GFP-RCP  
A. Vector map of GFP-RCP construct.  B. A2780 cells were transfected with GFP or GFP-RCP and 
visualised by live cell microscopy. Yellow arrows indicate the PNRC. Scale bar is 10μm. 
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RCP has been previously shown to associate with Rab11 and Rab4, but not Rab5 
(Caswell et al., 2008). I sought to ensure that these associations were detectable 
using this construct. GFP or GFP-RCP were transfected into A2780 cells and GFP 
was immunopreciptated with an anti-GFP antibody. Immunoprecipitates were 
analysed by SDS-PAGE and immunoblotting using antibodies recognising GFP, 
Rab11, Rab4 and Rab5 (Figure 3.3). Rab11 co-immunoprecipitated very 
efficiently and specifically with GFP-RCP. As expected Rab5 was absent from 
GFP-RCP immunoprecipitation indicating the specificity of the RCP-Rab11 
interaction. Surprisingly, Rab4 was not present in the GFP-RCP co-
immunoprecipitation. The association between Rab4 and RCP was demonstrated 
by yeast-2-hybrid (Lindsay et al., 2002), but only found weakly associated using 
in vitro binding assays (Peden et al., 2004), so perhaps this interaction is not 
found in vivo.  
 
Figure 3-3 GFP-RCP associates with Rab11, but not Rab4 or Rab5 
A2780 cells were transfected with GFP or GFP-RCP. GFP was immunoprecipitated from the 
lysates with an anti-GFP antibody 48 hours after transfection. Immunoprecipitates were analysed 
by SDS-PAGE. GFP, Rab11, Rab5 and Rab4 were detected by immunoblotting. 
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The association of EGFR and α5β1-integrin with RCP is known to be enhanced 
upon engagement of αvβ3-integrin with its soluble ligand osteopontin, or 
Cilengitide (Caswell et al., 2008; Dechantsreiter et al., 1999). To corroborate 
this finding, GFP-RCP was expressed and immunoprecipitated from A2780 cells 
treated with Cilengitide, osteopontin or vehicle control for 30 minutes. Indeed, 
GFP-RCP was found associated with both α5-integrin and EGFR and this 
association was enhanced upon osteopontin and Cilengitide treatment (Figure 
3.4). 
 
 
Figure 3-4 GFP-RCP associates with α5-integrin and EGFR 
A2780 cells were transfected with GFP or GFP-RCP and treated with 1μM Cilengitide, 0.5μg/ml 
Osteopontin or vehicle control for 30 minutes before cell lysis. GFP was immunoprecipitated from 
the lysates with an anti-GFP antibody. Immunoprecipitates were analysed by SDS-PAGE. GFP, 
α5-integrin and EGFR were detected by immunoblotting. This was performed by Pat Caswell. 
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3.2.1.2 RCP interactome 
Having confirmed the effectiveness and specificity of the GFP-RCP 
immunoprecipitation, I immunoprecipitated GFP-RCP (using GFP as a control) 
from A2780 cells under various conditions that might be expected to alter the 
RCP interactome (such as Cilengitide treatment or overexpressing Rab25). 
MALDI-TOF mass spectrometry was used to identify the co-immunoprecipitated 
proteins. Coomassie blue staining of SDS-PAGE gels of the immunoprecipitations 
revealed a number of proteins to be associated with both the GFP-RCP and GFP 
immunoprecipitates and these were deemed to be non-specific (Figure 3.5). 
Nevertheless, the GFP-RCP immunoprecipitates contained a number of proteins 
that were not detectable in the GFP immunoprecipitates and these are likely to 
be proteins that specifically associated with RCP. Amongst these a band 
corresponding to GFP-RCP itself was clearly visible. To identify these specifically 
associated proteins the SDS-PAGE gels were cut into strips and the protein was 
extracted from the gel and digested with trypsin. The resulting peptides were 
identified using MALDI-TOF mass spectrometry and analysed using Scaffold 
software. Proteins that were not significantly different between GFP-RCP and 
GFP immunoprecipitates (the non-specific contaminant proteins) were excluded. 
Under these stringent conditions I identified a small list of proteins that were 
found to be significantly more abundant in the GFP-RCP than the GFP 
immunprecipitates.  
No consistent differences were observed in the RCP interactome between the 
control and Cilengitide treated A2780 cells nor between the control or Rab25 
expressing cells. Therefore, I have pooled the data from all the conditions and 
will consider them together (Table 3.1). Several known RCP-associated proteins 
were detected, for example, β1-integrin, EGFR and Rab11B. Most interestingly, 
novel associated RCP proteins were also found. Many of the proteins identified 
have roles in trafficking or could be potential RCP-cargoes, whilst others have 
diverse roles, such as proteins with various enzymatic activities and heat shock 
proteins. Since I am interested in cancer cell migration and trafficking, novel 
RCP associations with Rab14, Rab6 and EphA2 were confirmed and investigated. 
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Figure 3-5 RCP interactome in Coomassie stained gels 
A2780 and A2780-Rab25 cells were transfected with GFP or GFP-RCP and treated with 1μM 
Cilengitide or vehicle control for 30 minutes. The cells were lysed and GFP was 
immunoprecipitated with an anti-GFP antibody. The lysates and immunoprecipitates were 
separated by SDS-PAGE and Coomassie stained. The immunoprecipitated samples were 
separated by SDS-PAGE, and GFP-RCP and α5-integrin were detected by immunoblotting. 
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  IP:GFP IP:GFP-RCP 
Protein Accession Number 
Number of 
Peptides 
(unique) 
Percentage 
covered (%) 
Number of 
Peptides 
(unique) 
Percentage 
covered (%) 
Ubiquitin P62988 - - 4 (3) 50 
Rab11B Q15907 - - 53 (8) 40 
Rab25 P57735 1 (1) 5 51 (7) 36 
Heat shock cognate 71kDa P11142 1 (1) 3 43 (16) 32 
Rab6A P20340 - - 18 (5) 25 
α-actinin 4  O43707 - - 32 (16) 23 
RCP Q6WKZ4 - - 60 (17) 16 
Clathrin heavy chain 1 Q00610 - - 27 (15) 13 
FIP5 Q9BXF6 - - 11 (5) 13 
Rab14 P61106 - - 6 (2) 13 
5'-nucleotidase P21589 1 (1) 2 9 (5) 13 
Myoferlin Q9NZM1 - - 34 (20) 12 
Aminopeptidase N  P15144 - - 21 (9) 12 
Ephrin type-A receptor  2 P29317 - - 18 (9) 12 
Peroxisomal multifunctional 
enzyme type 2 P51659 - - 11 (5) 10 
Desmoglein 2 Q14126 - - 8 (6) 10 
Myeloid-associated differentiation 
marker Q96S97 - - 8 (2) 10 
Heat shock 70 kDa protein 1  P08107 - - 3 (3) 10 
Integrin-β1 P05556 1 (1) 1 17 (5) 9 
EGFR P00533 - - 17 (7) 8 
Neurabin 2 Q96SB3 - - 7 (6) 8 
4F2 cell-surface antigen heavy 
chain  P08195 - - 3 (3) 8 
Leucyl-cystinyl aminopeptidase Q9UIQ6 - - 6 (6) 7 
Discoidin, CUB and LCCL domain-
containing protein 2 Q96PD2 1 (1) 2 4 (4) 7 
Integrin αv P06756 - - 8 (5) 6 
Podocalyxin-like protein 1 O00592 4 (1) 3 21 (2) 5 
Integrin α2  P17301 - - 6 (4) 4 
Myosin-Id O94832 - - 4 (4) 4 
Tyrosine-protein kinase receptor 
ufo P30530 - - 3 (3) 4 
Myosin-Ie Q12965 - - 3 (3) 3 
Cation-independent mannose-6-
phosphate receptor P11717 - - 4 (4) 2 
Filamin-A P21333 - - 6 (4) 2 
Table 3-1 RCP interactome in A2780 cells 
Proteins identified by MALDI-TOF mass spectrometry that are significantly more abundant in GFP-
RCP than GFP immunoprecipitates. Proteins identified in mock treated, Cilengitde treated and 
Rab25 overexpressing cells were pooled as no significant differences between the conditions were 
observed. The number of peptides identified by mass spectrometry and the percentage of protein 
coverage by these peptides are indicated. The mass spectrometry was performed by W. Bienvenut 
and D. Sumpton. 
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3.2.2 Rab14 associates with RCP 
3.2.2.1 The role of Rab14 in trafficking and cell migration  
Rab14 is closely related to Rab2 and Rab4 based on sequence homology, and 
localises to both the Golgi apparatus and the early endosomes (Junutula et al., 
2004). Rab14 has been shown to regulate the trafficking between these 
organelles as the GTP-locked form (Rab14Q70L) localises with early endosome 
associated vesicles, whilst the GDP-locked form (Rab14S25N) localises with the 
Golgi apparatus (Junutula et al., 2004). Yamamoto et al. (2010) were the first to 
identify a Rab14 effector, RUFYI, and depletion of either Rab14 or RUFYI was 
shown to prevent efficient transferrin recycling. This work was corroborated by 
live cell imaging, which demonstrated that the transferrin receptor is trafficked 
through a Rab14 compartment distinct from the Rab5 and Rab11 compartments 
(Linford et al., 2012). This more recent work suggests that Rab14 is involved in 
receptor recycling as well as Golgi to early endosome trafficking. 
Rab14 trafficking has been shown to have several important functions. It has a 
role in the apical targeting of proteins in polarised epithelial cells (Kitt et al., 
2008). In MDCK cells, Rab14 co-localises with the junctional protein Claudin 2, 
and atypical-PKC, in both an intracellular vesicular compartment and at the 
plasma membrane (Lu et al., 2015). Indeed, atypical-PKC and Rab14 associate 
and regulate Claudin-2 trafficking from the recycling endosome back to the 
plasma membrane (Lu et al., 2015; Lu et al., 2014). Furthermore it has been 
demonstrated that Rab14 is required for efficient incorporation of the envelope 
glycoprotein complex in the HIV lifecycle (Qi et al., 2013), and has a role in the 
fusion of phagosomes and lysosomes in Dictyostelium phagocytosis (Harris and 
Cardelli, 2002). Interestingly, it has been shown that suppression of Rab14 
expression reduces the speed of A549 lung epithelial cells migrating on plastic in 
a wound healing assay (Linford et al., 2012). Reducing Rab14 expression levels 
causes an increase in N-Cadherins at cell-cell junctions, preventing the cells 
migrating away from each other. Linford et al. (2012) found that this is because 
Rab14 is required for efficient trafficking of ADAM10, which sheds N-Cadherins 
from the cell-cell contacts allowing cells to migrate into the wound (Linford et 
al., 2012). 
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3.2.2.2 Rab14 associates and co-localises with RCP 
Since Rab14 has previously been shown to have an important role in regulating 
recycling (Yamamoto et al., 2010), and is required for efficient A579 cell 
migration (Linford et al., 2012), I sought to confirm its association with RCP. 
A2780 and A2780-Rab25 cells were transfected with GFP or GFP-RCP and treated 
with Cilengitide (or mock) for 30 minutes. GFP/GFP-RCP was 
immunoprecipitated from the cell lysates and proteins separated by SDS-PAGE, 
and Rab14 and GFP were detected by immunoblotting. Endogenous Rab14 was 
found associated with GFP-RCP but not GFP alone in both mock and Cilengitide-
treated A2780 cells, as well as in Rab25 overexpressing cells (Figure 3.6A). In 
parallel, A2780 cells were transfected with GFP-Rab14 and co-
immunoprecipitations were performed as previously described. Endogenous RCP 
was found associated with GFP-Rab14 (Figure 3.6B). The Rab11-Fip family of 
proteins are divided into two classes: Class 1 (RCP, Fip2 and Rip11) have a role 
in receptor trafficking (Caswell et al., 2008; Prekeris et al., 2000; Schwenk et 
al., 2007), and class 2 (Fip3 and Fip4) are involved in cytokinesis  (Fielding et 
al., 2005; Simon et al., 2008). My collaborators have analysed the association 
further and found that Rab14 associated with all Class1-Fips but not Class2-Fips 
in a GTP-dependent manner in yeast-2 hybrid studies (Kelly et al., 2010). 
To determine whether Rab14 and RCP co-localise, GFP-RCP and mCherry-Rab14 
were co-transfected into H1299 cells and seeded onto glass-bottomed plates. 
Confocal microscopy was used to visualise the cells, and showed that there is 
some co-localisation of Rab14 and RCP in the perinuclear region (Figure 3.6C). 
Furthermore, co-immunofluorescence studies demonstrated that Rab14 co-
localises with RCP, Fip2 and Rip11 (Kelly et al., 2010). Taken together these 
data show that Rab14 associates and colocalises with all the Class1-Fips.  
3.2.2.3 Rab14 associates with the C-terminal region of RCP containing the 
RBD 
To determine whether Rab14 associated with a specific RCP protein domain, the 
association between RCP and Rab14 was further analysed using several GFP-
tagged RCP truncations in co-immunoprecipitation studies (Figure 3.7A). Rab14 
associated with the C-terminal fragment of RCP, containing the coiled-coiled 
domain and the Rab Binding Domain (RBD) (Figure 3.7B). Interestingly, when 
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GFP-RCP is mutated in the RBD (I621E), a substitution that is known to prevent 
Rab11 binding, Rab14 was no longer found associated with GFP-RCP (Figure 
3.7B). Therefore, I propose that Rab11 and Rab14 both interact with RCP’s RBD, 
or that Rab14 can only associate with RCP only once it is already associated with 
Rab11. I have looked in detail at the role of Rab14 in cell migration in chapter 4 
(Section 4.2.3). 
 
Chapter 3  95 
 
 
Figure 3-6 Rab14 associates and partially co-localises with RCP 
A. A2780 and A2780-Rab25 cells were transfected with GFP or GFP-RCP for 48 hours. The cells 
were treated with 1μM Cilengitide or vehicle control for 30 minutes and GFP was 
immunoprecipitated from the cell lysates with an anti-GFP antibody. The immunoprecipitates were 
analysed by SDS-PAGE, and Rab14 and GFP were detected by immunoblotting. B. GFP or GFP-
Rab14 were transfected in A2780 cells for 48 hours. GFP was immunoprecipitated using an anti-
GFP antibody and the proteins were separated by SDS-PAGE. RCP and GFP were detected by 
immunoblotting. C. H1299 cells were transfected with GFP-RCP and mCherry-Rab14 and seeded 
onto glass-bottomed plates. The cells were visualised and representative images are shown. The 
scale bar represents 10µm. 
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Figure 3-7 Rab14 associates with the C-terminal region of RCP 
A. Schematic representation of RCP truncates and a point mutant, which abolishes the RCP-
Rab11 interaction. Green fragments were found associated with Rab14, whilst red fragments were 
not found associated with Rab14. B. A2780 cells were transfected with GFP, GFP-RCP2-649, GFP-
RCP2-199, GFP-RCP199-649, GFP-RCP379-649 or GFP-RCPI621E. GFP was immunoprecipitated 48 
hours after transfection with an anti-GFP antibody. Immunoprecipitates were analysed by SDS-
PAGE, and GFP and Rab14 were detected by immunoblotting. 
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3.2.3 Rab6 associates with RCP  
3.2.3.1 The role of Rab6 in retrograde trafficking and cytokinesis  
There are three Rab6 isoforms: Rab6A, Rab6A’ and Rab6B. Rab6A and Rab6A’ only 
differ by three amino acids in the GTP binding domain and are generated by 
alternative splicing of homologous exons within the gene (Figure 3.9A) (Echard 
et al., 2000). Rab6B is less well characterised and is encoded by a second gene, 
which displays 91% homology to Rab6A/A’ protein (Figure 3.8). Rab6A and 
Rab6A’ are ubiquitously expressed, whilst Rab6B is preferentially expressed in 
the brain (Opdam et al., 2000). 
The Rab6 subfamily were originally described as Golgi-associated GTPases 
involved in regulating retrograde transport (Goud et al., 1990). Rab6 has been 
shown to have a role in several diseases for which the retrograde trafficking 
pathway is important, for example, in Herpes (Johns et al., 2014), HIV (Brass et 
al., 2008) and Alzheimer’s disease (Elfrink et al., 2012). Overexpression of 
dominant positive (Q72L) and negative (T27N) Rab6A and Rab6A’ mutants showed 
that Rab6A’ regulates trafficking from endosomes to the trans-Golgi network 
(TGN), whilst Rab6A regulates Golgi to ER trafficking (Mallard et al., 2002; White 
et al., 1999). In another study Rab6A and Rab6A’ isoforms were specifically 
targeted by siRNA. This revealed that Rab6 is largely dispensable in Shiga toxin 
retrograde trafficking events, whilst suppressing Rab6A’ expression disrupted this 
trafficking (Del Nery et al., 2006). The consensus of these studies is that Rab6 
has a role in retrograde transport, but the exact order and involvement of the 
different isoforms is disputed.   
As well as retrograde trafficking, Rab6 has been shown to be involved in 
exocytosis. Indeed, Rab6A co-localises with the microtubule motor protein 
Kinesin-1 on exocytic vesicles (Grigoriev et al., 2007). Rab6A is thought to have a 
role in vesicular docking and fusion in both Hela cells and in C.elegans oocyte-
embryo transition (Grigoriev et al., 2011; Kimura and Kimura, 2012). It is unclear 
how and why Rab6 is involved in anterograde and retrograde trafficking. 
Interestingly, more recent studies have shown a role for Rab6A trafficking in the 
immune system. Expression of a Rab6A dominant-negative mutant, or depletion 
of its expression, inhibits TNF secretion in macrophages (Micaroni et al., 2013). 
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Rab6 has been shown to have an important role in three more functions: 
cytokinesis and maintaining Golgi homeostasis. Silencing Rab6 expression 
increases the number and size of TGN cisternae (Storrie et al., 2012), perhaps 
due to the accumulation of vesicles that can no longer bud from the TGN. Many 
Rab6 effector proteins have been identified, and several of these proteins have 
been shown to have a role with Rab6 in cytokinesis. For example, Rabkinesin-6 is 
a kinesin like interacting protein involved in transport along the cytoskeleton 
during cytokinesis (Echard et al., 1998), and GAPCenA is a Rab6 GAP that is 
associated with the centrosome, co-ordinating microtubule and Golgi dynamics 
(Cuif et al., 1999). 
3.2.3.2 A2780 cells express all isoforms of Rab6 
Many Rab6 peptides were identified in the GFP-RCP immunoprecipitates in A2780 
and A2780-Rab25 cells. The peptide sequences were analysed to determine 
whether the Rab6 association with RCP might be isoform-specific. However, the 
peptides identified from the GFP-RCP co-immunoprecipitation were a mix of 
Rab6A/A’ isoform-specific and non-specific peptides (Figure 3.8). To determine 
whether one specific Rab6 isoform associates with RCP, I first sought to 
determine whether all three isoforms were expressed in A2780 cells. Briefly, 
mRNA was extracted from A2780 and A2780-Rab25 cells and synthesised into 
cDNA. Rab6A/A’ and Rab6B specific primers were used to amplify Rab6A/A’ and 
Rab6B from the cDNA by PCR. The DNA products were run in a 1% agarose gel. 
Both cell types expressed both Rab6A/A’ and Rab6B isoforms (Figure 3.9B). It is 
possible to distinguish between the Rab6A and Rab6A’ isoforms, as the Rab6A’ 
alternatively spliced exon contains a unique Pst1 site (Figure 3.9A) (Echard et 
al., 2000). Therefore, the amplified Rab6A/A’ gene transcript was digested with 
Pst1 and the DNA products were run in a 1% agarose gel indicating that A2780 
and A2780-Rab25 cells express all three Rab6 isoforms (Figure 3.9C). 
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Figure 3-8 Rab6 peptides identified by mass spectroscopy in the RCP interactome 
The Rab6 family of proteins were aligned using BLAST. Differences in the isoforms are shown 
between Rab6A and Rab6A’ (*), and between RabA/A’ and Rab6B (#). Coloured text indicates the 
peptides identified by mass spectrometry that were found associated with GFP-RCP (orange 
represents peptides identified and brown represents overlapping peptides). 
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Figure 3-9 Rab6 family expression in A2780 and A2780-Rab25 cells 
A. Rab6A and Rab6A′ are generated by splicing alternative exons whereas Rab6B is encoded by a 
separate gene. Both isoforms were amplified by Rab6A/A′ specific primers but could be 
distinguished by a unique Pst1 site in the Rab6A′ specific exon. B. mRNA was extracted from 
A2780 and A2780–Rab25 cells and synthesised into cDNA. Isoform-specific primers were used in 
PCR to amplify Rab6A/A′ (675bp), Rab6B (383bp) and β-actin (235bp, control) from the template 
cDNA. DNA products were run in a 1% agarose gel.  C. Rab6A/A′ PCR product (B.) was purified 
and digested with Pst1. Undigested Rab6A is 675bp whilst digested Rab6A′ is 264bp and 411bp.  
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3.2.3.3 Rab6A and Rab6B associate with RCP 
Endogenous Rab6A was found to efficiently co-immunoprecipitate with GFP-RCP 
in both A2780 and A2780-Rab25 cells (Figure 3.10). To further confirm this 
association, and determine whether the RCP association is specific for the Rab6A 
isoform, plasmids were cloned in which Rab6A and Rab6B were N-terminally 
tagged to GFP (Figure 3.11A). These plasmids were transfected into A2780 cells 
and GFP was immunoprecipitated with an anti-GFP antibody. GFP-Rab6A and 
GFP-Rab6B were well-expressed in these cells, and immunoblot analysis using an 
anti-GFP antibody detected bands at the appropriate sizes (Figure 3.11B). 
Endogenous RCP was found to co-immunoprecipitate with both GFP-Rab6A and 
GFP-Rab6B. These data confirm that there is an association between RCP and 
both Rab6A and Rab6B. 
 
Figure 3-10 GFP-RCP associates with endogenous Rab6A 
A2780 and A2780-Rab25 cells were transfected with GFP or GFP-RCP. GFP was 
immunoprecipitated from the cell lysates 48 hours after transfection with an anti-GFP antibody and 
the immunoprecipitates were analysed by SDS-PAGE. Rab6A and GFP were detected by 
immunoblotting. 
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Figure 3-11 GFP-Rab6A and GFP-Rab6B associate with endogenous RCP 
A. Vector maps of the GFP-Rab6A and GFP-Rab6B constructs. B. A2780 cells were transfected 
with GFP-Rab6A or GFP-Rab6B. GFP was immunoprecipitated and the proteins were analysed by 
SDS-PAGE. RCP and GFP were detected by immunoblotting. 
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3.2.3.4 Rab6B directly interacts with RCP 
Co-immunoprecipitation assays show whether there is an association between 
two proteins, but do not indicate whether this association is a direct interaction 
or an indirect association. In order to ascertain whether Rab6 and RCP interact 
directly, in vitro binding assays were performed. First a GST-Rab6B fusion 
construct was cloned (Figure 3.12A). His-RCP and GST-Rab6B were expressed in 
E.coli and the proteins were purified. These recombinant proteins were then 
used in GST pull-down assays. Briefly, His-RCP was incubated with GST/GST-
Rab6B bound Gluthathione beads. The beads were thoroughly washed and then 
boiled in sample buffer. The proteins were separated by SDS-PAGE and analysed 
by immunoblotting. His-RCP was associated with GST-Rab6B but not GST alone, 
which indicates that these proteins are capable of forming a direct interaction 
with one another (Figure 3.12B). 
3.2.3.5 Rab6 associates with the central region of RCP  
Since the interaction between RCP and Rab6B was found to be potentially direct, 
I sought to identify which RCP domain interacts with Rab6. This showed that 
Rab6A associates with the central region of RCP, RCP199-379 by co-
immunoprecipitation (Figure 3.13A/B). Little is known about this region of RCP, 
except the presence of PEST sequences, which can target RCP for calpain 
cleavage (Marie et al., 2005). In comparison, Rab11 and Rab14 interact with the 
C-terminal fragment of RCP, RCP379-649, which contains the Rab binding domain 
(RBD). Mutating a key residue in this domain, I621E, reduced the association 
between Rab11 and RCP (Lindsay and McCaffrey, 2004) (Figure 3.13A). Although 
Rab6 and Rab11 associate with different RCP truncations, Rab6 was not found 
associated with RCPI621E, suggesting that the Rab11-RCP interaction is required 
before Rab6 can interact with RCP. 
3.2.3.6 GFP-Rab6 and mCherry-RCP do not co-localise  
Live cell microscopy was used to visualise RCP and Rab6 and to determine 
whether they are localised in the same sub-cellular compartment. mCherry-
tagged RCP and GFP-tagged Rab6A or Rab6B (as well as mCherry and GFP 
controls) were transfected into A2780 cells and visualised by confocal 
microscopy. Both RCP and Rab6 were found to be localised to a peri-nuclear 
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compartment (Figure 3.14). However, although the RCP and Rab6 
compartments were found very close together, under closer examination no co-
localisation was detected (Figure 3.14). 
 
Figure 3-12 RCP directly associates with Rab6B  
A. Vector maps of the GST-Rab6B and His-RCP constructs. B. Purified recombinant GST-Rab6B 
or GST were immobilised onto Glutathione agarose beads. The beads were washed and incubated 
for 2 hours at 4ºC with purified recombinant His-RCP. The beads were washed thoroughly and the 
associated protein eluted. Eluates were separated by SDS-PAGE. His and GST were detected by 
immunoblotting.  
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Figure 3-13 Rab6A associates with the central region of RCP  
A. A2780 cells were transfected with GFP, GFP-RCP2-649, GFP-RCP2-199, GFP-RCP199-649, GFP-
RCP379-649 or GFP-RCPI621E. GFP was immunoprecipitated 48 hours after transfection with an anti-
GFP antibody. Immunoprecipitates were analysed by SDS-PAGE, and GFP, Rab6A and Rab11 
were detected by immunoblotting. B. Schematic representation of RCP with a blue line showing the 
region in which Rab6A associated with RCP. 
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Figure 3-14 GFP-Rab6A/Rab6B and mCherry-RCP do not co-localise 
A2780 cells were transfected with the following plasmids: GFP and mCherry-RCP, GFP-Rab6B 
and mCherry, GFP-Rab6B and mCherry-RCP, and GFP-Rab6A and mCherry-RCP. The cells were 
directly seeded onto glass-bottomed dishes and visualised by live confocal microscopy 24 hours 
after transfection. Representative images are shown with a scale bar of 10μm. 
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Taken together these data show that RCP associates with both Rab6A and Rab6B 
and this association is potentially direct. Rab6 associates with the central region 
of RCP and is only found associated with RCP if the Rab11 binding site (I621) is 
maintained. Overexpressed GFP-Rab6A/B and mCherrry-RCP localise in 
neighbouring but non-overlapping compartments in A2780 cells.   
3.2.3.7 Depleting Rab6A and Rab6B expression increases A2780-Rab25 but 
not A2780 cell invasion 
The role of Rab6 in cell migration and invasion has not been previously 
investigated. I sought to determine whether Rab6 has an involvement in A2780 
cell invasion. First Rab6A/A’ expression was transiently suppressed using Rab6A-
specific siRNA SMARTpool and the Rab6A/A’ knockdown was assessed by Western 
blotting (Figure 3.16A). To determine whether the knockdown was isoform-
specific, mRNA was extracted from the Rab6A/A’ knockdown cells and used to 
synthesise cDNA. cDNA was used as a template in PCR using Rab6A/A’ and Rab6B 
specific primers and run in 1% agarose gels (Figure 3.16B). Taken together this 
showed that Rab6A/A’ (but not Rab6B) expression is reduced by transfection of 
siRNA targeting Rab6A, thus confirming the isoform-specificity of the siRNA 
strategy. A2780 cells treated with Rab6A/A’-targeting or non-targeting siRNA 
were seeded onto the bottom of transwells and allowed to migrate through a 
fibronectin enriched Matrigel plug towards an EGF serum gradient (Figure 3.15). 
This analysis revealed that the suppression of Rab6A expression had no effect on 
A2780 cell invasion (Figure 3.16C/D). 
A2780 cells are not particularly invasive, so I sought to determine whether Rab6 
is required for invasion in a more invasive cell line, A2780-Rab25 cells (Caswell 
et al., 2007). A2780-Rab25 cells were transfected with Rab6A, Rab6B and non-
targeting siRNA and lysed after 48 hours. Immunoblotting analysis using an anti-
Rab6A antibody demonstrated that Rab6A protein expression was suppressed 
(Figure 3.17A). The same anti-Rab6A antibody detected a weak suppression of 
Rab6A expression upon Rab6B-targeting siRNA transfection (Figure 3.17B), 
suggesting that the Rab6B-targeting siRNA treatment had an effect on Rab6A 
expression levels or that the antibody is not very specific. To ensure the 
specificity of the Rab6B siRNA, PCR was performed. Reduction in Rab6B but not 
Rab6A mRNA was observed in Rab6B-targeting siRNA transfected cells, which 
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demonstrated that the Rab6B-targeting siRNA was isoform-specific (Figure 
3.17C). A2780-Rab25 cells treated with Rab6A- or Rab6B-targeting siRNA were 
seeded onto inverse invasion assays. Intriguingly, suppression of either Rab6A or 
Rab6B expression significantly increased the invasiveness of A2780-Rab25 cells 
(Figure 3.18). I did not persue this association further due to time limitations 
and instead persued the functional relevance of the association between EphA2, 
Rab14 and RCP.  
 
 
 
Figure 3-15 Schematic representation of the invasion assay 
The cells migrated through the filter and invaded into the Matrigel up an EGF and serum gradient. 
Sample confocal optical sections of calcein-AM stained invading cells are shown. 
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Figure 3-16 Suppression of Rab6A/A’ has no effect on A2780 cell invasion 
A2780 cells were transfected with non-targeting (Nt) or Rab6A/A’-targeting siRNA. A. The cells 
were lysed 24, 48, and 72 hours after transfection, and the proteins were extracted and separated 
by SDS-PAGE. Rab6A and Rab14 (loading control) were detected by immunoblotting. The 
samples were run and transferred on the same gel and blot. B. mRNA was extracted from the 
transfected A2780 cells 48 hours after transfection and synthesised into cDNA. Isoform-specific 
primers were used in PCR to amplify Rab6A/A′ (675bp), Rab6B (383bp) and β-actin (235bp, 
control) from the template cDNA. DNA products were run in the same 1% agarose gel. C. Nt or 
Rab6A/A’ siRNA treated cells were plated on the underside of transwell plugs containing Matrigel 
enriched with 25μg/ml fibronectin. The cells migrated towards EGF supplemented serum rich 
media for 72 hours, and were stained with calcein-AM to visualise invasion by confocal microscopy. 
Optical sections were taken every 15μm and consecutive images were assembled from left to right. 
D. Quantification of cells invading beyond 30μm relative to A2780 cells transfected with Nt siRNA. 
The graph shows the averages and SEM of twelve regions of cell invasion in four transwell plugs 
from two separate experiments (n/s: not statistically significant). 
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Figure 3-17 Suppression of Rab6A/A’ and Rab6B expression in A2780-Rab25 cells 
A2780-Rab25 cells were transfected with Rab6A/A’-, Rab6B- or non-targeting (Nt) siRNA. A. 
Rab6A/A’ and Nt siRNA transfected cells were lysed 48 hours after transfection and Rab6A and 
Vinculin were detected by immunoblotting. B. Rab6B and Nt siRNA transfected cells were lysed 48 
and 72 hours after transfection and Rab6A and GAPDH were detected by immunoblotting. C. 
mRNA was extracted from the Rab6B and Nt siRNA transfected A2780 cells, 24, 48 and 72 hours 
after transfection and synthesised into cDNA. Isoform-specific primers were used in PCR to amplify 
Rab6A/A′ (675bp), Rab6B (383bp) and β-actin (235bp, control) from the template cDNA. DNA 
products were run in a 1% agarose gel. 
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Figure 3-18 Suppression of Rab6A/A’ or Rab6B increases the invasiveness of A2780-Rab25 
cells 
A2780-Rab25 cells were transfected with Rab6A-, Rab6B- or non-targeting (Nt) siRNA 
SMARTpools and were plated on the underside of transwell plugs containing Matrigel enriched with 
25μg/ml fibronectin. The cells migrated towards EGF-supplemented serum rich media for 72 hours, 
and were stained with calcein-AM to visualise invasion by confocal microscopy. A. Optical sections 
were taken every 15μm and consecutive images were assembled from left to right. B. 
Quantification of cells invading beyond 30μm relative to A2780-Rab25 cells transfected with Nt 
siRNA. The graph shows the averages and SEM of 24 regions of cell invasion in 8 transwell plugs 
from four separate experiments for Nt and Rab6A/A’ siRNA transfection, and 6 regions of cell 
invasion in 2 transwell plugs for Rab6B siRNA transfection.  
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3.2.4 EphA2 associates with RCP 
3.2.4.1 Ephs have a complex role in cancer and little is known about their 
trafficking 
The roles of Ephs and Ephrins in human cancers are thoroughly documented, but 
their roles in tumour etiology, progression and metastasis are complex and there 
are many discrepancies between different studies (Pasquale, 2010). They can act 
as both tumour suppressors and oncogenes, and have diverse roles in metastasis 
and cell migration, as previously discussed (Section 1.2.6.3). Some recent work 
has shown that EphA2 is internalised then either degraded or recycled back to 
the membrane (Section 1.3.5) (Boissier et al., 2013). However, no work has 
determined the role of EphA2 recycling or identified any proteins involved in 
EphA2 recycling. I identified EphA2 as a novel RCP-associated protein in my 
proteomic screen (Table 3.1). Since EphA2 has an interesting role in migration 
and little is known about its recycling, it would be interesting to confirm its 
association with RCP and investigate whether RCP has a role in known EphA2 
functions. 
3.2.4.2 EphA2 is the only EphA expressed in A2780 cells 
All but one of the ten unique EphA2-derived peptides identified in the proteomic 
screen were found in the C-terminal cytoplasmic region of the protein (Figure 
3.19). Since only one of the fourteen Eph proteins was identified in the screen, I 
sought to determine whether EphA2 is the only Eph expressed in A2780. RNA was 
extracted from the A2780 cells and subjected to microarray analysis on a HG U-
133 Plus 2.0 chip (performed by M. Dozynkiewicz). I analysed these data to 
determine which Eph receptors and ligands were expressed and found that 
EphA2 was the only EphA with mRNA present in A2780 cells, but two EphBs were 
also expressed: EphB1 and EphB2 (Table 3.2). Three Ephrins were also 
identified.    
Chapter 3  113 
 
 
Figure 3-19 Ten unique EphA2 peptides were identified in the proteomic screen  
A. Schematic representation of EphA2 with colours highlighting each protein domain and motif. B. 
EphA2 protein sequence with colours corresponding to A. The bold and underlined regions 
highlight peptides that were identified by mass spectrometry in the GFP-RCP but not GFP 
immunoprecipitates. (LBD: ligand binding domain, Cys Rich: cysteine rich region, FNIII: fibronectin 
type 3 repeats, TM: transmembrane domain, TK: tyrosine kinase domain, SAM: sterile α motif, 
PBM: PDZ binding motif)  
 
 
 
 
 
 
 
Chapter 3  114 
 
 
 Human Cell lines 
Gene A2780 H1299  PC3  
EphA1 
 
  
EphA2 + + + 
EphA3    
EphA4     + 
EphA5    
EphA6       
EphA7    
EphA8       
EphA10    
EphB1 +     
EphB2 + + + 
EphB3     + 
EphB4  + + 
EphB6     + 
EphrinA1  + + 
EphrinA2       
EphrinA3   + 
EphrinA4 + + + 
EphrinA5 +  + 
EphrinB1     + 
EphrinB2 + + + 
EphrinB3   + + 
Table 3-2 Expression profile of Eph Receptors and Ephrins in A2780, H1299 and PC3 cells 
RNA was extracted from A2780 and H1299 cells and subjected to microarray analysis on the HG 
U-133 Plus 2.0 chip and Illumina HT12 microarray, respectively (performed by M. Dozynkiewicz 
and P. Muller). At least one probe was present in the arrays for each gene of interest. The 
expression profile of Eph receptors and Ephrins in PC3 cells was taken from Astin et al. (2010). 
Eph receptor and Ephrin genes found to be expressed in each cell type are indicated (+). 
 
 
3.2.4.3 EphA2 associates with RCP 
EphA2 co-immunoprecipitated with GFP-RCP in both control and Rab25-
overexpressing A2780 cells (Figure 3.20A/B). To further confirm this association 
in cells that had not been transfected, endogenous EphA2 was 
immunoprecipitated from cell lysates of a number of different cell types. RCP 
was found to efficiently co-immunoprecipitate with EphA2 in A2780, PC3 and 
H1299 cells (but not with a control –RG16) (Figure 3.20C-E).  
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Figure 3-20 EphA2 associates with RCP 
A/B. A2780 (A.) or A2780-Rab25 (B.) cells were transfected with GFP or GFP-RCP for 48 hours. 
A2780 cells were treated with 1μM Cilengitide or mock for 30 minutes. The cells were lysed and 
GFP was immunoprecipitated from the cell lysates with an anti-GFP antibody. The 
immunoprecipitates were analysed by SDS-PAGE, and EphA2 and GFP were detected by 
immunoblotting. C-E. A2780 (C.), PC3 (D.) or H1299 (E.) cells were lysed and endogenous EphA2 
was immunoprecipitated using an anti-EphA2 or RG16 (control) antibody. The immunoprecipitates 
were separated by SDS-PAGE, and EphA2, RCP and Rab11 were detected by immunoblotting.  
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3.2.4.4 The internal pool of EphA2 co-localises with RCP and Rab11 
EphA2 has previously been reported to be localised in a peri-nuclear 
compartment in HT-29 colon carcinoma cells (Orsulic and Kemler, 2000). 
Therefore, immunofluorescence was used to determine whether EphA2 is found 
at the peri-nuclear recycling compartment (PNRC) in which RCP localises. Anti-
RCP or anti-Rab11 antibodies were used in combination with an anti-EphA2 
antibody on fixed H1299 cells. Confocal microscopy was used to visualise the 
localisation of these proteins. EphA2 was found localised at cell-cell junctions 
and in membrane ruffles (Figure 3.21). A fraction of EphA2 was found in an 
intracellular pool that co-localised with both RCP and Rab11 in the PNRC (Figure 
3.21). 
 
Figure 3-21 The internal pool of EphA2 co-localises with RCP and Rab11 
H1299 cells were seeded onto coverslips and fixed with 4% paraformaldehyde (PFA). The cell 
membranes were permeabilised with 0.2% Triton-X100 for 5 minutes and blocked in 5% BSA for 
30 minutes. Immunostaining was performed with mouse-anti-EphA2 and chicken-anti-RCP/rabbit-
anti-Rab11, and Cy2-anti-mouse and Cy-3-anti-chicken/rabbit antibodies for 1 hour. Coverslips 
were thoroughly washed with PBS and mounted with Vectashield mounting media. Cells were 
viewed by confocal microscopy and representative images are shown. 
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3.2.4.5 EphA2 associates with all Rab11-Fips 
The five members of the Rab11-Fip family of proteins are divided into two 
classes: Class 1 (RCP, Fip2 and Rip11) are involved in trafficking various 
receptors (Caswell et al., 2008; Prekeris et al., 2000; Schwenk et al., 2007), 
whereas class 2 (Fip3 and Fip4) have a role in cytokinesis  (Fielding et al., 2005; 
Simon et al., 2008) (Figure 3.22A). To determine which of these Rab11-Fips 
were able to associate with EphA2, I expressed GFP-fused proteins of each of the 
Rab11-Fips in A2780 cells. EphA2 was found to associate with all of the GFP 
tagged Rab11-Fips (Figure 3.22B), thus demonstrating that the association is not 
specific for RCP. 
3.2.4.6 EphA2 associates with the C-terminal region of RCP 
The association between RCP and EphA2 was further investigated by expressing 
GFP-tagged truncations of RCP in A2780 cells. EphA2 associated with the C-
terminal portion of RCP, which contains the coiled-coiled domain and RBD, but 
not the N-terminal portion (Figure 3.23). Interestingly, EphA2 associated with 
the same C-terminal portion of RCP that has previously been shown to bind to 
α5β1-integrin (Caswell et al., 2008). EphA2 was not found associated with the 
Rab11-binding deficient mutant of RCP (I621E) (Figure 3.23), indicating the 
likelihood that RCP must be recruited to membranes by association with Rab11 
in order to be capable of recruiting EphA2. 
3.2.4.7 α5β1-integrin does not act as a molecular bridge between EphA2 and 
RCP 
Previous studies have reported an association between α5β1-integrin and EphA2 
(Makarov et al., 2013; Prévost et al., 2005). Therefore, I hypothesised that 
α5β1-integrin could act as a molecular bridge holding EphA2 and RCP together 
into a co-immunoprecipitable complex. To test this, EphA2 was 
immunoprecipitated from cells in which α5-integrin levels were suppressed using 
siRNA. RCP co-immunoprecipitated with EphA2 in the presence and absence of 
α5-integrin (Figure 3.24), which suggests that α5β1-integrin is not acting as a 
molecular bridge between EphA2 and RCP. 
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Figure 3-22 EphA2 associates with all Rab11-FIPs  
A. Schematic representation of the class 1 and class 2 Rab11-Fips. B. A2780 cells were 
transfected with GFP, GFP-RCP, GFP-Fip2, GFP-Rip11, GFP-Fip3 or GFP-Fip4. GFP was 
immunoprecipitated 48 hours after transfection with an anti-GFP antibody. Immunoprecipitates 
were analysed by SDS-PAGE, and GFP and EphA2 were detected by immunoblotting. (C2: 
membrane targeting domain, CC: coiled-coiled region, RBD: Rab binding domain, PRR: Proline 
rich region, EF: EF hand motif). 
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Figure 3-23 EphA2 associates with the C-terminal region of RCP 
A. A2780 cells were transfected with GFP, GFP-RCP2-649, GFP-RCP2-199, GFP-RCP199-649, GFP-
RCP379-649 or GFP-RCPI621E. GFP was immunoprecipitated 48 hours after transfection with an anti-
GFP antibody. Immunoprecipitates were analysed by SDS-PAGE, and GFP and EphA2 were 
detected by immunoblotting. B. Schematic representation of RCP with the location of the EphA2 
association marked. 
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Figure 3-24 Suppression of α5-integrin levels has no effect on the association between 
EphA2 and RCP 
A2780 cells were transfected with non-targeting (Nt) or α5-integrin-targeting siRNA. The cells were 
lysed 48 hours after transfection and EphA2 was immunoprecipitated from the lysates with an anti-
EphA2 or an RG16 control antibody was used. The immunoprecipitates were analysed by SDS-
PAGE, and EphA2, α5-integrin, β-tubulin and RCP were detected by immunoblotting.  
 
 
3.2.4.8 Generation of a GFP-tagged EphA2 and validation of its functionality 
A GFP-EphA2 construct was cloned to determine whether it would associate with 
His-RCP, and as a tool for further work on EphA2. In addition, we tested whether 
it was functionally active by seeing whether it responded to EphrinA1. The 
EphA2 gene was amplified with primers, digested with restriction enzymes and 
ligated into the pEGFP-N1 plasmid (Figure 3.25A). The plasmid was transfected 
into A2780 cells, the cells were lysed and EphA2, GFP and β-tubulin were 
detected by immunoblotting. A band was observed at ~150kDa in the GFP and 
EphA2 blots, which is the predicted size of GFP-EphA2 (Figure 3.25B). This 
shows that GFP-EphA2 is well expressed by A2780 cells. Next, I sought to 
determine whether GFP-EphA2 is capable of associating with RCP. A2780 cells 
were co-transfected with His-RCP and GFP-EphA2/GFP. The cells were lysed and 
GFP was immunoprecipitated from the lysates. The immunoprecipitates were 
analysed by SDS-PAGE and Western blotting. Indeed, His-RCP was found co-
immunoprecipitated with GFP-EphA2 but not GFP, thus demonstrating that GFP-
EphA2 can associate with His-RCP (Figure 3.25C). 
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Figure 3-25 GFP-EphA2 associates with His-RCP 
A. Vector map of the GFP-EphA2 construct. B. H1299 cells were transfected with GFP or GFP-
EphA2. The cells were lysed 24 hours after transfection and the lysates were analysed by SDS-
PAGE. EphA2, β-tubulin and GFP were detected by immunoblotting. C. A2780 cells were 
transfected with GFP/GFP-EphA2 and His-RCP. The cells were lysed 48 hours after transfection 
and GFP was immunoprecipitated using an anti-GFP antibody. The immunoprecipitates were 
separated by SDS-PAGE, and EphA2 and His were detected by immunoblotting. 
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It has previously been shown that addition of EphrinA1-soluble ligand binds to 
EphA2 and leads to its internalisation (Astin et al., 2010). To determine whether 
GFP-EphA2 is functional in this regard, EphrinA1 was added to GFP-EphA2-
expressing cells and the localisation of the fluorescent reporter was visualised, 
whilst farnesylated-GFP expressing cells (GFP-f) were used as a control. GFP-f 
localises to the plasma membrane but would not be expected to bind to 
EphrinA1. GFP-EphA2 was localised to the plasma membrane and small positive 
vesicles were observed in the cells (Figure 3.26). The cells were then treated 
with EphrinA1-Fc coupled to IgG (to cluster the Eph ligands), or Fc coupled to 
IgG as a control. Addition of EphrinA1-Fc/IgG drove extensive internalisation of 
GFP-EphA2 into small cytoplasmic vesicles, whereas Fc/IgG was ineffective in 
this regard (Figure 3.26). Moreover, distribution of GFP-f was not affected by 
addition of clustered EphrinA1-Fc. These data indicate that the GFP-EphA2 
fusion protein is functionally active, and is capable of associating with and being 
activated by its cognate ligand, EphrinA1. 
 
 
Figure 3-26 GFP-EphA2 internalises upon EphrinA1 treatment 
A2780 cells were transfected with GFP-f or GFP-EphA2 and seeded onto glass coverslips. The 
cells were starved and then left untreated or treated with 1μg/ml EphrinA1-Fc or 1μg/ml Fc and 
10μg/ml IgG for 30 minutes. The coverslips were fixed in 4% PFA and mounted onto slides. The 
cells were visualised by confocal microscopy and representative cells are shown with a scale bar of 
10µm. 
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3.3 Discussion  
3.3.1 RCP interactome 
Although there have been several recent publications on RCP, this was the first 
non-biased proteomic screening approach to identify novel RCP associated 
proteins. Since this screen was performed, a similar screen has been performed 
in the Norman lab comparing the RCP interactome with and without p53273H 
expression in H1299 cells (Muller et al., 2013). Many of the same associations 
were found in both screens, including Rab6, Rab14 and EphA2. Rather few 
proteins were identified since my criteria for hits were set high and any proteins 
which were also found significantly associated with GFP were excluded. This 
suggests that the hits may not be an exhaustive list of associated proteins, 
especially of proteins with peptides that are notoriously hard to detect by 
MALDI-TOF mass spectrometry. However, many of the known RCP associated 
proteins were identified, which validated this approach, and many of the novel 
proteins identified are interesting and worth pursuing. 
Several plasma membrane proteins were identified, which could be novel RCP 
cargo proteins. Two isoforms of integrin, α2 and αv, associated with RCP, 
suggesting that RCP may have a role in regulating the trafficking of other 
integrins as well as α5β1 (Table 3.1). Interestingly, two proteins were identified 
that are found in cell-cell adhesions: EphA2 is an RTK that has been found to 
have a role in cancer (Pasquale, 2010), whilst desmoglein 2  is a cadherin-type 
membrane protein that is a component of the desmosome (Saito et al., 2012). 
Less is known about the other two membrane proteins identified: Podocalyxin-
like protein 1 is a transmembrane glycoprotein in the sialomucin family that is 
expressed in colorectal cancer (Larsson et al., 2013), and Tyrosine-protein 
kinase receptor Ufo is a member of the TAM RTK family (Lemke, 2013). 
Many proteins with known roles in trafficking were identified as RCP-associated 
proteins (Table 3.1). Fip5 is another family member of the Rab11-Fips and was 
found associated with RCP. Further work would be required to determine 
whether different members of the Rab11-Fips can associate and function 
together. RCP was also found associated with two more members of the Rab-
GTPase family: Rab14, which is localised in the Golgi apparatus and early 
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endosomes (Junutula et al., 2004), and Rab6A, which is found the trans-Golgi 
network and involved in retrograde transport (Martinez et al., 1994). In addition, 
several proteins were identified that have diverse roles in vesicular trafficking 
including: clathrin heavy chain, that coats and stabilises vesicles; myoferlin, a 
protein required for vesicle fusion (Bernatchez et al., 2009); myosin and filamin, 
proteins involved in transporting vesicles (DePina and Langford, 1999; Sheen, 
2014); and α-actinin-4, a protein required for required for transferrin receptor 
recycling (Yan et al., 2005). It would be interesting to confirm that these 
proteins associate with RCP and are involved in the trafficking of RCP-positive 
vesicles.  
Some proteins were found associated with RCP that have functions independent 
of trafficking and cell migration, such as ubiquitin, heat shock proteins, a 
protein involved in fatty acid dehydroxylation, and several enzymes that have 
various activities including peptidases and nucleotidases (Table 3.1). These 
associations may allude to novel RCP functions, but they would have to be 
confirmed before further investigation. Since I am interested in cancer cell 
migration and trafficking, this thesis contains work in which the associations 
between RCP and Rab14, Rab6 and EphA2 were investigated. 
3.3.2 The Rab14-RCP association 
Rab14 has previously been shown to regulate TfnR (Yamamoto et al., 2010) and 
ADAM10 trafficking, and has a role in cell migration (Linford et al., 2012), so it is 
an interesting hit in the proteome screen to follow up. The association between 
RCP and Rab14 is confirmable by co-immunoprecipitation experiments using 
GFP-RCP or GFP-Rab14. Furthermore, live microscopy revealed that GFP-RCP and 
mCherry-Rab14 co-localise in the PNRC. This work was published alongside 
yeast-2-hybrid and far-Western data demonstrating that Rab14 directly 
associates all the Class-1 Rab11-Fips, and co-localisation studies demonstrating 
that Rab14 and RCP are found in the same sub-cellular compartment (Kelly et 
al., 2010). However, a contrary study demonstrated that Rab14 associated with 
RCP but not Fip2 or Rip11 using the same in vitro methods, and that Rab14 
associates with RCP on a site adjacent to the RBD, rather than with the RBD as I 
had initially hypothesised. It is unclear why these conflicting findings have been 
reported. Further work is required to clarify these findings. Indeed, Qi et al. 
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(2013) mapped the Rab14-RCP interaction and found two key residues required 
for this association: Serine-580 and Serine-582. Mutating these residues 
(RCPS580N/S582L) prevented Rab14 but not Rab11 co-localisation with RCP (Qi et 
al., 2013). In my study, both RCP truncations (RCP199-649 and RCP379-649) that were 
found to be capable of associating with Rab14 contain both the RBD and Serine-
580/Serine-582, thus preventing us from distinguishing the precise site of 
interaction. Mutating RCP’s RBD abolishes association with either Rab14 or 
Rab11. I have also shown that RCPI621E is unable to associate with EphA2 or Rab6; 
previous work demonstrates it is also unable to associate with EGFR or α5β1-
integrin, and is found dispersed in the cytoplasm (Caswell et al., 2008). It is 
likely that this mutation prevents RCP’s recruitment to the membrane, so it 
cannot associate with any of its partners. 
Linford et al. (2012) identified Rab14 as a strong hit in a non-biased scratch-
assay screen in A549 cells. All Rab-GTPases were targeted with siRNA to 
determine which were involved in cell migration. Suppression of Rab14 
expression inhibited cell migration, thus preventing the scratch wound from 
closing (Linford et al., 2012). The role of Rab14 in RCP-dependent trafficking 
and cell migration will be further studied in Chapter 4. 
3.3.3 The Rab6-RCP association 
I have identified Rab6 as a novel RCP-associated protein. Two Rab6 isoforms, 
Rab6A and Rab6B, associate with RCP; the latter directly interacts in vitro. Since 
Rab6A and Rab6A’ differ by only 3 amino acids it is likely that both isoforms 
associate with RCP. Despite this, GFP-Rab6A and GFP-Rab6B do not co-localise 
with mCherry-RCP in A2780 cells. I sought to look at the localisation of 
endogenous Rab6 by immunofluorescence, however no signal was seen with 
several anti-Rab6 antibodies. Perhaps under certain conditions these proteins co-
localise, for example if cells are migrating or are in a different 
microenvironment. Further work would be required to investigate this. 
Rab6 has been shown to have a role in regulating retrograde trafficking (White 
et al., 1999). R6IP1 (Rab6 interacting protein 1) acts as a Rab6 effector and also 
associates with Rab11A, where it is proposed to regulate retrograde transport 
between Rab11-positive recycling endosomes and Rab6-positive Golgi apparatus. 
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FLIM-FRET analysis revealed that overexpression of R6IP1 promotes an 
interaction between Rab11a and Rab6 (Miserey-Lenkei et al., 2007). Perhaps RCP 
may have a similar function in promoting interactions with multiple Rab-GTPases 
in order to regulate trafficking between distinct membrane compartments. Rab6 
and Rab11 are found to associate with distinct sites on RCP, so RCP may 
associate with both these GTPases to co-ordinate trafficking to precise 
compartments. Indeed, RCP has also been shown to have a role in retrograde 
transport. The trafficking of Shiga toxin from the recycling endosomes to the 
TGN is disrupted by the suppression of RCP or Rab11 expression (Jing et al., 
2010). Jing et al. proposed that RCP binds Golgin-97, and that this association is 
required for both vesicle tethering and fusion between the vesicle and the TGN. 
Taken together, RCP, Rab6 and Rab11 have all been shown to be involved in 
retrograde transport. Further investigation would be required to determine if 
the RCP-Rab6 association is important for retrograde trafficking. 
Surprisingly, suppression of Rab6A or Rab6B expression increases cell invasion in 
Rab25-overexpressing A2780 cells. Perhaps depletion of all Rab6 isoforms would 
have a bigger effect on A2780-Rab25 cell invasion. As Rab25 is found associated 
with RCP, one hypothesis is that inhibiting Rab6 expression could free RCP and 
promote its association with Rab25, thus promoting α5β1-integrin and EGFR 
trafficking in the tip of the pseudopod and driving cell invasion. Further work is 
required to test this hypothesis and to determine whether Rab6 has a role in 
known RCP functions. 
3.3.4 The EphA2-RCP association 
I have identified a novel association between EphA2 and RCP using a non-biased 
proteomic approach, and I have confirmed this in three different carcinoma cell 
lines. A previous study demonstrated that EphA2 is found in a peri-nuclear 
compartment (Orsulic and Kemler, 2000). Since EphA2 associates with RCP, I 
sought to determine whether EphA2 localises in the peri-nuclear recycling 
compartment. Indeed, EphA2 is co-localised with RCP in this compartment. 
Rab11, which associates with RCP, has previously been shown to co-localise with 
EphA2 upon Ephrin stimulation (Boissier et al., 2013). I found that the 
intracellular pool of EphA2 co-localises with Rab11 in the recycling 
compartment, and that Rab11 co-immunoprecipitates with EphA2. This is the 
Chapter 3  127 
 
first Rab protein and effector that have been found to associate with EphA2. In 
order to determine whether there is a direct physical contact between EphA2, 
RCP and Rab11, in vitro protein binding assays would have to be performed. 
Unfortunately, EphA2 is large and has kinase activity, which prevents efficient 
expression in E.coli. Therefore it is difficult to purify, so these experiments 
could not be performed. 
α5- and β3-integrin associate much more efficiently with RCP than they do with  
Fip2 or Rip11 (Caswell et al., 2008). In contrast, EphA2 is found in a co-
immunoprecipitable complex with all the Rab11-Fip family members. Perhaps 
this means there are some functional redundancies between the Rab11-Fips. α5-
integrin associates with the C-terminal region of RCP containing the Rab binding 
domain and coiled-coiled  domain (RCP379-649). Interestingly, EphA2 is co-
immunoprecipitable with the C-terminal, but not the N-terminal portion of RCP. 
Two previous studies have detected an association between α5β1-integrin and 
EphA2 (Makarov et al., 2013; Prévost et al., 2005). Therefore, we hypothesised 
that EphA2 could be co-immunoprecipitable with RCP indirectly via α5-integrin. 
Indeed, endogenous α5-integrin associates with endogenous EphA2 in A2780 
cells. Interestingly, RCP is still co-immunoprecipitable with EphA2 in cells 
depleted of α5-integrin, demonstrating that EphA2 associates with RCP 
independently from α5-integrin.  
I have chosen to pursue the role played by RCP in the trafficking and functions of 
EphA2. In the following chapter I describe results indicating that RCP is involved 
in EphA2 trafficking, and that this influences EphA2’s ability to mediate CIL and 
cell-cell repulsion during cell scattering.  
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4 The role of RCP in EphA2 trafficking and EphA2-
dependent cell-cell repulsion  
4.1 Introduction  
4.1.1 The role of Ephs and Ephrins in contact inhibition of 
locomotion 
Contact inhibition of locomotion (CIL) is thought to play an important role in 
cancer metastasis (Section 1.1.3). Malignant cell migration is unimpeded when 
cancer cells contact non-cancerous cells, demonstrating a failure to undergo 
heterotypic CIL (Abercrombie and Turner, 1978). Nevertheless, cancer cells 
undergo normal homotypic CIL with other cancer cells, perhaps facilitating local 
cancer cell dispersion (Paddock and Dunn, 1986). It has been known for some 
time that Ephs and Ephrins have an important role in regulating CIL during 
development (Krull et al., 1997; Smith et al., 1997). More recently, a study using 
a prostate cancer cell line (PC3 cells) was the first to identify a role for Ephs and 
Ephrins in CIL in cancer (Astin et al., 2010). EphAs (EphA2 and EphA4), and not 
EphBs, are required for CIL between PC3 cells (Astin et al., 2010). Indeed, PC3 
cells undergo normal homotypic CIL, and this is opposed by knocking down all 
the EphAs expressed (EphA2 and EphA4), suggesting that the type-A receptors 
are required for CIL with neighbouring cancer cells (Astin et al., 2010). 
Ephs activate downstream Rho GTPases, which are also required for contact 
inhibition. In PC3 cells, EphA2/EphA4 activation via interaction with EphrinAs 
increases RhoA activity during homotypic collisions, while association of 
EphrinB2 with EphB3/EphB4 increases Cdc42 activity (Astin et al., 2010). In these 
cells EphA signals to RhoA via Vav2, which acts as a Rho GEF and is required for 
efficient CIL (Batson et al., 2014). Inhibition of Rho-ROCK signalling stabilises 
microtubules at the contact site and prevents formation of new lamellipodia, 
inhibiting CIL (Kadir et al., 2011). In glioma cells (U87MG), expression of 
EphrinB1 disrupts heterotypic CIL with glial cells via a mechanism involving the 
regulation of Tiam1, which contributes to the activation of Rac1 (Tanaka et al., 
2012). Tanaka et al. propose that the disruption of heterotypic CIL promotes 
invasion of glioblastoma in the brain of nude mice. 
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4.1.2 EphA2 and RCP in cell scattering 
Hepatocyte growth factor (HGF), also known as scatter factor, stimulates 
scattering of cell colonies via activation of its receptor cMet and downstream 
signalling to Akt, MAPK and FAK (Nakamura et al., 2011). Misregulation of HGF-
cMet signalling is common in cancer via upregulation of components in the 
pathway or activating mutations in cMet, so many drugs have been designed to 
target this pathway (Graveel et al., 2013). Considering EphA2’s role in CIL, I 
hypothesised that this RTK may be required for HGF-induced scattering. EphAs 
have been reported to have a role in several HGF-dependent functions. For 
example, HGF drives mammary branching morphogenesis in vivo and in Matrigel, 
and this is prevented in mammary epithelial cells derived from EphA2-/- mice 
(Vaught et al., 2009). Furthermore, addition of soluble EphrinA1 to MDCK cells 
antagonises HGF-induced epithelial branching morphogenesis and prevents HGF-
induced scattering of MDCK1 cells. To date no studies have investigated the role 
of EphA2 is HGF-driven cancer cell scattering. 
RCP has been shown to be required in cell scattering. Mutant-p53 drives 
scattering in H1299 cells and this is opposed by RCP knockdown (Muller et al., 
2013). Mutant-p53 increases invasion towards an HGF gradient in an RCP and 
cMet dependent fashion by enhancing RCP dependent cMet signalling and 
trafficking. Indeed, cMet is found in a co-immunoprecipitable complex with RCP 
(Muller et al., 2013). The role of RCP in HGF-induced scattering has not been 
examined, nor has the role of EphA2 in mutant-p53 or HGF induced scattering in 
cancer cells.  
4.1.3 Pancreatic mouse models 
Pancreatic cancer is an aggressive malignancy that is normally diagnosed in its 
later stages. Unfortunately, only ~5% of patients survive for more than 5 years 
after diagnosis. Pancreatic ductal adenocarcinoma (PDAC) accounts for over 85%  
of human pancreatic cancer cases (Warshaw and Fernández-del Castillo, 1992). 
The exact progenitor cell of PDAC is unidentified but it has been postulated to 
be a ductal epithelial cell (Stanger and Dor, 2006). Pancreatic intraepithelial 
neoplasms (PanINs) are microscopic lesions that contain columnar cells and are 
thought to be the main precursors to PDAC. Examination of human PanINs shows 
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that KRAS mutations, p16INK4 loss and TP53 mutations and loss are commonly 
found (Hruban et al., 2000). 
There has been substantial effort to genetically manipulate mice to generate 
pancreatic cancer models for studying disease and for testing potential 
treatments. Since mice that express constitutively active Kras (KrasG12D, a 
common mutation found in human invasive PDACs) succumb to lung cancer 
before PanINs develop (Johnson et al., 2001), conditional organ-specific models 
have been generated. In one such model, the mice have one allele of mutant 
Kras (G12D) and one allele of mutant-p53 (R172H), a common combination of 
mutations found in the human disease (Hruban et al., 2000). This model uses 
Cre-Lox technology in which the mutant proteins are only expressed upon the 
recombination of two lox sites that removes a stop codon located in between the 
gene and promoter. Recombination of the lox sites occurs in the presence of 
Cre-recombinase. Expression of Cre-recombinase is regulated by the pancreas-
specific promoter, Pdx1, so KrasG12D and p53R172H are specifically expressed in 
the pancreas. In this model PanINs are found, which progress to metastatic 
PDAC. The burden of the disease is observed in the animals within 10 weeks 
(Hingorani et al., 2005). The pathology of PDACs from these mice and the site of 
metastases recapitulate the human disease.  
4.1.4 The role of EphA2 in pancreatic cancer 
A large scale clinical study was recently performed to characterise the genetic 
changes in tumours from patients with PDAC (Biankin et al., 2012). Most 
interestingly, frequent and diverse somatic mutations were identified in genes 
involved in axon guidance and development, including genes involved in Slit, 
Semaphorin and Eph signalling (Biankin et al., 2012). It has previously been 
shown that EphA2 is expressed in 95% of human pancreatic cancers, and is highly 
expressed in lymph node metastases but less so in liver metastases, 
demonstrating some metastatic organ specificity (Mudali et al., 2006). Indeed, 
high EphA2 expression is associated with poor patient outcome (Van den Broeck 
et al., 2012). Furthermore, reducing EphA2 levels in pancreatic cancer cells 
decreases cell invasion in vitro and reduces tumour growth and metastasis in 
nude mice implanted subcutaneously with pancreatic cells (Duxbury et al., 
2004). Recent work shows that EphA4 is expressed in pancreatic cancer cell 
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lines, and suppression of its expression also reduces cell motility and invasion via 
upregulating E-cadherin expression and downregulation of MMP2 activity (Liu et 
al., 2014). In summary, EphA2 is highly expressed in aggressive human 
pancreatic cancer and has been shown to have a role in cancer cell invasion in 
vitro.  
4.1.5 Aims 
In this chapter I aim to identify whether RCP has a role in EphA2 function in the 
implementation of processes such as CIL and cell-cell repulsion. As RCP is a 
known regulator of RTK recycling, the role of RCP in EphA2 trafficking will be 
investigated. Since several Rab GTPases were identified as RCP associated 
proteins, I will test whether these are required for CIL, cell-cell repulsion and 
EphA2 trafficking. To determine whether EphA2 and RCP are important for cell 
migration and metastasis in vivo, EphA2-/- and RCPfl/fl mice will be crossed into 
the KPC (KrasG12D, p53R172H and Cre1-Pdx1) model of PDAC. Also, the in vitro 
invasiveness of cells derived from tumours removed from these animals will be 
investigated to determine the degree of cell autonomy in EphA2’s control of 
cell-cell repulsion and invasion. 
 
 
4.2 Results 
4.2.1 RCP, but not Fip2, Fip3 or α5-integrin, is required for 
efficient contact inhibition of locomotion  
The two EphA receptors, EphA2 and EphA4, are required for efficient homotypic 
contact inhibition of locomotion (CIL) in PC3 cells (Astin et al., 2010). As EphA2 
associates with RCP, I wanted to determine whether RCP is important for 
contact inhibition phenomena in the assay established by Astin et al. (2010) to 
quantify CIL in PC3 cells. These cells were seeded sparsely onto 6 well Matrigel-
coated glass-bottomed plates, serum starved for 24 hours, and treated with HGF 
to activate cell migration. Cell movement was recorded using time-lapse 
microscopy over a period of 24 hours. Under these conditions, PC3 cells migrated 
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on Matrigel and numerous examples of CIL could be observed when the migrating 
cells collided with one another. A typical example of PC3 cells undergoing CIL is 
shown in Figure 4.1B. Two PC3 cells migrated towards one another (green 
arrows). At the point of cell-cell contact (0 min) the cells stopped migrating for 
several minutes. Following this, the two cells migrated away from each other in 
a direction that was different from the one in which they approached one 
another (red arrow). Quantification of a large number of collisions indicate that 
the average cell-cell contact time during the collision was ~39 minutes (+/-5 
min) (Figure 4.2B), and the average vectoral difference between the direction 
of cell migration before and after the collision was 91º (+/- 6º) (Figure 4.1C). 
Since I have shown that EphA2 associates with all the Rab11-Fip family members, 
I wanted to determine whether suppression of RCP and other Rab11-Fips 
influences CIL in PC3 cells. PC3 cells expressed RCP, Fip2 and Fip3 at levels that 
were detectable by Western blotting and these could be selectively reduced by 
siRNA (Figure 4.2A, 4.3A). siRNA of RCP or Fip3 had no effect on migration 
speed of non-colliding cells, whilst Fip2 knockdown significantly reduced the 
speed of cell migration (Figure 4.2C, 4.3E). Interestingly, knockdown of RCP 
(using either a SMARTpool or 2 individual oligo sequences) significantly increased 
the time that colliding cells remained in contact prior to migrating away from 
one another (Figure 4.2B, 4.3D), whilst siRNA of Fip2 or Fip3 were ineffective in 
this regard (Figure 4.3D). Moreover, siRNA of RCP increased the difference 
between the direction of cell migration before and after the collision (Figure 
4.3B/C) indicating the decreased tendency of RCP knockdown cells to change 
direction following collisions.  
Given the role that RCP plays in α5β1-integrin trafficking, I sought to determine 
whether this integrin contributes to CIL. However, knockdown of α5-integrin did 
not increase the cell-cell contact time during collisions (Figure 4.4), 
demonstrating that this integrin does not influence contact inhibition nor the 
reacquisition of cell migration following collisions. 
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Figure 4-1 Suppression of RCP expression prevents efficient contact inhibition of 
locomotion 
A. PC3 cells were transfected with a SMARTpool of siRNA targeting RCP or non-targeting siRNA. 
Proteins were extracted 72 hours after transfection. RCP and β-tubulin were detected by Western 
blotting. B. Transfected cells were sparsely seeded onto Matrigel-coated glass plates. The cells 
were serum-starved for 24 hours and then treated with 10ng/ml HGF for 12-14 hours. Time-lapse 
microscopy was used to record cell migration. Representative collisions are shown. The scale bar 
is 10µm. C. Lines represent the vectorial tracks of cell migration 40 minutes before and after cell-
cell collisions. The green line is the average distance travelled before the cells collide, the black 
lines are representative tracks of the distance and angle of cell migration after the collision and the 
red line shows the average distance and angle of cell migration after the collision. Over 50 
collisions were tracked per condition. 
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Figure 4-2 Suppression of RCP, with two different targeted siRNAs, prevents efficient 
contact inhibition of locomotion 
A. PC3 cells were transfected with two different siRNA oligos targeting RCP or non-targeting 
siRNA. Proteins were extracted 72 hours after transfection. RCP and β-tubulin were detected by 
Western blotting. B/C. Transfected cells were sparsely seeded onto Matrigel-coated glass plates. 
The cells were serum starved for 24 hours and then treated with 10ng/ml HGF for 12-14 hours. 
Time-lapse microscopy was used to record cell migration. Time of contact during the collision (B) 
and speed of cell migration (C) are represented graphically. Over 50 collisions were tracked per 
condition in 3 separate experiments. Mann-Whitney statistical tests were performed and p-values 
are shown. 
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Figure 4-3 Fip2 and Fip3 are not required for efficient contact inhibition of locomotion 
A. PC3 cells were transfected with a SMARTpool of siRNA targeting RCP, Fip2 or Fip3, or a non-
targeting siRNA. Proteins were extracted 72 hours after transfection. RCP, Fip2, Fip3 and β-tubulin 
were detected by Western blotting. B-E. Transfected cells were sparsely seeded onto Matrigel 
coated glass plates. The cells were serum starved for 24 hours and treated with 10ng/ml HGF for 
12-14 hours. Time-lapse microscopy was used to record cell migration. B. Average vectorial tracks 
of cell migration 40 minutes before and after cell-cell collisions. The green line is the average 
distance travelled before the cells collide, the black (Nt), blue (RCP), yellow (Fip2) and purple 
(Fip3) lines show the average distance and angle of cell migration after the collision. The angle of 
migration after the collision (C), time of cell-cell contact during the collision (D) and speed of cell 
migration (E) are represented graphically. Over 50 collisions were tracked per condition in 3 
separate experiments. Mann-Whitney statistical tests were performed and p-values are shown. 
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Figure 4-4 α5-integrin is not required for efficient contact inhibition of locomotion 
A. PC3 cells were transfected with α5-integrin-targeting or non-targeting siRNA. Proteins were 
extracted 72 hours after transfection. α5-integrin and β-tubulin were detected by Western blotting. 
B-C. Transfected cells were sparsely seeded onto Matrigel-coated glass plates. The cells were 
serum starved for 24 hours and then treated with 10ng/ml HGF for 12-14 hours. Time-lapse 
microscopy was used to record cell migration. Time of contact during the cell-cell collision (B) and 
the speed of cell migration (C) are represented graphically. Over 50 collisions were tracked per 
condition in 3 separate experiments. Mann-Whitney statistical tests were performed and p-values 
are shown. 
4.2.2 EphA2 and RCP are required for HGF induced cell scattering 
As cell-cell repulsion is likely to contribute to cancer cell dissemination, I tested 
the requirement for EphA2 and RCP in cell scattering. H1299 cells were used for 
this as they grow in tight colonies that scatter in response to HGF (Figure 4.5). 
Unlike PC3 cells, EphA2 is the only EphA expressed by H1299 cells (Table 3.2). 
Addition of HGF drove a rapid increase in scattering of H1299 cells, as 
determined by scoring the number of cells that contacted 2 or fewer cells 
(scattered cells) as a proportion of the total number of cells (Figure 4.6B). 
Scattering was scored for untreated and HGF-treated cells (Figure 
4.7B/4.8B/4.9B) and HGF-induced scattering was analysed by quantifying the 
difference between the scattering of HGF and untreated cells and normalising to 
the control (Nt siRNA treated cells) (Figure 4.7C/4.8C/4.9C). These different 
quantification methods focus on HGF-independent or –depedent events. Both 
methods are shown as focus on HGF-dependent phenotypes alone may mask 
phenotypic differences from knockdown alone. The ability of HGF to promote 
scattering was partially (but significantly) opposed by siRNA of RCP (Figure 
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4.6D, 4.8) and ablated by knockdown of EphA2 (Figure 4.6C, 4.7) using either 
an siRNA SMARTpool or 2 different siRNA oligos to target either protein. 
Conversely siRNA of Fip2 or Fip3 was ineffective in this regard (Figure 4.9).  
 
Figure 4-5 Suppression of EphA2 expression prevents HGF-induced cell scatter 
H1299 cells were transfected with EphA2- or non-targeting siRNA and seeded sparsely. 10ng/ml 
HGF was added to the appropriate wells 48 hours after transfection. Representative pictures were 
taken at 0 and 6 hours. 
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Figure 4-6 HGF-induced cell scatter is reduced by depletion of EphA2 or RCP expression 
A. H1299 cells were transfected with non-targeting, EphA2- (oligo #4), RCP- (SMARTpool) or 
EphA2- & RCP-targeting siRNA and seeded sparsely. Proteins were extracted 48 hours after 
transfection. EphA2, RCP and β-tubulin were detected by Western blotting. B-E. 43 hours after 
transfection, 10ng/ml HGF/mock was added to the cells and at the appropriate times representative 
pictures of the cells were taken. The cells in each picture were counted as either ‘scattered’ (cells 
attached to less than 2 other cells) or ‘in colonies’ (cells attached to 3 or more other cells). The 
average percentage of scattered cells is plotted at each time point for cells transfected with non-
targeting control (B) and for the first 6 hours for cell transfected with EphA2 (C), RCP (D) or EphA2 
& RCP (E) siRNA. 20 pictures from 4 separate experiments were analysed. Statistical analysis was 
performed using a Mann-Whitney test comparing the scattering from the 0 and 6 hour time point 
(***:p <0.001, +:not significant) 
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Figure 4-7 Suppression of EphA2 expression levels prevents HGF-induced cell scatter 
A. H1299 cells were transfected with non-targeting siRNA, two different single siRNAs or a 
SMARTpool targeting EphA2, and seeded sparsely. Proteins were extracted 48 hours after 
transfection. EphA2 and β-tubulin were detected by Western blotting. B/C. 10ng/ml HGF/mock was 
added to each well 43 hours after transfection. After 6 hours of HGF treatment, representative 
pictures were taken from each condition. B. The percentage of scattered cells is plotted. C. HGF-
induced cell scatter was calculated by subtracting the untreated value from the HGF treated value 
for each condition, and normalising to the non-targeting control. 15 pictures from 3 separate 
experiments were analysed. Statistical analysis was performed using a Mann-Whitney test and p 
values are shown. 
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Figure 4-8 Suppression of RCP expression levels prevents HGF-induced cell scatter 
A. H1299 cells were transfected with non-targeting siRNA, two different single siRNAs or a 
SMARTpool targeting RCP, and seeded sparsely. Proteins were extracted 48 hours after 
transfection. RCP and β-tubulin were detected by Western blotting. B/C. 10ng/ml HGF/mock was 
added to each well 43 hours after transfection. After 6 hours of HGF treatment, representative 
pictures were taken from each condition. B. The average percentage of scattered cells is plotted. 
C. HGF-induced cell scatter was calculated by subtracting the untreated value from the HGF 
treated value for each condition, and normalising to the non-targeting control. 15 pictures from 3 
separate experiments were analysed. Statistical analysis was performed using a Mann-Whitney 
test and p-values are shown. 
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Figure 4-9 Suppression of Fip2 and Fip3 expression levels has no effect on HGF-induced 
cell scatter 
H1299 cells were transfected with RCP (SMARTpool), Fip2 (SMARTpool), Fip3 (SMARTpool) or 
non-targeting siRNA and seeded sparsely. Proteins and mRNA were extracted 48 hours after 
transfection. A. RCP, Fip3 and β-tubulin were detected by Western blotting. B. mRNA was copied 
into cDNA. Quantitative-PCR was performed with Fip2 and GAPDH primers. The fold change of 
Fip2 cDNA was normalised to GAPDH, and is represented graphically. B/C. 10ng/ml HGF/mock 
was added to each well 43 hours after transfection. After 6 hours of HGF treatment, representative 
pictures were taken. B. The percentage of scattered cells is plotted. C. HGF-induced cell scatter 
was calculated by subtracting the untreated value from the HGF treated value for each condition, 
and normalising to the non-targeting control. 15 pictures from 3 separate experiments were 
analysed. Statistical analysis was performed using a Mann-Whitney test and p-values are shown. 
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The approach used to quantify scattering (described in the previous paragraph) 
suffers from the drawback that it does not discriminate between RCP or EphA2 
contributing to dissemination of cell colonies, and these proteins affecting re-
formation of colonies following a successful scatter reaction. Therefore, I 
performed time-lapse microscopy to obtain a detailed picture of the influence of 
RCP and EphA2 on colony dissemination. H1299 cells were allowed to form into 
groups of ~4/8 cells per colony. They were treated with HGF and the resulting 
scattering of the colonies was followed by time-lapse microscopy and cell 
tracking. Examination of the movies displayed in Figure 4.10 and the track-plots 
derived from movies such as these (Figure 4.11A) indicated that HGF drove 
rapid scattering of cells from their colonies, and that cells moved up to 100µm 
from their start point within 6 hours of HGF addition. 
Suppression of cellular levels of either EphA2 or RCP (each with two siRNA 
sequences) strongly suppressed the ability of HGF to stimulate cell scattering as 
measured by this time-lapse/cell tracking approach (Figures 4.10-4.13). 
Indeed, following knockdown of EphA2 or RCP, cells were able to respond to HGF 
by ruffling and extending flat lamellae, but were incapable of losing contact 
with their neighbours to move away from their start positions (Figures 4.10, 
4.12). Furthermore, and consistent with the ‘colony scoring’ approach 
previously described, siRNA of Fip2 or α5-integrin did not suppress HGF-driven 
scattering in H1299 cells (Figure 4.14). Taken together these data support a role 
for EphA2 in cell-cell repulsion and scattering, and indicate that RCP may be 
required for EphA2 functions. 
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Figure 4-10 HGF-driven cell scattering is inhibited by depletion of EphA2 expression 
H1299 cells were transfected with EphA2- or non-targeting siRNA and seeded sparsely. The cells 
were recorded by time-lapse microscopy 43 hours after transfection when 10ng/ml HGF/mock was 
added to the appropriate wells. Representative pictures and movies are shown for the first 6 hours. 
Scale bar is 50µm. 
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Figure 4-11 Depletion of EphA2 expression reduces the speed and distance of cell migration 
upon HGF addition 
H1299 cells were transfected with two different EphA2 targeting siRNA oligos or non-targeting 
siRNA and seeded sparsely. The cells were recorded by time-lapse microscopy 43 hours after 
transfection when 10ng/ml HGF/mock was added to the appropriate wells. A. Representative tracks 
of cell migration for the first 6 hours. The total distance (B), HGF-induced distance (C), vectorial 
distance (D) and HGF-induced vectorial distance (E) are represented graphically. The HGF-
induced cell speed and distance were calculated by subtracting the untreated value from the HGF 
treated value for each condition, and normalising to the non-targeting control. Cells were tracked 
from 8 different regions on the plate in 3 separate experiments. Statistical analysis was performed 
using a Mann-Whitney test and p-values are shown. 
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Figure 4-12 HGF-driven cell scattering is inhibited by depletion of RCP expression 
H1299 cells were transfected with RCP- or non-targeting siRNA and seeded sparsely. The cells 
were recorded by time-lapse microscopy 43 hours after transfection when 10ng/ml HGF was added 
to the appropriate wells. Representative pictures and movies are shown for the first 6 hours. Scale 
bar is 50µm. 
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Figure 4-13 Depletion of RCP expression reduces the speed and distance of cell migration 
upon HGF addition 
H1299 cells were transfected with a single or SMARTpool set of four siRNA RCP-targeting oligos 
or non-targeting siRNA and seeded sparsely. The cells were recorded by time-lapse microscopy 43 
hours after transfection when 10ng/ml HGF was added to the appropriate wells. A. Representative 
tracks of cell migration for the first 6 hours are shown. The total distance (B), HGF-induced total 
distance (C), vectorial distance (D) and HGF-induced vectorial distance (E) are represented 
graphically. The HGF-induced cell speed and distance were calculated by subtracting the untreated 
value from the HGF treated value for each condition, and normalising to the non-targeting control. 
Cells were tracked in 8 different regions on the plate in 3 separate experiments. Statistical analysis 
was performed using a Mann-Whitney test and p-values are shown. 
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Figure 4-14 Suppression of Fip2 and α5-integrin expression has no effect on the speed and 
distance of cell migration upon HGF addition 
H1299 cells were transfected with α5-integrin, Fip2 or non-targeting (Nt) siRNA and seeded 
sparsely. The cells were recorded by time-lapse microscopy 43 hours after transfection when 
10ng/ml HGF was added to the appropriate wells. A. Representative tracks of cell migration for the 
first 6 hours. The total distance (B), HGF-induced total distance (C), vectorial distance (D) and 
HGF-induced vectorial distance (E) are represented graphically. The HGF-induced cell speed and 
distance were calculated by subtracting the untreated value from the HGF treated value for each 
condition, and normalising to the non-targeting control. Cells were tracked from 8 different regions 
on the plate in 3 separate experiments.  Statistical analysis was performed using a Mann-Whitney 
test and p-values are shown. 
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4.2.3 Rab14, but not Rab6A/B or Rab11A/B, is required for HGF 
induced cell scattering and contact inhibition of locomotion 
Rab6, Rab11 and Rab14 were identified as RCP associated proteins (Sections 
3.2.2.2 & 3.2.3.3), therefore, I sought to determine if any of these Rab GTPases 
were required for cell-cell repulsion. H1299 cells expressed Rab6A/B, Rab11A/B 
and Rab14 at levels that were detected by Western blotting and the levels of 
each of these could be selectively reduced by siRNA (Figure 4.15A). Throughout 
the rest of this chapter, I refer to these double knockdowns as their gene name 
alone (ie. Rab11 is Rab11A/B double knockdown). Interestingly Rab11A/B or Fip3 
knockdown (Figure 4.9, Figure 4.15B) increased HGF-independent scattering 
suggesting they may possibly act together to supress scattering. As assessed by 
scoring scattered cells (Figure 4.15) or using time-lapse microscopy analysed by 
cell tracking (Figure 4.16), siRNA of Rab14 significantly reduced HGF-induced 
scattering of H1299 cells, whilst knockdown of either Rab11A/B or Rab6A/B was 
completely ineffective in this regard. Consistent with this, Rab14 (but not 
Rab11A/B) was found to suppress cell-cell repulsion in PC3 cells. Indeed, whilst 
siRNA of Rab11A/B or Rab14 had no effect on the ability of non-colliding PC3 
cells to migrate (Figure 4.17E), knockdown of Rab14 significantly increased the 
time that colliding cells remained immobile prior to resuming migration and 
moving away from one another (Figure 4.17D). siRNA of Rab11A/B, on the other 
hand, did not influence this index. It is important to note, however, that unlike 
RCP, Rab14 did not seem to influence the direction of cell migration following a 
collision (Figure 4.17B/C). 
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Figure 4-15 Suppression of Rab14 expression, but not Rab6A/B or Rab11A/B expression, 
inhibits HGF-induced cell scatter 
H1299 cells were transfected with Rab6A/B (SMARTpool), Rab11A/B (SMARTpool), Rab14 
(SMARTpool) or non-targeting (Nt) siRNA and seeded sparsely. A. Proteins were extracted 48 
hours after transfection. Rab6A/B, Rab11A/B, Rab14 and β-tubulin were detected by Western 
blotting. B/C. 10ng/ml HGF/mock was added to each well 43 hours after transfection. After 6 hours 
of HGF treatment, representative pictures were taken. B. The average percentage of scattered 
cells is plotted. C. The HGF-induced cell scatter was calculated by subtracting the untreated value 
from the HGF treated value for each condition, and normalising to the non-targeting control. 15 
pictures from 3 separate experiments were analysed. Statistical analysis was performed using a 
Mann-Whitney test and p-values are shown. Rab11 and Rab6 in the figure refer to the double 
knockdown conditions. 
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Figure 4-16 Suppression of Rab14 expression, but not Rab6 or Rab11 expression, reduces 
the speed and distance of cell migration upon HGF addition 
H1299 cells were transfected with Rab6A/B, Rab11A/B and Rab14 or non-targeting (Nt) siRNA and 
seeded sparsely. The cells were recorded by time-lapse microscopy 43 hours after transfection 
when 10ng/ml HGF/mock was added to the appropriate wells. A. Representative tracks of cell 
migration are shown with HGF treatment for the first 6 hours. The total distance (B), HGF-induced 
total distance (C), vectorial distance (D) and HGF-induced vectorial distance (E) are represented 
graphically. The HGF-induced cell speed and distance were calculated by subtracting the untreated 
value from the HGF treated value for each condition, and normalising to the non-targeting control. 
Cells were tracked from 8 different regions on the plate in 3 separate experiments.  Statistical 
analysis was performed using a Mann-Whitney test and p-values are shown. 
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Figure 4-17 Depletion of Rab14 expression increases cell-cell contact time during contact 
inhibition of locomotion 
A. PC3 cells were transfected with Rab11A/B, Rab14 or non-targeting (Nt) siRNA. Proteins were 
extracted 72 hours after transfection. Rab11A/B, Rab14 and β-tubulin were detected by Western 
blotting. B-E. Transfected cells were sparsely seeded onto Matrigel-coated glass plates. The cells 
were serum-starved for 24 hours and then treated with 10ng/ml HGF for 12-14 hours. Time-lapse 
microscopy was used to record cell migration. B. Representative vectorial tracks of cell migration 
40 minutes before and after cell-cell collisions. The green line shows the average distance travelled 
before the cells collide, the black (Nt), orange (Rab11) and blue (Rab14) lines show the average 
distance and angle of cell migration after the collision. The angle of migration after the collision (C), 
time of cell-cell contact during the collision (D) and speed of cell migration (E) are represented 
graphically. Over 50 collisions were tracked per condition in 3 separate experiments. Mann-
Whitney statistical tests were performed and p-values are shown. 
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4.2.4 Depletion of Rab14 or RCP does not increase N-cadherin 
expression 
A previous report indicated that Rab14 promotes disruption of cell-cell junctions 
by driving recycling of the disintegrin metalloprotease, ADAM10, to cleave N-
cadherin at the plasma membrane (Linford et al., 2012). Thus, a consequence of 
Rab14 action is that it may lead to shedding of N-cadherin from the cell surface. 
Accordingly the authors reported that Rab14 knockdown cells had increased 
levels of N-cadherin (Linford et al., 2012). As it was possible that 
Rab14/ADAM10-mediated cleavage of N-cadherin might contribute to HGF-
induced scattering of H1299 cells, I investigated the influence of Rab14 
knockdown on N-cadherin levels in these cells. However, in H1299 cells siRNA of 
Rab14 or RCP did not lead to increased N-Cadherin levels (Figure 4.18), 
indicating that this is unlikely to be a mechanism by which either Rab14 or RCP 
influence cell scattering in these cells. 
 
 
Figure 4-18 Depletion of Rab14 or RCP expression does not increase N-cadherin expression 
H1299 cells were transfected with Rab14, RCP or non-targeting (Nt) control siRNA. Proteins were 
extracted 48 hours after transfection. The proteins were separated by SDS-PAGE and analysed by 
immunoblotting using antibodies that recognise N-cadherin, RCP and Rab14. 
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4.2.5 HGF increases RCP-dependent EphA2 trafficking  
4.2.5.1 Development of an EphA2 trafficking assay 
As RCP and Rab14 have a known role in receptor recycling, I sought to determine 
whether they are required for EphA2 trafficking and whether HGF treatment 
alters EphA2 trafficking. EphA2 trafficking has not been well studied, so a biotin-
labelling based approach was established (Caswell et al., 2008; White et al., 
2007). This approach had to be validated and optimised to detect EphA2. First, I 
tested whether EphA2 was efficiently labelled with sulfo-NHS-SS-biotin at the 
cell surface and whether this could be detected by immunoprecipitation. H1299 
cells were labelled with sulfo-NHS-SS-biotin, which forms covalent bonds with 
the free amino groups in proteins. As it is membrane impermeant, only 
extracellular proteins and ectodomains were labelled. Moreover, sulfo-NHS-SS-
biotin has a disulphide bond in a linker between the biotin and NHS moieties, 
which can be cleaved by the treatment of cells with the membrane-impermeant 
reducing agent, MesNa, thus removing the label from receptors that remain at 
the cell surface. The cells were thoroughly washed to remove any remaining 
label, thus preventing free sulfo-NHS-SS-biotin from binding to proteins when 
the cells were then lysed in a Triton-x100 lysis buffer. Anti-EphA2 was 
conjugated to magnetic beads, which were added to the cell lysates to 
immunoprecipitate EphA2. The immunoprecipitates were analysed by SDS-PAGE 
and Western blotting. EphA2 was efficiently immunoprecipitated by the EphA2 
antibody, but not by a control IgG (RG16) (Figure 4.19A). Exposing the blots to 
HRP-conjugated streptavidin, which associates with biotin, revealed a 
predominant band of biotinylated protein corresponding to the size of EphA2 
(~120kDa) in the EphA2 immunoprecipitate. This indicates that EphA2 may be 
efficiently labelled at the cell surface using sulfo-NHS-SS-biotin.  
A capture-ELISA was developed to accurately quantify biotinylated EphA2. In 
this, anti-EphA2 was used as a capture antibody and biotinylated receptor was 
detected using HRP-conjugated streptavidin followed by colorimetric reaction 
with ortho-phenylenediamine and hydrogen peroxide substrate (Figure 4.19B). I 
first established the specificity and antibody coating-concentration for the 
capture-ELISA, and then proceeded to confirm that the assay responded linearly 
to increasing concentrations of biotinylated EphA2 in the lysate (Figure 4.19C).  
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Figure 4-19 Validation of the EphA2 trafficking assay in H1299 cells 
H1299 cells were surface labelled with 0.13mg/ml sulfo-NHS-SS-biotin (or mock) for 30 minutes at 
4ºC. The cells were thoroughly washed with PBS and lysed. A. Immunoprecipitations were 
performed on these lysates with an anti-EphA2 or RG16 (negative control) antibody. 
Immunoprecipitates were analysed by SDS-PAGE. EphA2 was detected by immunoblotting and 
biotin was detected using HRP-conjugated streptavidin. B. Schematic representation of the 
capture-ELISA detection method. (SA: streptavidin, HRP: horseradish peroxidase) C. Biotinylated-
EphA2 was detected from the cell lysates by capture-ELISA using microtiter wells coated with 
increasing concentrations of anti-EphA2 monoclonal antibody. D. Labelled and unlabelled cell 
lysates were prepared and mixed at the appropriate ratios. Biotinylated-EphA2 was detected by 
capture-ELISA.  
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4.2.5.2 EphA2 trafficking 
Having developed a capture-ELISA to quantify biotinylated EphA2, I then 
proceeded to measure the rate of the receptor’s internalisation. To do this, 
H1229 cells were surface-labelled with sulfo-NHS-SS-biotin at 4ºC, warmed to 
37ºC for various times to allow internalisation, then treated with MesNa at 4ºC to 
remove any biotin from receptors remaining at the cell surface. Biotinylated 
EphA2 remaining in the cells was then determined using capture-ELISA. This 
indicated that ~30% of surface EphA2 was internalised by H1299 cells in 22.5 
minutes (Figure 4.20B). 
Most receptors are in continuous flux between the plasma membrane and 
internal compartments (Figure 4.20A), rendering it difficult to obtain ‘pure’ 
measurements of internalisation that are uncontaminated by the rapid return of 
receptor to the plasma membrane. To determine whether EphA2 is a ‘cycling’ 
receptor, I measured the rate of apparent EphA2 internalisation in presence of 
the receptor recycling inhibitor, primaquine. Addition of primaquine caused a 
very marked increase (>10 fold) in the internalisation rate of EphA2 (Figure 
4.20B). From this, I concluded that EphA2 is internalised and recycled very 
quickly-thus the measure of apparent EphA2 internalisation observed in the 
absence of primaquine represents components of both internalisation and 
recycling. 
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Figure 4-20 EphA2 trafficking kinetics in H1299 cells upon HGF addition 
A. Schematic diagram showing possible EphA2 trafficking routes and the action site of primaquine. 
B. H1299 cells were surface labelled with 0.13mg/ml sulfo-NHS-SS-biotin for 30 minutes at 4ºC. 
Internalisation of cell surface protein was allowed for the indicated time points in DMEM media with 
0.6mM primaquine/mock and 10ng/ml HGF at 37ºC. Biotin was removed from proteins on the 
plasma membrane by incubating the cells with 20mM MesNa for 30 minutes at 4ºC. This reaction 
was quenched by the addition of 20mM IAA for a further 10 minutes. Biotinylated-EphA2 was 
detected by capture-ELISA using microtiter wells coated with an EphA2 targeted antibody. 
Internalized proteins are plotted as a proportion of the total labelled protein at the indicated time 
points. 
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4.2.5.3 HGF increases RCP-dependent EphA2 trafficking 
HGF drove a significant increase (~1.5 fold) in the apparent internalisation of 
EphA2, and knockdown of RCP did not affect EphA2 internalisation in the 
absence of HGF (Figure 4.21). However, the HGF-induced increase in apparent 
EphA2 internalisation was completely opposed by knockdown of RCP. To 
determine the specificity of RCP’s influence over EphA2 trafficking, I measured 
the internalisation of two other RTK’s (cMet and EGFR) and TfnR as a control. As 
expected, HGF drove internalisation of its receptor, cMET (Figure 4.21). 
However, cMet trafficking and that of EGFR and TfnR was not altered by RCP 
knockdown, indicating that RCP’s influence over HGF-driven EphA2 trafficking 
has some specificity. 
To determine whether RCP influences EphA2 internalisation per se, I performed 
these assays in the presence of primaquine. siRNA of RCP had no effect on the 
internalisation of EphA2 when receptor recycling was blocked (Figure 4.22). 
Taken together, these data indicate that HGF influences the intracellular 
trafficking of EphA2 so as to slow or delay its return to the plasma membrane, 
and RCP is required for this to occur. 
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Figure 4-21 HGF increases EphA2 trafficking in an RCP-dependent fashion 
A. H1299 cells were transfected with RCP- or non-targeting (Nt) control siRNA. Proteins were 
extracted 48 hours after transfection, and RCP and β-tubulin were detected by Western blotting. B. 
Transfected H1299 cells were surface labelled with 0.13mg/ml sulfo-NHS-SS-biotin for 30 minutes 
at 4ºC. Internalisation of cell surface protein was allowed for the indicated time points in DMEM 
media with 10ng/ml HGF/mock stimulation at 37ºC. Biotin was removed from proteins on the 
plasma membrane by incubating the cells in 20mM MesNa for 30 minutes at 4ºC. This reaction 
was quenched by the addition of 20mM IAA for a further 10 minutes. Biotinylated-EphA2, -cMet, -
EGFR, and -TfnR were detected by capture-ELISA using microtiter wells coated with the 
appropriate targeted monoclonal antibodies. Internalized proteins are plotted as a proportion of the 
total labelled protein at the indicated time points. The graphs show the averages and SEM of 8 
replicates of 4 separate experiments. Two way Anova statistical tests were performed and any 
significant difference between Nt and RCP siRNA transfected HGF treated cells is indicated on the 
graph (* : p<0.05, **: p<0.01, ***: p<0.001). 
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Figure 4-22 RCP is not required for EphA2 internalisation upon HGF treatment 
A. H1299 cells were transfected with RCP targeting SMARTpool or non-targeting (Nt) control 
siRNA. Proteins were extracted 48 hours after transfection, and RCP and β-tubulin were detected 
by Western blotting. B. Transfected H1299 cells were surface labelled with 0.13mg/ml sulfo-NHS-
SS-biotin for 30 minutes at 4ºC. Internalisation of cell surface protein was allowed for the indicated 
time points in DMEM media with 0.6mM primaquine and 10ng/ml HGF at 37ºC. Biotin was removed 
from proteins on the plasma membrane by incubating the cells in 20mM MesNa for 30 minutes at 
4ºC. This reaction was quenched by the addition of 20mM IAA for a further 10 minutes. 
Biotinylated-EphA2, -cMet, -EGFR, and  -TfnR were detected by capture-ELISA using microtiter 
wells coated with the appropriate targeted monoclonal antibodies. Internalized proteins are plotted 
as a proportion of the total labelled protein at the indicated time points.  
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4.2.5.4 HGF does not influence EphA2 degradation  
EphA2 has been reported to be substrate for MT1-MMP resulting in its shedding 
from the cell surface (Sugiyama et al., 2013). Furthermore, EphA2 is known to 
be subject to lysosomal degradation following ligation with its Ephrin ligands 
(Wang et al., 2002). As it is probable that either shedding or lysosomal 
degradation of EphA2 could influence the values obtained from surface 
biotinylation/capture-ELISA assays, I determined whether HGF or RCP affected 
EphA2 degradation over the time course of the internalisation assays that I had 
performed. Clearly there was no detectable reduction in EphA2 levels following 
addition of HGF and this was unaffected by RCP knockdown (Figure 4.23). 
Furthermore, EphA2 ran at its predicted molecular weight, and I was unable to 
detect the presence of any proteolytic fragments of the receptor (such as those 
that would result from MT1-MMP cleavage) in the presence or absence of HGF. 
 
Figure 4-23 Neither HGF treatment nor suppression of RCP expression alters EphA2 
degradation 
H1299 cells were transfected with RCP- or non-targeting (Nt) control siRNA and treated with 
10ng/ml HGF for the appropriate times. Proteins were extracted 48 hours after transfection and 
separated by SDS-PAGE. EphA2, RCP and β-tubulin were detected by immunoblotting. 
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4.2.6 HGF drives sorting of EphA2 to an RCP-positive 
compartment 
The internalisation assays (described previously) indicated that HGF alters 
intracellular trafficking of EphA2 in an RCP-dependent fashion. Therefore, I used 
a fluorescence live cell imaging approach to directly visualise EphA2 trafficking. 
H1299 cells were co-transfected with GFP-EphA2 and mCherry-RCP, seeded onto 
glass-bottomed plates and viewed by confocal microscopy. GFP-EphA2 was 
present at the plasma membrane and in a set of intracellular vesicles that were 
in constant motion (Figure 4.24A/B & movie 4.11). mCherry-RCP was seen to 
localise, as expected, to a vesicular compartment that was concentrated in the 
peri-nuclear region. Reviewing stills for these movies indicated that there was 
little co-localisation between GFP-EphA2 and mCherry-RCP (Figure 4.24B). 
Following addition of HGF, GFP-EphA2 was seen to relocate to RCP-positive 
structures, such that the two proteins were then seen to move around together 
(Figure 4.24A), and quantitative analysis indicated that increased co-
localisation of EphA2 and RCP was statistically significant across a number of 
experiments (Figure 4.24C). Taken together with the results from the 
internalisation assays in the previous sections, these data indicate that HGF 
diverts EphA2 from a rapid recycling pathway into one that is slower and 
includes passage through an RCP-positive compartment. 
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Figure 4-24 HGF increases the co-localisation between GFP-EphA2 and mCherry-RCP in 
vesicles 
H1299 cells were co-transfected with GFP-EphA2 and mCherry-RCP and seeded onto glass-
bottomed dishes. 24 hours after transfection, 10ng/ml HGF/mock was added to the plates. Short 
time-lapse recordings were taken of the cells by confocal microscopy. A. Representative merged 
images during the time-lapse are shown. B. Representative images of GFP-EphA2, mCherry-RCP, 
merged GFP-EphA2 & mCherry-RCP and co-localised regions are shown. C. ImageJ software was 
used to quantify co-localised pixels relative to the GFP-EphA2 and mCherry-RCP pixels in 
individual cells. The average co-localisation is represented graphically. The co-localisation of 
approximately 60 cells from 3 separate experiments was measured. Mann-Whitney statistical tests 
were performed and the p-value is indicated. 
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4.2.7 HGF induces EphA2 trafficking through a Rab14-positive 
compartment  
I have previously shown that Rab14 associates with RCP (Section 3.2.2). 
Moreover, my observation that Rab14, but not Rab11, is required for HGF-
induced cell scattering and CIL led me to investigate the role of this GTPase in 
EphA2 trafficking. siRNA of Rab14 completely opposed the ability of HGF to drive 
the apparent internalisation of EphA2 (Figure 4.25), suggesting that this GTPase 
is required for HGF to delay EphA2 recycling. Consistent with this, I found that 
HGF may be able to divert trafficking of EphA2 to Rab14-positive endosomes. In 
the absence of HGF, EphA2 vesicles are relatively motile and do not often come 
into contact with Rab14, which is localised primarily in the perinuclear region, 
as is RCP (Figure 4.26B & movie 4.13). Following addition of HGF, EphA2 began 
to co-localise with Rab14 and structures that contain both proteins were seen to 
move together (Figure 4.26A & movie 4.13). A quantitative analysis of a 
number of movies indicated that HGF induced a statistically significant increase 
in co-localisation between EphA2 and Rab14 (Figure 4.26C). Taken together 
these data indicate that EphA2 is internalised and recycled in H1299 cells. 
Addition of HGF delays EphA2 recycling whilst the receptor is diverted to RCP- 
and Rab14-positive vesicles, and this requires the presence of both RCP and 
Rab14. 
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Figure 4-25 HGF increases EphA2 trafficking in a Rab14-dependent fashion 
A. H1299 cells were transfected with Rab14 or non-targeting (Nt) control siRNA. Proteins were 
extracted 48 hours after transfection, and Rab14 and β-tubulin were detected by Western blotting. 
B. Transfected H1299 cells were surface labelled with 0.13mg/ml sulfo-NHS-SS-biotin for 30 
minutes at 4ºC. Internalisation of cell surface protein was allowed for the indicated time points in 
DMEM media with 10ng/ml HGF/mock stimulation at 37ºC. Biotin was removed from proteins on 
the plasma membrane by incubating the cells in 20mM MesNa for 30 minutes at 4ºC. This reaction 
was quenched by the addition of 20mM IAA for a further 10 minutes. Biotinylated-EphA2, -cMet, 
and -TfnR were detected by capture-ELISA using microtiter wells coated with the appropriate 
targeted monoclonal antibodies. Internalized proteins are plotted as a proportion of the total 
labelled protein at the indicated time points. The graphs show the averages and SEM of 6 
replicates of 3 separate experiments. Two way Anova statistical tests were performed between Nt 
and Rab14 siRNA transfected HGF treated cells and any significant difference is indicated on the 
graph (*: p<0.05, **: p<0.01, ***: p<0.001). 
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Figure 4-26 HGF increases the co-localisation between GFP-EphA2 and mCherry-Rab14 in 
vesicles 
H1299 cells were co-transfected with GFP-EphA2 and mCherry-Rab14 and seeded onto glass-
bottomed dishes. 24 hours after transfection, 10ng/ml HGF/mock was added to the plates. Short 
time-lapse recordings were taken of the cells by confocal microscopy. A. Representative merged 
images during the time-lapse are shown. B. Representative images of GFP-EphA2, mCherry-
Rab14, merged GFP-EphA2 & mCherry-Rab14 and co-localised regions are shown. C. ImageJ 
software was used to quantify co-localised pixels relative to the GFP-EphA2 and mCherry-Rab14 
pixels in individual cells. The average co-localisation is represented graphically. The co-localisation 
of approximately 60 cells from 3 separate experiments was measured. Mann-Whitney statistical 
tests were performed and the p-value is indicated. 
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4.2.8 RCP is phosphorylated at Serine435 
Prior to my arrival in the lab, a mass spectrometry phospho-mapping approach 
was used to identify residues in RCP that might function as phospho-acceptors. 
To do this, GFP-RCP was expressed in A2780 cells and then immunoprecipitated 
using an anti-GFP antibody coupled to magnetic beads. The resulting 
immunoprecipitated material was trypsinised and analysed by MALDI-TOF mass 
spectrometry. Peptides that were potentially phosphorylated were identified, 
and the most abundant of these were 430ESRRSS(HPO3)LLSLMTGK443 and 
523RPPISS(HPO3)PRAPQTRA537.   
A phospho-specific antibody was then raised by injecting rabbits with a synthetic 
peptide corresponding to RCP427-439(pSer-435) (427KKPESRRSS(HPO3)LLSL439). The 
resulting anti-serum was affinity purified using the RCP427-439(pSer-435) peptide and 
then pre-cleared with the non-phosphorylated version of the same sequence to 
remove antibodies that were not phospho-specific. To assess this antibody and 
to determine whether RCP is phosphorylated on Serine435 in cells, GFP-RCP was 
expressed in A2780 cells, GFP was immunoprecipitated and the product was 
probed with the anti-pSer435-RCP antibody by immunoblotting. This antibody 
recognised a single band corresponding to phosphorylated GFP-RCP, but did not 
recognise a mutant of RCP in which the phosphor-acceptor Serine435 had been 
substituted with Alanine (Figure 4.27A). Furthermore, addition of the broad-
spectrum Serine/Threonine kinase inhibitor, Staurosporine, for 1 hour led to a 
substantial reduction in the signal detected by anti-pSer435-RCP (Figure 4.27B) 
indicating that RCP phosphorylation is potentially regulated in these cells. 
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Figure 4-27 RCP is phosphorylated on Serine435 and this phosphorylation is blocked by 
Staurosporine treatment 
A. A2780 cells were transfected with GFP, GFP-RCP or GFP-RCPS435A. The cells were lysed and 
GFP was immunoprecipitated with an anti-GFP antibody. The immunoprecipitates were analysed 
by SDS-PAGE, and Western blotting with antibodies that recognise GFP and pSer435-RCP. Each 
condition was performed in duplicate. B. A2780 cells were transfected with GFP-RCP. The cells 
were treated with 10ng/ml Staurosporine (SP) for 1 hour, lysed, and GFP was immunoprecipitated 
with an anti-GFP antibody. The immunoprecipitates were analysed by SDS-PAGE and Western 
blotting with antibodies that recognise GFP and pSer435-RCP. This work was performed by 
Andrew Campbell. 
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4.2.9 HGF drives RCP phosphorylation and enhances the 
association between EphA2, RCP and Rab14 
Using the approaches discussed in the previous section, I found that RCP was 
phosphorylated on Serine435 in H1299 cells, and this was increased by the 
addition of HGF (Figure 4.28A). Although the degree of HGF-induced RCP 
phosphorylation varied between experiments, densitometric analysis of Western 
blots of 4 independent experiments indicated that HGF addition for 1 minute 
drove a ~4 fold increase in RCP phosphorylation (Figure 4.28B). Consistently, 
endogenous pSer435-RCP was found to be co-immunoprecipitated with 
endogenous EphA2 and this was also enhanced following HGF addition (Figure 
4.29). 
 
Figure 4-28 RCP is phosphorylated upon HGF treatment 
H1299 cells were transfected with GFP, GFP-RCP or GFP-RCPS435A. The cells were treated with 
10ng/ml HGF for the indicated times, 48 hours after transfection. The cells were lysed and GFP 
was immunoprecipitated with an anti-GFP antibody. A. The immunoprecipitates were analysed by 
SDS-PAGE and Western blotting with antibodies that recognise RCP and pSer435-RCP. B. 
ImageJ software was used to quantify the amounts of pSer435-RCP relative to RCP in 4 separate 
experiments. The mean and SEM are represented graphically.  
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Figure 4-29 The association between endogenous EphA2, RCP and Rab14 is enhanced by 
HGF treatment 
H1299 cells were treated with HGF for the indicated times. Endogenous EphA2 was 
immunoprecipitated with an anti-EphA2 antibody and RG16 was used as a non-specific control. 
The immunoprecipitates were analysed by SDS-PAGE and immunoblotting with antibodies that 
recognise RCP, pSer435-RCP, EphA2 and Rab14. 
Analysis of fluorescent-protein dynamics in living cells (Section 4.2.6) indicated 
that HGF treatment drives sorting of EphA2 to an RCP/Rab14 positive 
compartment. To determine whether this was also reflected in altered physical 
association between the proteins, co-immunoprecipitation analysis was 
performed. As before, EphA2 and Rab14 specifically immunoprecipitated with 
GFP-RCP, and the co-immunoprecipitation of both of these proteins was 
significantly enhanced following HGF addition (Figure 4.30A). As for RCP 
phosphorylation this varied somewhat between experiments, but densitometric 
analysis of three independent experiments indicated that HGF enhanced EphA2 
(6-fold) and Rab14 (3-fold) co-immunoprecipitation with RCP (Figure 4.30B). 
Moreover, although Rab11 associated with RCP under basal conditions, this 
association was not enhanced (and in some experiments reduced) by HGF 
addition (Figure 4.30A). EphA2 and Rab14 were found to weakly co-
immunoprecipitate with mutant RCP that lacks the phospho-acceptor site, GFP-
RCPS435A. However, addition of HGF was unable to enhance the association of 
EphA2 and Rab14 with GFP-RCPS435A (Figure 4.30A). Taken together these data 
indicate that an HGF-activated kinase is responsible for phosphorylation of RCP 
at Serine435, and that this is necessary for effective recruitment of one of its 
receptor cargo, EphA2, and an important regulatory GTPase, Rab14, to an RCP-
containing complex.  
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Figure 4-30 HGF enhances the association of RCP with Rab14 and EphA2 
H1299 cells were transfected with GFP, GFP-RCP or GFP-RCPS435A. The cells were treated with 
10ng/ml HGF for the indicated times, 48 hours after transfection. The cells were lysed and GFP 
was immunoprecipitated with an anti-GFP antibody. A. The immunoprecipitates were analysed by 
SDS-PAGE and Western blotting with antibodies that recognise RCP, pSer435-RCP, EphA2, 
Rab11 and Rab14. B. ImageJ software was used to quantify the amounts of EphA2, Rab11 and 
Rab14 relative to RCP in 4 separate experiments for Rab11 and Rab14, and 2 separate 
experiments for EphA2. The mean and SEM are represented graphically.  
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4.2.10 Phosphorylation of RCP at Serine435 is required for 
EphA2 trafficking and cell scattering 
My observation that phosphorylation of RCP at Serine435 is required for its 
association with two proteins that are key to cell scattering prompted me to test 
whether RCP phosphorylation contributes to EphA2 trafficking and function. In 
H1299 cells that expressed GFP-RCP, HGF drove a significant increase in the 
apparent internalisation rate of EphA2 (Figure 4.31), indicating that 
overexpression of RCP does not have a detectable influence on the ability of HGF 
to delay EphA2 recycling. However, expression of GFP-RCPS435A completely 
opposed the ability of HGF to increase EphA2 trafficking (Figure 4.31). 
 
Figure 4-31 Expression of an unphosphorylatable mutant of RCP, GFP-RCPS435A, reduces 
HGF-driven EphA2 trafficking 
H1299 cells were transfected with GFP-RCP and GFP-RCPS435A. Transfected H1299 cells were 
surface labelled with 0.13mg/ml sulfo-NHS-SS-biotin for 30 minutes at 4ºC. Internalisation of cell 
surface protein was allowed for the indicated time points in DMEM media with 10ng/ml HGF/mock 
stimulation at 37ºC. Biotin was removed from proteins on the plasma membrane by incubating the 
cells in 20mM MesNa for 30 minutes at 4ºC. This reaction was quenched by the addition of 20mM 
IAA for a further 10 minutes. Biotinylated-EphA2, cMet, and TfnR were detected by capture-ELISA 
using microtiter wells coated with the appropriate targeted monoclonal antibodies. Internalized 
proteins are plotted as a proportion of the total labelled protein at the indicated time points. The 
graphs show the averages and SEM of 6 replicates of 3 separate experiments. Two way Anova 
statistical tests were performed and any significant difference, between GFP-RCP and GFP-
RCPS435A transfected and HGF stimulated cells, is indicated on the graph (*:p<0.05, **:p<0.01, 
***:p<0.001). 
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Next I sought to determine whether phosphorylation of RCP at Serine435 
influenced EphA2-dependent scattering. Despite indications that expression of 
GFP-RCP in H1299 cells drove a small but significant increase in HGF-
independent cell scattering, GFP-RCP-expressing cells scattered efficiently in 
response to HGF addition (Figures 4.32B, 4.33A/B/D). However, expression of 
GFP-RCPS435A inhibited the ability of HGF to drive cell scattering and this was 
significant when quantified by the colony-scoring (Figures 4.32) and cell 
tracking approaches (Figure 4.33). Taken together, these data indicate that 
HGF drives phosphorylation of RCP at Serine435 to promote EphA2 trafficking, 
which, in turn, contributes to the ability of cells to move away from one another 
as they scatter. 
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Figure 4-32 Expression of an unphosphorylatable mutant of RCP, GFP-RCPS435A, reduces 
HGF-driven cell scattering  
H1299 cells were transfected with GFP, GFP-RCP and GFP-RCPS435A and seeded sparsely. A. 
Proteins were extracted 48 hours after transfection. GFP, RCP and β-tubulin were detected by 
Western blotting. B/C. 10ng/ml HGF/mock was added to the cells, 43 hours after transfection. After 
6 hours of HGF addition, representative pictures were taken from each condition. B. The 
percentage of scattered cells is represented graphically. C. HGF-induced cell scatter was 
calculated by subtracting the untreated value from the HGF treated value for each condition, and 
normalising to the GFP control. 15 pictures from 3 separate experiments were analysed. Statistical 
analysis was performed using a Mann-Whitney test and p-values are shown. 
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Figure 4-33 Expression of an unphosphorylatable mutant of RCP, GFP-RCPS435A, reduces 
the speed and distance of cell migration upon HGF addition  
H1299 cells were transfected with GFP, GFP-RCP and GFP-RCPS435A and seeded sparsely. The 
cells were recorded by time-lapse microscopy, 43 hours after transfection when 10ng/ml 
HGF/mock was added. A. Representative tracks of cell migration are shown with HGF addition for 
the first 6 hours. The total distance (B), HGF-induced total distance (C), vectorial distance (D) and 
HGF-induced vectorial distance (E) are represented graphically. The HGF-induced cell speed and 
distance were calculated by subtracting the untreated value from the HGF treated value for each 
condition, and normalising to the GFP control. Cells were tracked from 8 different regions on the 
plate from 3 separate experiments.  Statistical analysis was performed using a Mann-Whitney test 
and p-values are shown. 
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4.2.11 Knockout of EphA2 or RCP reduces liver metastasis in 
a mouse model of PDAC. 
Having identified a clear role for EphA2 and its RCP-dependent trafficking in 
cell-cell repulsion and cell scattering, I sought to determine whether this RTK 
contributes to invasion and metastasis. To do this, an autochthonous model of 
metastatic PDAC was chosen (described in Section 4.1.3). The EPHA2 gene, 
which is located on chromosome 1p36, has previously been disrupted in mice, 
and these animals were obtained from the Jackson Laboratory (Brantley-Sieders 
et al., 2004). EphA2-/- mice are viable and have no overt developmental 
abnormalities. The morphology of the pancreas was found to be unaffected by 
disruption of the EPHA2 gene. Therefore, EphA2-/- mice were crossed into the 
KPC (Pdx1-Cre, KrasG12D/+, p53R172H/+) PDAC model by my collaborator Bryan Miller 
(Figure 4.34A). Disruption of the EPHA2 gene did not oppose initiation or growth 
of primary PDAC in the KPC mice. In fact, PDAC formation was increased in 
EphA2-/- mice, and this was reflected in decreased survival of the knockout 
animals (Figure 4.34B/C), as it is the growth of the primary tumour and the 
resulting gastrointestinal complications, rather than the incidence of metastasis, 
that dictate survival in the KPC model of PDAC. We then investigated the 
incidence of liver metastasis in KPC EphA2+/+, KPC EphA2+/- and KPC EphA2-/- 
animals by examination of the liver and staining sections of this tissue with H&E. 
In these experiments liver metastases were observed in 33% of control tumour-
bearing animals (KPC EphA2+/+) and this was unaffected by loss of one allele of 
EphA2 (KPC EphA2+/-) indicating that this RTK exhibits haplosufficieny in the 
context of PDAC metastasis (Figures 4.34D). Moreover, KPC EphA2-/- mice had 
reduced incidence of liver metastasis indicating a possible role for this RTK in 
the dissemination of PDAC in vivo. 
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Figure 4-34 KPC EphA2-/- mice have reduced survival, increased formation of PDAC and 
decreased liver metastasis 
A. KPC (Pdx1-Cre, KasG12D/+, p53R172H/+) mice were crossed with EphA2-/- mice. B. The survival of 
KPC EphA2+/+ mice, KPC EphA2-/+ mice and KPC EphA2-/- mice was represented by a Kaplan-
Meier curve. Statistical analysis was performed using log-rank tests (*:p=0.03). Mice that 
succumbed but did not develop PDAC were excluded. C. The percentage of mice that developed 
PDAC is represented graphically. D. Representative image of a liver metastasis stained with 
hematoxylin and eosin (H&E). The number of mice that had detectable liver metastasis is plotted 
as a percentage. Scale bar is 50µm. This work was performed by Bryan Miller. 
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Given that I have established a role for RCP in EphA2 trafficking and function, I 
wished to determine whether this Rab effector contributes to metastasis of 
PDAC. First, I sought to determine whether RCP was expressed in pancreatic 
tissue, pancreatic intraepithelial neoplasms (PanINs) and PDACs. Slices of normal 
mouse pancreas, KPC PanINs and KPC PDACs were stained by 
immunohistochemistry with an antibody that recognises mouse RCP. In PanINs 
the expression of RCP appeared to be localised to the apical region of neoplasms 
that displayed some glandular structure, but was also present as a diffuse 
staining in the more dysplastic PanINs (Figure 4.35B). In PDAC, RCP expression 
was markedly elevated and RCP-positive structures were distributed throughout 
the cells of the tumours Figure 4.35D. To ensure the specificity of the RCP 
staining in PanINs, a pre-absorption control is displayed in Figure 4.35C 
demonstrating the specificity of the staining. 
Next, an inducible RCP KO mouse was generated that contains a Neomycin 
cassette flanked by Lox sites following exon 2 of RCP in the mouse genome by 
the Beatson Transgenic Services (Figure 4.36A). Recombination of the Lox sites 
induces a frameshift mutation resulting in the transcription of a non-functional 
translation product. To determine whether RCP expression is diminished in the 
presence of Cre- recombinase, mouse embryonic fibroblasts (MEFs) were 
extracted and Western blot analysis demonstrated that RCP levels were 
suppressed in cells treated with Adeno-Cre (Figure 4.36B). RCPfl/fl mice are 
viable and had no obvious developmental abnormalities, so they were crossed 
into the KPC (Pdx1-Cre, KrasG12D/+, p53R172H/+) PDAC model (Figure 4.36C). 
Immunohistochemistry staining of tumour tissue from these mice demonstrated 
that RCP expression was efficiently depleted in PDAC from these mice (Figure 
4.35D). Most interestingly, KPC RCPfl/fl and KPC RCPfl/+ mice had fewer 
metastases in the liver (Figure 4.36E), however no difference in survival was 
detected (Figure 4.36D). 
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Figure 4-35 RCP is highly expressed in KPC PanINs and PDAC 
A/B. Immunohistochemistry images using anti-RCP antibody on tissue sections of normal mouse 
pancreas (A) and PanINs from KPC mice (B). C. Tissue sections of PanINs from KPC mice were 
stained with anti-RCP antibody that was pre-absorbed with GST-RCP. D. Immunohistochemistry 
images of KPC RCP+/+ and KPC RCPfl/fl PDAC stained with anti-RCP antibody. This work was 
performed by Joan Grindlay. 
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Figure 4-36 KPC RCPfl/fl mice have reduced liver metastasis 
A. Schematic representation of the strategy for the generation of RCPfl/fl mice. B. Mouse embryonic 
fibroblasts (MEFs) were taken from the RCP+/+ and RCPfl/fl mice and treated with Adeno-Cre. The 
cells were lysed and subjected to SDS-PAGE and immunoblot analysis using anti-mouse-RCP and 
anti-β-tubulin antibodies. C. KPC (Pdx1-Cre, KasG12D/+, p53R172H/+) mice were crossed with RCPfl/fl 
mice. D. The survival of KPC RCP-/-, KPC RCPfl/+ and KPC RCPfl/fl mice was plotted in a Kaplan-
Meier curve. Statistical analysis was performed using log-rank tests and no significant differences 
were found. Mice that succumbed but did not develop pancreatic cancer were excluded. E. The 
number of mice that had detectable liver metastasis is plotted as a percentage of total mice. This 
work was performed by Joan Grindlay. 
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4.2.12 Knockout of EphA2 and RCP oppose KPC PDAC cell 
invasion in vitro 
To determine whether the reduced metastasis in EphA2-/- and RCPfl/fl animals is 
due to cell autonomous effects on PDAC cell invasion, I derived cell lines from 
several pancreatic tumours. Primary PDACs from KPC WT, KPC EphA2-/- and KPC 
RCPfl/fl mice were examined and placed in culture for several weeks until the 
tumour cells continued to grow. The resulting cell lines expressed Cre-
recombinase (as determined by RT-PCR), confirming that their cells of origin 
were from the pancreas and not from a tumour-associated stromal lineage. 
Moreover, Western blotting confirmed the knockout of RCP and EphA2 in these 
PDAC cell lines (Figure 4.37A), and interestingly there were indications that 
RCP-depleted cells had reduced levels of EphA2, perhaps indicating a 
requirement for RCP dependent trafficking in the maintenance of cellular levels 
of EphA2. RCP and EphA2 knockout KPC-PDAC cell lines proliferated at rates that 
were similar to the KPC WT controls, indicating that EphA2 and its trafficking 
does not influence cell growth (Figure 4.37B).  
I then proceeded to investigate the migratory and invasive properties of these 
PDAC lines. Cells derived from KPC WT PDAC tumours were found to grow as 
loose colonies in which cells did not appear to form stable junctions. It was 
normally possible to see substantial spaces between cells within the same loose 
colonies and many migratory cells at the colonies’ edges. By contrast, cells from 
RCP and EphA2 knockout tumours grew in closely-knit colonies with a defined 
edge and there was very little indication that these cells were able to migrate 
away from the colonies (Figure 4.37C). Next, I sought to determine whether cell 
lines derived from EphA2 and RCP knockout tumours had altered ability to 
invade into Matrigel towards an HGF gradient. The two cell lines derived from 
KPC WT tumours invaded efficiently into Matrigel as previously shown by 
Timpson et al. (2011) (Figure 4.38). By contrast, cell lines from KPC EphA2-/- 
and KPC RCPfl/fl tumours had severely reduced capability to invade into Matrigel 
(Figure 4.38). These data indicate that expression of both EphA2 and RCP is 
necessary for PDAC cells to assume a scattered and invasive phenotype, 
consistent with the role that I had described for RCP-mediated EphA2 trafficking 
in cell scattering. 
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Figure 4-37 Cells derived from KPC EphA2-/- and KPC RCPfl/fl PDAC have a less scattered 
phenotype  
Cells lines were derived from KPC WT, KPC EphA2-/- and KPC RCPfl/fl PDAC. A. The cells were 
lysed and the proteins subjected to SDS-PAGE and Western blotting analysis using anti-mouse-
RCP, anti-EphA2 and anti-β-tubulin antibodies. B. These cells were seeded onto plates and 
counted using a Casy cell counter at the appropriate times. Cell number is represented graphically. 
The graphs show the averages and SEM of 6 replicates of 2 separate experiments. C. 
Representative images of the cells with a scale bar of 100µm. 
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Figure 4-38 Cells derived from KPC EphA2-/- and KPC RCPfl/fl PDAC are less invasive than 
those derived from KPC WT PDAC 
Cells lines were derived from KPC WT, KPC EphA2-/- and KPC RCPfl/fl PDAC. These cells were 
plated onto the underside of transwells containing Geltrex plugs enriched with 25μg/ml fibronectin. 
Cells migrated up towards HGF-supplemented serum-rich media for 72 hours. Cells were stained 
with Calcein-AM and visualised by confocal microscopy. A. Optical sections were taken every 
10μm and consecutive images were assembled from left to right. B. The average cell invasion 
beyond 20μm was quantified. The graph shows the averages and SEM of 18 regions in six 
transwell plugs from three separate experiments. 
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4.3 Discussion 
Having identified and confirmed an association between endogenous EphA2 and 
RCP (Section 3.2.4), I sought to find the functional significance of this 
interaction. Indeed, I have demonstrated that RCP has a role in the trafficking of 
EphA2 between the plasma membrane and a Rab14-positive internal 
compartment. Using a transgenic mouse model of PDAC we have shown that both 
EphA2 and RCP contribute to liver metastasis. Since in vitro cell invasion is 
reduced in PDAC cells derived from EphA2 or RCP knockout mice, these effects 
are anticipated to be cell autonomous. It is possible that the effects on 
metastasis and cell invasion are influenced by the requirement of EphA2 and RCP 
for CIL and cell scattering, which has been demonstrated in human cancer cell 
lines. Furthermore, the roles of EphA2, RCP and Rab14 in CIL and cell scattering 
maybe specific, as expression of other RCP-associated Rab GTPases and Rab11-
Fips are not required for these phenomena. From the data shown in this chapter, 
I postulate that HGF treatment activates a kinase responsible for 
phosphorylating RCP on Serine435. RCP phosphorylation recruits EphA2 and Rab14 
into a co-immunoprecipitable complex in a vesicular compartment, slowing the 
return of EphA2 back to the plasma membrane and promoting cell-cell repulsion. 
I speculate that this HGF-dependent change in EphA2 trafficking may alter 
downstream signalling of this receptor which drives cell-cell repulsion events 
(Section 5.2.2). 
4.3.1 Contact inhibition of locomotion 
CIL was originally defined by Abercrombie as ‘the stopping of the continued 
locomotion of a cell in the direction which has produced a collision with another 
cell’ (Abercrombie, 1979). This definition has been subsequently elaborated to 
describe not just contact inhibition, but also includes the formation of new 
lamellipodia and subsequent cell migration (Mayor and Carmona-Fontaine, 
2010). For interpreting and quantifying my results, however, I have not found 
the more recent description of CIL useful. Also, I have found some technical 
problems with the contact acceleration index, Cx, which some previous studies 
have used to analyse CIL. This index uses several parameters, including the 
vectorial distance a cell moves 40 minutes before and after a collision, and the 
angle of change in direction upon a collision. I observed that PC3 cells migrate 
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with low persistence, so the vectorial distance does not reflect the total path 
length of cell migration. Furthermore, the angle is influenced not only by the 
collision, but also by random changes in the direction of cell migration in the 40 
minute periods. Therefore, I simplified my analysis by measuring the time that 
the cells remain in contact before migrating away from the collision site. 
Knockdown of RCP or Rab14 increased the time cells remained in contact before 
migrating away from one another. This indicates that RCP and Rab14 do not 
affect contact inhibition per se, but are required for cell-cell repulsion after two 
cells have collided. As I have shown that EphA2, RCP and Rab14 are also required 
for HGF-driven scattering, this suggests that these proteins may have an 
important role in tumour dissemination. 
4.3.2 Proteolytic cleavage 
Rab14 delivers ADAM10 to the plasma membrane where the protease cleaves N-
cadherin, thereby promoting cell junction disassembly and cell migration 
(Linford et al., 2012). In H1299 cells, N-cadherin levels are not altered by the 
suppression of Rab14 expression, suggesting that this mechanism does not 
account for the defects in scattering of H1299 cells depleted of Rab14 
expression. EphA2 is cleaved by MMP-MT1 internalisation of membrane-bound 
EphA2 to activate Src and RhoA, thereby promoting single cell migration 
(Sugiyama et al., 2013). These studies led me to hypothesise that Rab14 may 
deliver a protease to the plasma membrane to cleave EphA2 and trigger this 
RTK’s internalisation, thereby activating downstream signalling proteins and 
cell-cell repulsion. However, upon further investigation, no cleaved EphA2 
products were observed after siRNA of RCP or HGF treatment, nor were any 
reductions in full-length EphA2 protein detected. Furthermore, only full-length 
EphA2 was detected in a co-immunoprecipitable complex with GFP-RCP, and no 
cleaved EphA2 products were detected in the trafficking assay by Western 
blotting. As there is no evidence that EphA2 was cleaved in these cells, and I 
found that full-length EphA2 associated with both RCP and Rab14, I propose an 
alternative mechanism for the involvement of EphA2, RCP and Rab14 is HGF-
driven cell scattering. 
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4.3.3 Diversion of EphA2 trafficking 
In H1299 cells, EphA2 is in rapid flux between the plasma membrane and 
internal compartments. I postulate that HGF treatment diverts EphA2 from a 
rapid recycling route into a slower pathway that proceeds via an RCP/Rab14-
positive compartment (Figure 4.39). This hypothesis is supported by my 
experimental data showing that HGF increases the size of the EphA2 internal 
pool in an RCP- and Rab14-dependent fashion. Further investigation revealed 
that this change is not due to increased internalisation, but a delay in EphA2 
recycling back to the plasma membrane. Moreover, I have shown that the 
addition of HGF increases EphA2 co-localisation with RCP and Rab14 in stable 
vesicular structures. It has recently been proposed that Rab14 has a role in 
recycling ADAM10 and transferrin from (Rab4- and Rab5-positive) early 
endosomes  back to the plasma membrane (Linford et al., 2012). Consistent with 
this work, I have found that Rab14 is required for EphA2 recycling, suggesting 
that EphA2 is another cargo for the Rab14 recycling pathway. 
In this work EphA2 trafficking was analysed using a biotin-labelling based 
approach. The main drawback of this assay is that it gives only an indirect 
snapshot readout of EphA2 recycling. To confirm that HGF alters EphA2 
trafficking in an RCP-dependent fashion, further experiments should be 
performed, for example 17ºC temperature blocks or photoactivatable 
approaches could be used. At 17ºC receptors are accumulated in endosomes as a 
number of recycling pathways are inhibited whilst endocytosis proceeds (Song et 
al., 1994). When cells are returned to 37ºC recycling of these receptors can be 
measured. Alternatively, it would be interesting to study EphA2 recycling by 
photo-activating paGFP-EphA2 in vesicles and using time-lapse microscopy to 
visualise its trafficking back to the plasma membrane (Caswell et al., 2007). 
Futhermore, this approach could be used to visualise how HGF alters EphA2 
recycling. 
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Figure 4-39 Working model of EphA2 trafficking 
In untreated cells EphA2 is in rapid flux between the plasma membrane and an internal 
compartment. HGF addition diverts EphA2 into an RCP- and Rab14-rich compartment, and delays 
EphA2 recycling to the plasma membrane (EE: early endosomes, RC: recycling compartment). 
 
4.3.4 RCP phosphorylation 
Rab14 and Rab11 have recently been proposed to associate with RCP at distinct 
neighbouring sites (Qi et al., 2013). Indeed, mutating RCP on Serine580 and 
Serine582 disrupts Rab14 association, but has little effect on Rab11 binding (Qi et 
al., 2013). Several other Rab effector proteins have been shown to have several 
binding domains for different GTPases, for example, Fip3 associates with both 
Arf6 and Rab11 (Fielding et al., 2005) and Rabaptin5 associates with both Rab4 
and Rab5 (Christoforides et al., 2012). Most interestingly, in migrating cells PKD 
phosphorylates Rabaptin5 at Serine407 favouring Rab4 association over Rab5 
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(Christoforides et al., 2012). Consistent with this, I have shown that 
phosphorylation of RCP on Serine435 enhances RCP’s association with Rab14, but 
has little effect on Rab11 binding. Thus it is probable that phosphorylation of 
Rab effectors may alter the trafficking routes of cargo by influencing the Rab 
GTPase they associate with. Phosphorylation of RCP could either provide a 
phosphor-specific site for Rab14, or alter intramolecular interactions to remodel 
the structure of the protein to expose a Rab14-binding site. X-ray 
crystallography would be required to determine the exact nature of the 
association and how phosphorylation affects it. I postulate that phosphorylation 
of RCP is key in altering Rab GTPase association and thereby regulating the 
trafficking of EphA2 during cell-cell repulsion. Further work is required to 
determine how altering EphA2 trafficking contributes to cell-cell repulsion 
(Section 5.2). RCP and EphA2 are required for both PDAC metastasis in a mouse 
model and scattering/CIL in vitro, suggesting that cell-cell repulsion may have 
an important role in cancer dissemination in vivo. Further work is required to 
examine the role of cell-cell repulsion in PDAC metastasis (Section 5.4). 
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5 Summary and Future Directions  
5.1 Summary 
The role of EphA2 in tumourigenesis and metastasis has been investigated 
previously by ablating EphA2 expression in several transgenic mouse models. For 
example, EphA2 deficiency impairs tumourigenesis and reduces metastasis in a 
ErbB2-overexpressing breast cancer model (Brantley-Sieders et al., 2008), and 
reduces the number and size of tumours in the APCMin/+ colorectal model (Bogan 
et al., 2009). Since EphA2 is often upregulated in human PDAC (Mudali et al., 
2006), we crossed EphA2-/- mice into a transgenic mouse model of PDAC. In 
contrast to the breast and colon models, EphA2 does not reduce the formation of 
primary tumours (in fact it increases tumour formation), but does reduce liver 
metastasis. As I have shown that EphA2 associates with RCP, and that it is 
recycled through an RCP-positive compartment during cell scattering, we 
investigated RCP’s role in PDAC tumourigenesis and metastasis. Like EphA2, 
ablation of RCP expression in the PDAC model reduces liver metastasis, but has 
no effect on primary tumour formation. Since EphA2 and RCP are required for 
cell-cell repulsion, I propose that this phenomenon may be involved in PDAC 
tumour dissemination in vivo. Rab14 is also required for cell-cell repulsion, 
however other RCP-associated Rab GTPases are not. Interestingly, HGF addition 
increases RCP phosphorylation on Serine435, and enhances the association and co-
localisation of EphA2, RCP and Rab14. This phosphorylation is required for cell 
scattering, so the kinase responsible for it is likely to have a role in cell-cell 
repulsion events. In summary, I propose that HGF addition activates a kinase 
that phosphorylates RCP, thereby diverting internalised EphA2 into an 
RCP/Rab14-positive compartment, thus stimulating cell-cell repulsion (Figure 
5.1). 
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Figure 5-1 Working model of EphA2 trafficking during HGF driven cell-cell repulsion 
A. EphA2 is in constant flux between the plasma membrane and an internal compartment. These 
cells remain attached and invade poorly. B. HGF increases RCP phosphorylation by LMTK3, which 
recruits Rab14 into a recycling compartment. EphA2 is internalised into this compartment, which 
stimulates cell-cell repulsion and results in a more invasive phenotype. 
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5.2 Future Directions 
5.2.1 Which kinases phosphorylate RCP? 
Two kinases were found associated with RCP in proteomic screens (Peter van den 
Berge & Patricia Muller, unpublished): CK2, a pleiotropic, ubiquitous and 
constitutively active kinase often overexpressed in tumours (Piazza et al., 2012); 
and LMTK2, a transmembrane kinase that colocalises with Rab11 in endosomes 
(Takano et al., 2012). The Serine/Threonine Lemur Tyrosine Kinase (LMTK) 
family has three members: LMTK1/AATK1, LMTK2/BREK and LMTK3. In human 
breast cancer, high LMTK3 expression correlates with poor disease-free survival 
and predicts patients’ responses to endocrine therapy (Giamas et al., 2011). 
Furthermore, Giamas et al. (2011) showed that suppressing LMTK3 expression 
reduces tumour growth in an orthotypic mouse model. Interestingly, LMTK3 has a 
role in NMDA trafficking (Inoue et al., 2014), while LMTK2 has a role in CFTR 
trafficking (Luz et al., 2014).  
Wang and Brautigan (2006) identified several peptides that LMTK2 
phosphorylates, including a sequence contained in CFTR (Wang and Brautigan, 
2006). Most interestingly, this sequence is very similar to RCP’s phosphorylation 
site (Figure 5.2), suggesting it is a good candidate as an RCP kinase. Therefore, I 
performed some preliminary experiments using siRNA to suppress levels of LMTKs 
in H1299 cells, to investigate whether these kinases influence phosphorylation of 
RCP on Serine435. As I have been unable to obtain antibodies recognising LMTKs, I 
used RT-PCR to confirm suppressed expression of the kinases in H1299 cells (not 
shown). Knockdown of LMTK3 prevented HGF-induced phosphorylation of RCP; 
however siRNA of LMTK2 (not shown) and LMTK1 had little effect (Figure 5.3A). 
Consistent with this, co-immunoprecipitation of EphA2, Rab14 and RCP is 
reduced in cells treated with LMTK3 siRNA (Figure 5.3). These data indicate that 
LMTK3 is activated downstream of HGF and is in itself responsible for RCP 
phosphorylation on Serine435. Furthermore, preliminary work in the lab has 
shown that LMTK3 is required for HGF-dependent EphA2 trafficking, RCP-EphA2 
co-localisation and cell-cell repulsion events (not shown). 
Chapter 5  191 
 
 
Figure 5-2 Sequence alignment of LMTK’s consensus phosphorylation site with potential 
candidate sequences in CFTR and RCP. 
Single amino acid code is used in which X represents any amino acid and Φ represents a 
hydrophobic amino acid. 
 
LMTK3 has a role in cancer progression of ERα+ but not ERα- breast cancer, and is 
thought to phosphorylate ERα, which prevents the receptor from proteasomal 
degradation (Giamas et al., 2011). Recently it has been shown that LMTK3 
regulates α5β1-integrin expression in vitro, and in human breast cancer tumours 
the expression levels of these proteins positively correlate (Xu et al., 2014). 
Interestingly, RCP and its phosphorylation are also required for α5β1-integrin 
trafficking (not shown), which confirms that LMTKs may have a role in regulating 
α5β1-integrins. 
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Figure 5-3 Suppression of LMTK3 expression, but not LMTK1, prevents RCP 
phosphorylation and the association between EphA2, RCP and Rab14 
A. H1299 cells were co-transfected with GFP, GFP-RCP or GFP-RCPS435A and LMTK1, LMTK3 
or non-targeting siRNA and stimulated with 10ng/ml HGF for the indicated times. The cells were 
lysed and GFP was immunoprecipitated with an anti-GFP antibody. The immunoprecipitates were 
analysed by SDS-PAGE and Western blotting with antibodies that recognise RCP, pSer435-RCP, 
EphA2, Rab11 and Rab14. B. H1299 cells were transfected with LMTK3 or non-targeting siRNA 
and stimulated with 10ng/ml HGF for the indicated times. The cells were lysed and endogenous 
EphA2 was immunoprecipitated with an anti-EphA2 antibody. The immunoprecipitates were 
analysed by SDS-PAGE and Western blotting with antibodies that recognise RCP, pSer435-RCP, 
EphA2 and Rab14. 
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5.2.2 Are Rho GTPases activated downstream of EphA2/RCP 
trafficking? 
RhoA is activated during cell-cell repulsion to regulate the actomyosin 
cytoskeleton, thereby promoting cell-cell junction protein disassembly and cell 
migration (Carmona-Fontaine et al., 2008). Several studies have shown that Rho-
GTPases are activated downstream of EphA signalling during cell-cell repulsion 
events in axon guidance and CIL (Astin et al., 2010; Wahl et al., 2000). I 
hypothesise that during HGF-induced scattering, EphA2 activates Rho GTPases, 
but there is an apparent paradox as HGF decreases the levels of EphA2 on the 
plasma membrane (where one might expect RhoA to be activated to promote 
cell-cell repulsion). However, there is increasing evidence that trafficking 
regulates and spatially restricts Rho GTPase activity. For example, RhoA is 
activated by ENDO180 (a pro-migratory receptor for collagen) on endosomes at 
the rear of the cell, promoting detachment from the ECM (Sturge et al., 2006). 
Also, Tiam1 (a Rac1 GEF) localises on endosomes where it locally activates and 
triggers Rac1 recycling to dorsal ruffles (Palamidessi et al., 2008). Most 
interestingly, a novel Akt substrate, RacGAP1, is activated downstream of RCP-
driven α5β1-integrin/EGFR recycling (Jacquemet et al., 2013). Once activated, 
RacGAP1 is recruited to IQGAP1 at the tip of the pseudopod, where it locally 
inhibits Rac1 and stimulates a spike in RhoA activity, thus driving cancer cell 
invasion into a 3D matrix (Jacquemet et al., 2013). Moreover, it has been shown 
that EphA2 trafficking is required for Rac1 activation. EphA2 is internalised into 
endosomes where it associates with and activates Tiam1 to switch on Rac1 
(Boissier et al., 2013). I postulate that HGF diverts EphA2 trafficking into an 
RCP/Rab14-positive compartment. It remains unclear how trafficking into a 
Rab14 vs Rab11 compartment affects the fate of EphA2.  One hypothesis is that 
altering EphA2’s trafficking pathway may alter its downstream signalling, such as 
Rho GTPases, and thereby promoting cell-cell repulsion (Figure 5.1). 
Althernatively altered trafficking kinetics may alter downstream signalling. To 
test this, the spatial and temporal activity of Rho GTPases could be analysed 
using FRET reporter probes following HGF treatment. 
 
 
Chapter 5  194 
 
5.2.3 How could mutant-p53 modulate HGF driven EphA2 
trafficking? 
Muller et al. (2013) showed that mutant-p53 increases RCP-dependent α5β1-
integrin and cMet recycling, thereby increasing the cells’ sensitivity to HGF-
induced phosphorylation of key tyrosine residues in the catalytic domain of cMet 
(Figure 5.4). In this thesis, I have shown that HGF addition increases RCP 
phosphorylation on Serine435 by LMTK3, diverting EphA2 trafficking into an 
RCP/Rab14-positive compartment, and thus driving cell scattering (Figure 5.4). 
Taken together, I postulate that RCP has two different roles in scattering: it is 
involved first in setting the sensitivity of cMet to HGF, and second in controlling 
EphA2 trafficking. Since the concentration of HGF is much lower in tumours than 
in scattering assays, both of RCP’s roles in scattering are likely to have an 
important role in cancer dissemination. 
 
Figure 5-4 Schematic summary of mutant-p53’s proposed role in HGF-induced scattering 
Mutant-p53 increases α5β1-integrin and cMet recycling in an RCP-dependent fashion, thereby 
increasing the cells’ sensitivity to HGF-induced phosphorylation of key tyrosine residues in the 
catalytic domain of cMet. HGF drives LMTK3 phosphorylation of RCP on Serine435, altering the 
EphA2 trafficking route into an RCP/Rab14 compartment, thus driving cell scattering.  
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5.2.4 What is the role of cell-cell repulsion in PDAC metastasis? 
EphA2 and RCP contribute similarly to liver metastasis in the PDAC mouse model. 
These proteins could be required for several different steps during metastasis, 
such as cancer cell dissemination from the primary tumour, invasion through the 
basement membrane, survival in the circulation or at the secondary site, or 
establishment and growth of metastases. As I have shown that EphA2 and RCP 
are required for in vitro cell-cell repulsion and invasion, I would postulate that 
these proteins are likely to contribute to cancer cell dissemination and/or 
invasion. Histological analysis of the invasive front of metastasising human PDAC 
suggests that these cancer cells invade collectively with only a few isolated 
cancer cells being observed (Bronsert et al., 2014). However, it is difficult to 
gain a full understanding of dynamic cell migration and invasion using tissue 
samples from single time points. Furthermore, it has been shown using intravital 
imaging that the acquisition of a single cell migratory mode is reversible in vivo 
(Giampieri et al., 2009). My data show using single cell systems (not just clonal 
cell lines but also tumour-derived mixed population of cells), that metastasis 
correlates with cell-cell repulsion. The pathway required for HGF-induced 
scattering involves LMTK3 phosphorylating RCP and recruiting EphA2 and Rab14 
into an internal compartment. I postulate that this pathway is activated at 
certain times in vivo, promoting tumour dissemination in a reversible fashion. 
Further studies are required to investigate the contributions of this mechanism 
to metastasis. To determine the distribution of EphA2, Rab14, RCP and pSer435-
RCP in the invasive front of tumours, human PDAC microarrays will be stained 
with the appropriate antibodies. Genetic studies using LMTK3 and Rab14 knock-
out and RCPS435A knockin mice will be used to investigate the importance of RCP 
phosphorylation in tumourigenesis and metastasis. This will determine whether 
LMTK3 would be a good novel target for cancer therapeutics.  
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Appendix 
Sequence of EphA2 cloned into pEGFP-N1     
 
C C C G A A T T C A C A T G G A G C T C C A G G C A G C C C G C G C C T G C T T C G C C C T G C T G T G G G G C T G T G 
C G C T G G C C G C G G C C G C G G C G G C G C A G G G C A A G G A A G T G G T A C T G C T G G A C T T T G C T G C A 
G C T G G A G G G G A G C T C G G C T G G C T C A C A C A C C C G T A T G G C A A A G G G T G G G A C C T G A T G C A 
G A A C A T C A T G A A T G A C A T G C C G A T C T A C A T G T A C T C C G T G T G C A A C G T G A T G T C T G G C G A 
C C A G G A C A A C T G G C T C C G C A C C A A C T G G G T G T A C C G A G G A G A G G C T G A G C G  T A T C T T C A 
T T G A G C T C A A G T T TA C T G T A C G T G A C T G C A A C A G C T T C C C T G G T G G C G C C A G C T C C T G C A 
A G G A G A C T T T C A A C C T C T A C T A T G C C G A G T C G G A C C T G G A C T A C G G C A C C A A C T T C C A G A 
A G C G C C T G T T C A C C A A G A T T G A C A C C A T T G C G C C C G A T G A G A T C A C C G T C A G C A G C G A C T 
T C G A G G C A C G C C A C G T G A A G C T G A A C G T G G A G G A G C G C T C C G T G G G G C C G C T C A C C C G C 
A A A G G C T T C T A C C T G G C C T T C C A G G A T A T C G G T G C C T G T G T G G C G C T G C T C T C C G T C C G T 
G T C T A C T A C A A G A A G T G C C C C G A G C T G C T G C A G G G C C T G G C C C A C T T C C C T G A G A C C A T C 
G C C G G C T C T G A T G C A C C T T C C C T G G C C A C T G T G G C C G G C A C C T G T G T G G A C C A T G C C G T G 
G T G C C A C C G G G G G G T G A A G A G C C C C G T A T G C A C T G T G C A G T G G A T G G C G A G T G G C T G G T 
G C C C A T T G G G C A G T G C C T G T G C C A G G C A G G C T A C G A G A A G G T G  G A G G A T G C C T G C C A G G 
C C T G C T C G C C T G G A T T T T T T A A G T T T G A G G C A T C T G A G A G C C C C T G C T T G G A G T G C C C T G 
A G C A C A C G C T G C C A T C C C C T G A G G G T G C C A C C T C C T G C G A G T G T G A G G A A G G C T T C T T C C 
G G G C A C C T C A G G A C C C A G C G T C G A T G C C T T G C A C A C G A C C C C C C T C C G C C C C A C A C T A C C 
T C A C A G C C G T G G G C A T G G G T G C C A A G G T G G A G C T G C G C T G G A C G C C C C C T C A G G A C A G C 
G G G G G C C G C G A G G A C A T T G T C T A C A G C G T C A C C T G C G A A C A G T G C T G G C C C G A G T C T G G 
G G A A T G C G G G C C G T G T G A G G C C A G T G T G C G C T A C T C G G A G C C T C C T C A C G G A C T G A C C C 
G C A C C A G T G T G A C A G T G A G C G A C C T G G A G C C C C A C A T G A A C T A C A C C T T C A C C G T G G A G G 
C C C G C A A T G G C G T C T C A G G C C T G G T A A C C A G C C G C A G C T T C C G T A C T G C C A G T G T C A G C A 
T C A A C C A G A C A G A G C C C C C C A A G G T G A G G C T G G A G G G C C G C A G C A C C A C C T C G C T T A G C G 
T C T C C T G G A G C A T C C C C C C G C C G C A G C A G A G C C G A G T G T G G A A G T A C G A G G T C A C T T A C C 
G C A A G A A G G G A G A C T C C A A C A G C T A C A A T G T G C G C C G C A C C G A G G G T T T C T C C G T G A C C C 
T G G A C G A C C T G G C C C C A G A C A C C A C C T A C C T G G T C C A G G T G C A G G C A C T G A C G C A G G A G 
G G C C A G G G G G C C G G C A G C A A G G T G C A C G A A T T C C A G A C G C T G T C C C C G G A G G G A T C T G G 
C A A C T T G G C G G T G A T T G G C G G C G T G G C T G T C G G T G T G G T C C T G C T T C T G G T G C T G G C A G 
G A G T T G G C T T C T T T A T C C A C C G C A G G A G G A A G A A C C A G C G T G C C C G C C A G T C C C C G G A G G 
A C G T T T A C T T C T C C A A G T C A G A A C A A C T G A A G C C C C T G A A G A C A T A C G T G G A C C C C C A C A 
C A T A T G A G G A C C C C A A C C A G G C T G T G T T G A A G T T C A C T A C C G A G A T C C A T C C A T C C T G T G 
T C A C T C G G C A G A A G G T G A T C G G A G C A G G A G A G T T T G G G G A G G T G T A C A A G G G C A T G C T G 
A A G A C A T C C T C G G G G A A G A A G G A G G T G C C G G T G G C C A T C A A G A C G C T G A A A G C C G G C T A 
C A C A G A G A A G C A G C G A G T G G A C T T C C T C G G C G A G G C C G G C A T C A T G G G C C A G T T C A G C C 
A C C A C A A C A T C A T C C G C C T A G A G G G C G T C A T C T C C A A A T A C A A G C C C A T G A T G A T C A T C A C 
T G A G T A C A T G G A G A A T G G G G C C C T G  G A C A A G T T C C T T C G G G A G A A G G A T G G C G A G T T C A 
G C G T G C T G C A G C T G G T G G G C A T G C T G C G G G G C A T C G C A G C T G G C A T G A A G T A C C T G G C C 
A A C A T G A A C T A T G T G C A C C G T G A C C T G G  C T G C C C G C A A C A T C C T C G T C A A C A G C A A C C T G 
G T C T G C A A G G T G T C T G A C T T T G G C C T G T C C C G C G T G C T G G A G G A C G A C C C C G A G G C C A C 
C T A C A C C A C C A G T G G C G G C A A G A T CC C C A T C C G C T G G A C C G C C C C G G A G G C C A T T T C C T A 
C C G G A A G T T C A C C T C T G C C A G C G A C G T G T G G A G C T T T G G C A T T G T C A T G T G G G A G G T G A 
T G A C C T A T G G C G A G C G G C C C T A C T G G G A G T T G T C C A A C C A C G A G G T G A T G A A A G C C A T C A 
A TG A T G G C TT C C G G C T C C C C A C A C C C A T G G A C T G C C C C T C C G C C A T C T A C C A G C T C A T G A T 
G C A GT G C T GG C A G C A G G A G C G T G C C C G C C G C C C C A A G T T C G C T G A C A T C G T C A G C A T C C T 
G G A C A A G C T C A T T C G T G C C C C T G A C T C C C T C A A G A C C C T G G C T G A C T T T G A C C C C C G C G T 
G T C T A T C C G G C T C C C C A G C A C G A G C G G C T C G G A G G G G G T G C C C T T C C G C A C G G T G T C C G 
A G T G G C T G G A G T C C A T C A A G A T G C A G C A G T A T A C G G A G C A C T T C A T G G C G G C C G G C T A C A 
C T G C C A T C G A G A A G G T G G T G C A G A T G A C C A A C G A C G A C A T C A A G A G G A T T G G G G T G C G G 
C T G C C C G G C C A C C A G A A G C G C A T C G C C T A C A G C C T G C T G G G A C T C A A G G A C C A G G T G A A C 
A C T G T G G G G AT C C C C A T C C T G T C G A C C C C 
 
Sequence of Rab6B cloned into pEGFP-C3                                                                      
 
A A A G A A T T C A T G T C C G C A G G G G G A G A T T T T G G G A A T C C A C T G A G A A A 
A T T C A A G T T G G T G T T C T T G G G G G A G C A G A G C G T C G G G A A G A C G T C 
T C T G A T T A C G A G G T T C A T G T A C G A C A G C T T C G A C A A C A C A T A C C A 
G G C A A C C A T T G G G A T T G A C T T C T T G T C A A A A A C C A T G T A C T T G G A G 
G A C C G C A C G G T G C G A C T G C A G C T C T G G G A CA C A G C T G G T C A G G A G 
A G G T T C C G C A G C C T G A T C C C C A G C T A C A T C C G G G A C T C C A C G G T G G 
C T G T G G T G G T G T A C G A C A T C A C A A A T C T C A A C T C C T T C C A A C A G A C 
C T C T A A G T G G A T C G A C G A C G T C A G G A C A G A G A G G G G C A G T G A T G T 
T A T C A T C A T G C T G G T G G G C A A C A A G A C G G A C C T G G C T G A T A A G A G 
G C A G A T A A C C A T C G A G G A G G G G G A G C A G C G C G C C A A A G A A C T G A G 
C G T C A T G T T C A T T G A G A C C A G T G C G A A G A C T G G C T A C A A C G T G A A G 
C A G C T T T T T C G A C G T G T G G C G T C G G C T C T A C C C G G A A T G G A G A A T 
G T C C A G G A G A A A A G C A A A G A A G G G A T G A T C G A C A T C A A G C T G G A C 
A A A C C C C A G G A G C C C C C G G C C A G C C A G C T G A A A 
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Sequence of Rab6A in pEGFP-C2  
 
A T G T C C A C G G G C G G A G A C T T C G G G A A T C C G C T G A G G A A A T T C A A G C T G G T G T T C C T G G G 
G G A G C A A A G C G T T G G A A A G A C A T C T T T G A T C A C C A G A T T C A T G T A T G A C A G T T T T G A C A A 
C A C C T A T C A G G C A A C A A T T G G C A T T G A C T T T T T A T C A A A A A C T A T G T A C T T G G A G G A T C G 
A A C A G T A C G A T T G C A A T T A T G G G A C A C A G C A G G T C A A G A G C G G T T C A G G A G C T T G A T T C C 
T A G C T A C A T T CG T G A C T C C A C T G T G G C A G T T G T T G T T A T G A T A T C A C A A A T G T T A A C T C A T 
T C C A G C A A A C T A C A A A G T G G A T T G A T G A T G T C A G A A C A G A A A G A G G A A G T G A T G T T A T C A 
T C A T G C T A G T A G G A A A T A A A A C A G A T C T T G C T G A C A A G A G G C A A G T G T C A A T T G A G G A G G 
G A G A G A G G A A A G C C A A A G A G C T G A A T G T T A T G T T T A T T G A A A C T A G T G C A A A A G C T G G A T 
A C A A T G T A A A G C A G C T C T T T C G A C G T G T A G C A G C A G C T T T G C C G G G A A T G G A A A G C A C A C 
A G G A C A G A A G C A G A G A A G A T A T G A T T G A C A T A A A A C T G G A A A A G C C T C A G G A G C A A C C A G 
T C A G T G A A G G A G G C T G T T C C T G C T A A                 
 
                                                     
Sequence of Rab14 in pEGFP-C2  
 
A T G G C A A C T G C A C C A T A C A A C T A C T C T T A C A T C T T T A A A T A T A T T A T T A T T G G G G A C A T G G 
G A G T A G G A A A A T C T T G C T T G C T T C A T C A A T T T A C A G A A A A A A A A T T T A T G G C T G A T T G T C C 
T C A C A C A A T T G G T G T T G A A T T T G G T A C A A G A A T A A T C G A A G T T A G T G G C C A A A A A A T A A A 
A C T G C A G A T T T G G G A T A C G G C A G G A C A G G A G C G A T T T A G G G C T G T T A C A C G G A G C T A C T A 
C A G A G G A G C T G C G G G A G C T C T T A T G G T C T A T G A T A T C A C T A G A A G A A G T A C A T A T A A C C A 
C T T A A G C A G C T G G T T G A C A G A T G C A A G G A A T C T C A C C A A T C C A A A T A C T G T A A T A A T T C T C 
A T A G G A A A T A A A G C A G A T T T G G A G G C A C A G A G A G A T G T T A C A T A T G A A G A A G C C A A A C A G 
T T T G C T G A A G A A A A T G G C T T A T T G T T C C T C G A A G C G A G T G C A A A A A C G G G A G A G A A T G T A 
G A A G A T G C C T T C C T T G A G G C T G C C A A G A A A A T C T A T C A G A A C A T T C A G G A T G G A A G C T T G 
G A T C T G A A T G C T G C T G A G T C T G G T G T A C A A C A C A A A C C T T C A G C C C C G C A G G G A G G C C G G 
C T A A C C A G T G A A C C C C A A C C C C A G A G A G A A G G C T G T G G C T G C T A G  
 
 
Sequence of RCP in pEGFP-C3  
 
A G T G T T A T C G T C A C C A T G T C C C T A A T G G T C T C G G C T G G C C G G G G C C T G G G G G C C G T G T G 
G T C C C C A A C C C A C G T G C A G G T G A C G G T G C T G C A G G C G C G G G G C C T G C G G G C C A A G G G C C 
C C G G G G G C A C G A G C G A C G C G T A C G C G G T G A T C C A G G T G G G C A A G G A G A A G T A C G C C A C C 
T C C G T G T C G G A G C G C A G C C T G G G C G C G C C C G T G T G G C G C G A G G A G G C C A C C T T C G A G C T 
G C C A T C G C T G C T G T C C T C C G G A C C C G C G G C C G C C G C C A C C C T G C A G C T C A C C G T G C T G C A 
C C G C G C G C T G C T C G G C C T C G A C A A G T T C C T G G G C C G C G C C G A G G T G G A C C T G C G G G A T C 
T G C A C C G C G A C C A G G G C C G C A G G A A G A C G C A G T G G T A T A A G T T G A A A T C C A A A C C A G G A A 
A G A A G G A C A A G G A G C G A G G A G A A A T T G A G G T T G A C A T C C A G T T T A T G A G A A A C A A C A T G A 
C T G C C A G C A T G T T T G A C C T T T C T A T G A A A G A C A A G T C T C G G A A T C C A T T T G G A A A G C T G A 
A G G A C A A G A T C A A G G G G A A G A A T A A G G A C A G T G G G T C A G A C A C C G C C T C C G C C A T C A T C C 
C T A G C A C G A C A C C T T C G G T C G A C A G T G A T G A T G A G T C T G T G G T T A A A G A C A A G A A A A A G A 
A A T C A A A G A T C A A G A C C T T A C T T T C C A A G T C A A A T T T G C A G A A G A C G C C T C T T T C C C A G T C 
C A T G T C T G T C C T G C C G A C T T C A A A G C C A G A A A A A G T G C T G C T T C G T C C C G G A G A C T T T C A 
G T C C C A G T G G G A T G A A G A T G A C A A T G A G G A T G A G T C C T C C T C G G C C T C G G A T G T C A T G T C 
T C A C A A G A G A A C A G C G A G T A C G G A T C T T A A G C A A C T G A A C C A G G T C A A C T T T A C C C T T C C 
C A A G A A G G A A G G A C T T T C C T T T C T T G G T G G C C T T C G G T C T A A G A A T G A T G T C C T T T C C C G 
C T C T A A T G T C T G C A T C A A T G G G A A C C A T G T T T A C C T G G A G C A G C C A G A A G C C A A G G G T G A 
G A T C A A G G A T A G C A G C C C G T C C T C C T C C C C A T C C C C C A A G G G C T T C A G A A A G A A G C A T T T 
G T T C T C T T C T A C A G A G A A C C T G G C G G C T G G G T C T T G G A A G G A G C C T G C T G A A G G A G G T G 
G G C T G T C T T C T G A C A G G C A G C T C T C C G A A T C T T C C A C C A A G G A C T C C T T G A A G T C T A T G A 
C C C T G C C G T C C T A C C G A C C T G C C C C A C T G G T C A G T G G G G A C C T C A G G G A A A A C A T G G C C C 
C C G C A A A C T C A G A G G C C A C A A A A G A A G C T A A G G A G A G C A A G A A G C C A G A G A G C A G G A G G T 
C C T C T T T G C T G T C T C T G A T G A C G G G G A A G A A G G A T G T G G C T A A G G G C A G T G A A G G T G A A 
A A C C C T C T C A C G G T C C C A G G G A G G G A G A A G G A A G G C A T G C T G A T G G G G G T T A A G C C G G G 
G G A G G A C G C A T C G G G G C C T G C T G A A G A C C T T G T G A G A A G A T C T G A G A A A G A T A C T G C A G 
C T G T T G T C T C C A G A C A G G G C A G C T C C C T G A A C C T C T T T G A A G A T G T G C A G A T C A C A G A A C 
C A G A A G C T G A G C C A G A G T C C A A G T C T G A A C C G A G A C C T C C A A T T T C C T C T C C G A G G G C T C 
C C C A G A C C A G A G C T G T C A A G C C C C G A C T T C A T C C T G T G A A G C C A A T G A A T G C A A T G G C C A 
C C A A G G T T G C T A A C T G C A G C T T G G G A A C T G C C A C C A T C A T C A G T G A G A A C T T G A A C A A T G 
A G G T C A T G A T G A A G A A A T A C A G C C C C T C G G A C C C T G C A T T T G C A T A T G C G C A G C T G A C C C 
A C G A T G A G C T G A T T C A G C T G G T C C T C A A A C A G A A G G A A A C G A T A A G C A A G A A G G A G T T C C 
A G G T C C G C G A G C T G G A A G A C T A C A T T G A C A A C C T G C T T G T C A G G G T C A T G G A A G A A A C C C 
C C A A T A T C C T C C G C A T C C C G A C T C A G G T T G G C A A A A A A G C A G G A A A G A T G T A A  
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Sequence of Fip2 in pEGFP-C3 
 
A T G A T G C T G T C C G A G C A A G C C C A A A A G T G G T T T C C A A C C C A C G T G C A G G T C A C A G T G C T C 
C A A G C C A A A G A T C T G A A G C C A A A A G G C A A A A G T G G T A C C A A T G A C A C A T A C A C T A T A A T T 
C A G C T G G G C A A G G A A A A G T A C T C C A C C T C T G T A G C T G A G A A A A C C C T T G A G C C A G T T T G G 
A A G G A G G A G G C C T C T T T C G A G C T A C C T G G A T T G C T A A T T C A G G G A A G T C C A G A G A A A T A C 
A T T C T T T T C C T T A T A G T T A T G C A C A G G T C C C T G G T G G G T C T G G A T A A A T T T T T A G G G C A G 
G T G G C A A T C A A T C T C A A T G A C A T C T T T G A G G A C A A A C A A A G A A G G A A A A C A G A G T G G T T T 
A G A T T A G A A T C C A A A C A A G G A A A A C G A A T C A A A A A C A G G G G T G A G A T A A A G G T C A A T A T T 
C A G T T T A T G A G G A A C A A T A T G A C C G C A A G T A T G T T T G A C T T A T C A A T G A A G G A C A A A A C C 
A G A T C T C C T T T T G C A A A G T T A A A A G A T A A G A T G A A G G G T A G A A A A A A T G A T G G A A C A T T T 
T C T G A T A C G T C T T C T G C A A T C A T T C C A A G T A C T C A C A T G C C C G A T G C C A A T A G T G A A T T T T 
C A A G T G G T G A A A T A C A G A T G A A A T C C A A A C C A A A A A A G C C T T T T C T C T T G G G T C C T C A G C 
G A C T C T C G T C A G C G C A T T C A A T G T C T G A T T T A T C T G G G T C C C A T A T G T C T T C T G A G A A A C 
T G A A G G C T G G C A C C A T A G G T C A A A C A C A T C T T C T C G G A C  A C C A G T T A G A T T C C T T T G G A A 
C A G T T C C A G A A A G T G G A A G T C T C A A A T C T C C A C A C A G A A G A A C A T T A A G C T T T G A T A C T T C 
T A A A A T G A A C C A A C C T G A C A G C A T T G T G G A T G A A G G T G A A T T G T G T T T C G G A A G A C A A A A 
T G A C C C A T T T A C A A A T G T G A C T G C T T C A T T A C C C C A A A A A T T T G C A A C A C T G C C A A G G A A G 
A A A A A T C C A T T T G A A G A A A G C A G C G A A A C A T G G G A C A G C A G C A T G A A T T T A T T T T C A A A A 
C C A A T T G A A A T A A G A A A A G A A A A T A A A A G A G A G A A A A G G G A G A A A G T T A G C C T G T T T G A A 
A G A G T G A C T G G A A A A A A A G A T A G C A G A A G A T C T G A T A A A C T T A A C A A T G G G G G A T C T G A T 
A G C C C T T G T G A C T T G A A A T C A C C T A A T G C A T T T A G T G A A A A T C G C C A G G A C T A T T T T G A T 
T A T G A G T C A A C C A A T C C A T T T A C A G C A A A A T T C A G G G C T T C A A A T A T A A T G C C A T C T T C A A 
G T T T T C A T A T G A G T C C A A C A A G C A A T G A A G A C C T C A G G A A A A T C C C G G A C A G C A A C C C C T 
T T G A T G C C A C T G C A G G G T A T C G T A G T C T G A C C T A T G A A G A G G T T C T A C A G G A G C T G G T G A 
A A C A C A A A G A A C T C C T T A G G A G G A A A G A C A C C C A C A T C C G G G A A C T C G A G G A C T A C A T C G 
A C A A C C T C C T T G T A A G G G T A A T G G A A G A A A C G C C C A G T A T T C T C A G A G T G C C G T A T G A A C 
C A T C C A G G A A A G C T G G C A A A T T C T C T A A C A G T T A A T A A A G C C A A T T G T A T T G T A T T G A T A A 
T T G G A C A A A G A G A G A G A A A G A A A G A A G G A A G G A A G G A A A A A C T T G T T A C T G A A A G A G A C T 
A C A C T A T C A G G T T T C A T T A C A T A T T C T C C T T T A T  
 
 
Sequence of Rip11 in pEGFP-C3 
 
A G G T C C T G G G G T C T G C A C C G G C T C G G C C A G A C C T C G C C C C C C G C T T C T C C G C C A T G G C C C 
T G G T G C G G G G C G C G G A G C C G G C G G C G G G G C C T T C C C G C T G G C T G C C C A C G C A C G T C C A G 
G T G A C G G T G C T G C G G G C C C G C G G G C T G C G G G G C A A G A G C T C G G G A G C G G G C A G C A C C A G 
C G A C G C G T A C A C G G T G A T C C A G G T G G G C C G C G A G A A G T A C A G T A C G T C G G T G G T G G A G A 
A G A C G C A C G G C T G C C C C G A G T G G C G T G A G G A G T G C T C C T T C G A G C T G C C G C C G G G G G C C 
C T G G A T G G C C T G C T G C G G G C G C A G G A G G C C G A C G C G G G C C C G G C G C C C T G G G C C G C G A G 
C T C C G C C G C C G C C T G C G A G C T G G T G C T C A C C A C C A T G C A C C G C T C G C T C A T C G G C G T C G A 
C A A G T T C C T G G G C C A G G C C A C G G T G G C G C T G G A C G A G G T C T T C G G C G C A G G C C G C G C C C 
A G C A C A C G C A G T G G T A C A A G C T G C A C T C C A A G C C A G G C A A G A A G G A G A A G G A A C G C G G  C 
G A G A T T G A A G T C A C C A T C C A G T T C A C G C G C A A C A A C C T G A G C G C C A G T A T G T T T G A C C T G 
T C C A T G A A G G A C A A G C C A A G G T C T C C C T T C A G C A A G A T C A G G G A C A A G A T G A A G G G C A A G 
A A G A A G T A T G A T C T G G A A T C T G C C T C T G C C A T C C T C C C A A G C A G C G C C A T A G A G G A T C C T 
G A C C T G G G C A G C C T G G G C A A G A T G G G C A A A G C C A A A G G C T T C T T C C T C C G C A A C A A G C T G 
C G C A A G T C G T C C C T G A C C C A G T C C A A C A C C T C G C T G G G C T C G G A C A G C A C C C T G T C C T C A 
G C C A G C G G G A G C T T G G C C T A C C A G G G A C C T G G C G C C G A A C T C C T C A C C C G C T C A C C A A G C 
C G T A G C A G C T G G C T G T C C A C T G A A G G G G G C A G G G A C T C T G C A C A G T C C C C C A A G C T G T T C 
A C C C A T A A G A G G A C C T A C A G C G A T G A G G C C A A C C A G A T G C G A G T G G C T C C T C C T C G G G C C 
C T T C T G G A C C T T C A G G G C C A C C T G G A T G C T G C C T C C C G C T C T T C G C T C T G T G T C A A T G G G 
A G C C A C A T T T A C A A T G A G G A G C C C C A G G G C C C T G T G C G G C A C C G C A G C T C C A T C T C G G G C 
T C G C T T C C A T C C T C T G G C T C C T T G C A A G C T G T C T C T T C C C G G T T C T C C G A G G A G G G G C C T 
C G T T C C A C A G A T G A C A C C T G G C C C A G A G G C A G T C G T A G C A A C A G C A G C T C A G A G G C A G T G 
C T T G G A C A G G A G G A G C T G A G T G C T C A G G C T A A A G T C C T G G C C C C T G G G G C C A G C C A C C C 
T G G A G A G G A G G A G G G G G C C C G G C T A C C A G A G G G C A A G C C A G T C C A G G T T G C C A C A C C C A 
T A G T G G C C T C C T C T G A G G C T G T G G C A G A G A A G G A G G G A G C C C G G A A G G A G G A A C G C A A G 
C C C C G G A T G G G T C T C T T C C A C C A C C A C C A C C A A G G C C T A A G T C G G A G C G A G T T G G G T C G C 
C G A A G C T C T C T G G G G G A A A A G G G G G G T C C C A T C C T G G G G G C C T C C C C A C A T C A C T C A T C C 
A G T G G G G A G G A A A A G G C C A A G A G T A G C T G G T T T G G C T T G A G A G A A G C C A A G G A C C C G A C 
T C A G A A A C C C A G T C C C C A C C C C G T G A A G C C C C T C A G T G C C G C C C C T G T G G A G G G C A G C C C 
C G A  C A G G A A G C A G T C C C G C T C C A G T C T G A G C A T A G C C C T G A G C A G T G G G C T G G A G A A G C 
T C A A A A C A G T C A C A T C T G G G A G C A T T C A G C C T G T G A C C C A G G C C C C C C A G G C T G G C C A G A 
T G G T G G A C A C C A A A A G G C T G A A G G A C T C A G C T G T G C T G G A C C A G T C G G C C A A G T A C T A C C 
A C C T G A C C C A C G A T G A G C T C A T C A G C C T G C T C C T G C A G C G G G A G C G G G A G C T G A G C C A G C 
G G G A C G A G C A T G T G C A G G A G C T G G A G A G C T A C A T C G A C C G G C T G C T G G T G C G G A T C A T G 
G A G A C C T C A C C C A C G C T G C T G C A G A T C C C C C C G G G C C C C C C C A A A T A G  
 
 
 
 
 
 
199 
 
Sequence of Fip3 in pEGFP-C3  
 
A T G G C G T C G G C C C C G C C G G C C T C G C C C C C G G G C T C G G A G C C G C C G G G G C C C G A C C C G G A 
G C C G G G C G G G C C G G A C G G G C C G G G G G C G G C A C A A C T G G C T C C G G G C C C T G C G G A G C T A C 
G C C T C G G A G C G C C C G T C G G C G G C C C C G A C C C G C A G T C C C C G G G C C T G G A T G A G C C T G C G 
C C C G G G G C C G C T G C A G A T G G C G G G G C G C G T T G G A G C G C C G G G C C G G C C C C G G G G C T G G 
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